



**RUSSIAN
SOCIETY
OF CARDIOLOGY**

RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY

**CARDIOLOGY OF 21 OF THE XXI CENTURY —
NEW CHALLENGES, NEW ACHIEVEMENTS**

OCTOBER 21-23, 2021 | SAINT-PETERSBURG

SCIENTIFIC PROGRAMME



DEAR COLLEAGUES!

It is a great honor for me to welcome the participants of the Russian National Congress of Cardiology!

Every year we come together to exchange views on the most important issues in the battling cardiovascular diseases; our congress is becoming larger, offers new topics for discussion, and becomes more and more attractive for young professionals.

This time the congress is being held in Saint-Petersburg, a beautiful and majestic city where science and education have been woven together for three centuries, and I am sure that the traditions of innovation and progress, laid down by Peter the Great, will contribute to our successful work.

We are meeting today in difficult circumstances. Russian cardiologists, who have made a huge contribution to the fight against the new coronavirus infection, returned to providing specialized planned and emergency care, to active research and educational activities.

On this path, many difficulties await us: the danger of a new wave of a pandemic still remains; tens of thousands of patients who have undergone an infection need rehabilitation, many of them are faced with an exacerbation of cardiovascular pathology, but I am convinced that the Russian cardiological community today can become an example in how to intensify work and achieve world-class results.

This will require not only resources, but also innovative solutions: the transition to personalized and patient-centered medicine; development of integrative medical care, which will cover the entire cycle of treatment of the disease — from prevention and primary care to an effective rehabilitation system. Bridging the gap between the rapid development of technology and the level of medical education should be a priority for us.

The scientific program of the congress was prepared according mentioned concepts, and consists the most modern achievements in cardiology and related fields. In this context the motto of the congress “Cardiology of the 21st year of the XXI century — new challenges, new achievements” is as relevant as possible.

Our Society, perhaps, never in its almost sixty-year history has developed so rapidly and has not expanded the scope of its activities on such a large scale as it does now, and I am sure that our congress will once again become one of the most significant events for national healthcare and will contribute to strengthening the credibility of Russian medicine in every possible way.

I wish you success and fruitful work!

President
Russian Society of Cardiology

Evgeny Shlyakhto

The Congress is held in accordance with the Order No. 1387 of the Ministry of Health of the Russian Federation on December 28, 2020 “On approval of the Plan of scientific and practical meetings of the Ministry of Health of the Russian Federation for 2021”.

PROGRAMME COMMITTEE OF THE RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY

Chairperson of the Programme Committee — Vice-President of the Russian Society of Cardiology, corresponding members of the Russian Academy of Sciences **A.O. Konradi** (Saint-Petersburg)

Secretary general of the Congress — Vice-President of the Russian Society of Cardiology, corresponding members of the Russian Academy of Sciences **G.P. Arutyunov** (Moscow)

Programme Committee:

Abugov S.A. (Moscow)
Averkov O.V. (Moscow)
Areeb Ф.Т. (Moscow)
Ageev R.S. (Moscow)
Alekyan B.G. (Moscow)
Arutyunov G.P. (Moscow)
Baranova E.I. (Saint-Petersburg)
Barbarash O.L. (Kemerovo)
Belenkov Yu. N. (Moscow)
Bogachev-Prokofiev A.V. (Novosibirsk)
Boytsov S.A. (Moscow)
Bokeria L.A. (Moscow)
Boldueva S.A. (Saint-Petersburg)
Vasyuk Yu.A. (Moscow)
Villevalde S.V. (Saint-Petersburg)
Galagudza M.M. (Saint-Petersburg)
Galyvich A.S. (Kazan)
Gapon L.I. (Tyumen)
Gafarov V.V. (Novosibirsk)
Gendlin G.E. (Moscow)
Glezer M.G. (Moscow)
Golitsyn S.P. (Moscow)
Golukhova E.Z. (Moscow)
Gordeev I.G. (Moscow)
Gordeev M.L. (Saint-Petersburg)
Grinshtein Yu.I. (Krasnoyarsk)
Demin A.A. (Novosibirsk)
Dzemeshevich S.L. (Moscow)
Drapkina O.M. (Moscow)

Duplyakov D.V. (Samara)
Ezhov M.V. (Moscow)
Zaklyazminskaya E.V. (Moscow)
Zateyschikov D.A. (Moscow)
Zemtsovskiy E.V. (Saint-Petersburg)
Zyryanov S.K. (Moscow)
Imaev T.E. (Moscow)
Kavteladze Z.A. (Moscow)
Kapustina A.V. (Moscow)
Karpenko A.A. (Novosibirsk)
Karpov R.S. (Tomsk)
Karpov Yu.A. (Moscow)
Koziolova N.A. (Perm)
Kozlov B.N. (Tomsk)
Kontsevaya A.V. (Moscow)
Kosmacheva E.D. (Krasnodar)
Kostareva A.A. (Saint-Petersburg)
Kotovskaya Yu.V. (Moscow)
Kuznetsov V.A. (Tyumen)
Kukharchuk V.V. (Moscow)
Lebedev D.S. (Saint-Petersburg)
Libis R.A. (Orenburg)
Lishmanov Yu.B. (Tomsk)
Lopatin Yu.M. (Volgograd)
Mareev V.Yu. (Moscow)
Marskeplishvili S.T. (Moscow)
Mitrofanova L.B. (Saint-Petersburg)
Mikhailov E.N. (Saint-Petersburg)
Mikhin V.P. (Kursk)
Moiseeva O.M. (Saint-Petersburg)

Nebieridze D.V. (Moscow)
Nedogoda S.V. (Volgograd)
Nikulina S.Yu. (Krasnoyarsk)
Oganov R.G. (Moscow)
Orlova Ya.A. (Moscow)
Pavlyukova E.N. (Tomsk)
Paleev F.N. (Moscow)
Panchenko E.P. (Moscow)
Pervunina T.M. (Saint-Petersburg)
Pogosova N.V. (Moscow)
Podzolkov V.I. (Moscow)
Pozdnyakov Yu.M. (Moscow)
Popov S.V. (Tomsk)
Poteshkina N.G. (Moscow)
Puzyrev V.P. (Tomsk)
Revishvili A.Sh. (Moscow)
Rotar O.P. (Saint-Petersburg)
Ryzhkova D.V. (Saint-Petersburg)
Saidova M.A. (Moscow)
Samko A.N. (Moscow)
Skibitskiy V.V. (Krasnodar)
Smilenskiy A.V. (Moscow)

Tarlovskaya E.I. (Nizhny Novgorod)
Tereschenko S.N. (Moscow)
Ternovoy S.K. (Moscow)
Tkachuk V.A. (Moscow)
Trufanov G.E. (Saint-Petersburg)
Fokin V.A. (Saint-Petersburg)
Fomin I.V. (Nizhny Novgorod)
Tsaregorodtsev D.A. (Moscow)
Chazova I.E. (Moscow)
Charchyan E.R. (Moscow)
Chernyavskiy A.M. (Novosibirsk)
Chesnikova A.I. (Rostov-on-Don)
Chumakova G.A. (Barnaul)
Shalnova S.A. (Moscow)
Shkolnikova M.A. (Moscow)
Shlyak S.V. (Rostov-on-Don)
Shulman V.A. (Krasnoyarsk)
Shumakov D.V. (Moscow)
Yavelov I.S. (Moscow)
Yakovlev A.N. (Saint-Petersburg)
Yakushin S.S. (Ryazan)

GENERAL INFORMATION

The Organizing Committee invites you to take part in the work of the Russian National Congress of Cardiology, which will be held in Saint-Petersburg on October 21-23, 2021.

CONGRESS VENUE

EXPOFORUM Convention and Exhibition Center
(196140, Saint-Petersburg, 64 Peterburgskoe highway).


HOW TO GET THERE

By car

5 min from the Pulkovo Airport
 5 min from the ring road
 15 min from the Moskovskaya Metro station

Points:

turn from Pulkovskoe highway to the left into the tunnel to the town of Pushkin further riding according to the map



By the hotel transfer

Check the bus schedule with the official accommodation partner of the Congress participants Конгресса

MIR INTERNATIONAL Travel Company — congress@mirint.ru
Tel. +7 (812) 315 56 92, +7 (812) 312 06 40

RSC AWARD COMMITTEE 2021

Shlyakhto E.V. (Saint-Petersburg) — chairperson

Boytsov S.A. (Moscow), **Galyavich A.S.** (Kazan), **Duplyakov D.V.** (Samara),
Karpov R.S. (Tomsk), **Koziolova N.A.** (Perm), **Konradi A.O.** (Saint-Petersburg)

COMMITTEE OF THE YOUNG SCIENTISTS CONTEST

Duplyakov D.V. (Samara), **Villevalde S.V.** (Saint-Petersburg), **Galagudza M.M.** (Saint-Petersburg),
Grinshtein Yu.I. (Krasnoyarsk), **Kontsevaya A.V.** (Moscow),
Mayanskaya S.D. (Kazan), **Melekhov A.V.** (Moscow), **Mikhailov E.N.** (Saint-Petersburg),
Nikulina S.Yu. (Krasnoyarsk), **Osipova I.V.** (Barnaul), **Sumin A.N.** (Kemerovo),
Khaisheva L.A. (Rostov-on-Don)

SECRETARIAT OF THE CONGRESS PROGRAMME COMMITTEE

Nedoshivin A.O. (Saint-Petersburg), **Ratova L.G.** (Saint-Petersburg),
Tanicheva A.A. (Saint-Petersburg), **Chumak I.B.** (Saint-Petersburg)

OFFICIAL EVENTS OF THE CONGRESS

October 21st — 11:00-12:30

Opening Ceremony of the Congress.

Awarding of the winners of the competition for young scientists and laureates of the awards of the Russian Society of Cardiology. Конференция

October 22nd — 17:15-18:30

Assembly of the Russian Society of Cardiology

October 23rd — 15:30-17:00

Closing Plenary Session.

Venue for official events of the Congress: Plenary Hall (1st floor).

Scientific Sessions will be held

October, 21 from 09:00 to 19:00

October, 22-23 from 09:00 to 17:00

All lecture halls are located on the 1st, 2nd and 3rd floors of the Congress Center:

FLOOR 1

Halls №1 (E8-E9), №2 (E7), №3 (D1), №4 (D2), №5 (D3), №6 (D4) and Plenary Hall.

FLOOR 2

Halls №7 (B1), №8 (B2), №9 (B6-B8), №13 (F200)

FLOOR 3


Halls №10 (A1-A3), №11 (A4-A5), №12 (A8-A9).

E-posters are placed at the exhibition area (1st floor).


FLOOR 1



FLOOR 2



FLOOR 3



AN EXHIBITION of medicines, diagnostic and therapeutic equipment, modern information technologies, medical specialized publications will be presented daily on the 1st floor of the Congress Center (Passage and zone E).

Exhibition opening hours

October, 21 — 08:00-19:00

October, 22-23 — 08:00-17:00

Congress registration

October, 21-22 — 07:30-17:30

October, 23 — 08:00-13:30

Entrance to the Congress Center (Passage).

REGISTRATION of the Congress participants is carried out online on the website of the Russian Society of Cardiology www.scardio.ru until October 13, 2021. After October 13th registration is only possible at the Congress venue.

For safety and health reasons, please register online!

Admission to all meetings and the exhibition is free; it is carried out by badges, which are issued (free of charge) to registered participants!

Those participants who registered on the website of the Society www.scardio.ru and paid for the materials of the Congress will be able to receive the participant's bag and badge in the registration area at a separate counter.

Those registered on the website of the Society www.scardio.ru will be able to receive a badge in the registration area.

SIMULTANEOUS TRANSLATION

The official language of the Congress is Russian. Simultaneous translation will be organized during all plenary sessions, as well as international sessions and symposia with the participation of foreign lecturers.

WI-FI

You can use free Wi-Fi at the Congress Center: Expoforum-Free.

It is prohibited to use mobile phones during sessions!

Organizing Committee room

The organizing committee room is located in the exhibition area (1st floor, zone E).

ONLINE SPEAKING ROOM

The online speaking room is located on the 2nd floor of the Congress Center (entrance from the Passage side).

SMOKING

The Russian Society of Cardiology actively promotes a healthy lifestyle and smoking cessation as a serious risk factor for cardiovascular diseases. The organizing committee strongly recommends that all participants withhold smoking during the Congress. **Контрпекча**

NOTE!

Please pay attention to the fact that in accordance with Russian legislation and anti-terrorist law enforcement measures, as well as measures to prevent the spread of the new coronavirus infection COVID-19, there will be a security post at the entrance to the Congress Center and you will need to go through the frame. Temperature will be measured remotely for each participant.

Protective masks and hand sanitizers will be available at the reception and in the lounges.

Take care of yourself and your health!

09:00–10:30

PLENARY HALL

**PLENARY SESSION
HEART FAILURE — NEW PARADIGM OF THE XXI
CENTURY**

On-line broadcasting/ Simultaneous translation

Chairpersons: Sitnikova M.Yu. (Saint-Petersburg), **Skibitsky V.V.** (Krasnodar)

- **Villevalde S.V.** (Saint-Petersburg). Clinical diagnosis of the type of heart failure. How not to be mistaken with a patient profile?
- **Bax J.** (the Netherlands). Imaging in heart failure with preserved LVEF.
- **Coats A.** (UK). Novel approaches to improving functional capacity in Heart Failure.
- **Christodoulides T.** (Cyprus). Mechanisms and management of diuretic resistance.
- **Lopatin Yu.M.** (Volgograd). Wide range of drugs for the treatment of CHF. How to create a personalized treatment therapy.

09:00–10:30

CONFERENCE HALL №1 (E8-E9)

**SATELLITE SYMPOSIUM
MYOCARDIAL INFARCTION 2021
(IN MEMORY M.Y. RUDA)**

(supported by Sanofi, CME credits are not accrued)

Chairpersons: Staroverov I. (Moscow), **Barbarash O.** (Kemerovo)

- **Barbarash O.** (Kemerovo). Acute coronary syndrome without ST segment elevation
- **Averkov O.** (Moscow). Myocardial infarction with ST segment elevation
- **Yavelov I.** (Moscow). Key changes in clinical guidelines in Russia and in the world.
- **Shakhnovich R.** (Moscow). "Aspirin-free" strategy: P2Y12 inhibitor monotherapy in secondary prevention post MI.

09:00–10:30

CONFERENCE HALL №2 (E7)

**SATELLITE SYMPOSIUM
A DECADE SAVING NVAF PATIENT LIVES!**

(supported by Pfizer, CME credits are not accrued)

Chairperson: Ageev F. (Moscow)

- **Mareev V.** (Moscow). How the standards of management of patients with AF have changed since the emergence of POAC.
- **Ostroumova O.** (Moscow). Aristotle trial 10th year anniversary. Lessons and results.
- **Duplyakov D.** (Samara). Life-changing Science: DOAC and NVAF.
- **Ageev F.** (Moscow). A real-life AF patient at the doctor's appointment: putting theory into practice.

09:00–10:30

CONFERENCE HALL №3 (D1)

**SATELLITE SYMPOSIUM
2021: WHAT'S NEW IN THE DIAGNOSIS AND
TREATMENT OF HFREF?**

(joint symposium of the Russian Society of Cardiology and AstraZeneca, CME credits are not accrued. Symposium is held within the joint project on the chronic heart failure)

Chairpersons: Shlyakhto E. (Saint-Petersburg)

- **Lopatin Y.** (Volgograd). SGLT-2i in the treatment of HFREF: why have they become the fundamental therapy?
- **Glezer M.** (Moscow). Practical issues of prescribing basic therapy for HFREF.
- **Nedogoda S.** (Volgograd). The value of the standards and medical care quality assessing criteria for a practical physician.

09:00–10:30

CONFERENCE HALL №4 (D2)

**SATELLITE SYMPOSIUM
TIME TO CHANGE THE PARADIGM OF
DYSLIPIDEMIA TREATMENT**

(supported by Novartis, CME credits are not accrued)

Chairpersons: Voevoda M. (Moscow), **Ezhov M.**

- **Voevoda M.** (Moscow). Major trends in lipidology.
- **Ezhov M.** Implementation of federal clinical guidelines on lipid metabolism disorders in practical health care.
- **Sergienko I.** (Moscow). Problems in Routing Dyslipidemic Patients
- **Gurevich V.** (Saint-Petersburg). Organization of lipid service in the region. Barriers and ways to overcome.

09:00–10:30

CONFERENCE HALL №5 (D3)

**SATELLITE SYMPOSIUM
PAH: LET THE EXPERTS SPEAK**

(supported by Johnson & Johnson, CME credits are not accrued)

Chairpersons: Avdeev S. (Moscow)

- **Gorbachevsky S.** (Moscow). The importance of invasive assessment of haemodynamics in patients with PAH.
- **Goncharova N.** (Saint-Petersburg). Possibilities of non-invasive methods in diagnostics and risk assessment.
- **Moiseeva O.** (Saint-Petersburg). Starting combination therapy — future or reality?
- **Tsareva N.** (Moscow). Continuous combination therapy as the main therapy strategy today.
- **Martyniuk T.** (Moscow). Drugs of the prostacyclin pathway as a component of dual combination therapy.
- **Shmalts A.** (Moscow). Expert consensus on the use of drugs in the prostacyclin pathway.

09:00–10:30

CONFERENCE HALL №6 (D4)

**SATELLITE SYMPOSIUM
POST-COVID-19 SYNDROME AND
CARDIOVASCULAR DISEASE. A HIDDEN THREAT
OR FALSE FEARS?**

(supported by Merck, CME credits are not accrued)

Chairpersons: Kobalava Z. (Moscow)

- **Konradi A.** (Saint-Petersburg). Features of cardiovascular disease in patients with post-covid syndrome
- **Nedogoda S.** (Volgograd). How to help a patient with cardiac consequences of COVID-19.
- **Ostromova O.** (Moscow). Patients with uncontrolled blood pressure and heart rate after COVID-19.

09:00–10:30

CONFERENCE HALL №7 (B1)

**SATELLITE SYMPOSIUM
THEORY AND PRACTICE IN CLINICAL
APPROACHES: WHAT ARE THE CONTRADICTIONS
AND WHERE IS THE COMPROMISE?**

(supported by Abbott, CME credits are not accrued)

Chairpersons: Orlova Ya. (Moscow)

- **Gurevich V.** (Saint-Petersburg). Expert discussion: “Personalized approach vs clinical guidelines in the treatment of patients with arterial hypertension”, «The importance of adherence to clinical guidelines in the treatment of arterial hypertension».
- **Novikova T.** (Saint-Petersburg). Expert discussion: “Personalized approach vs clinical guidelines in the treatment of patients with arterial hypertension”, Why it is necessary to take into account the personal experience in the treatment of arterial hypertension”.
- **Orlova Y.** (Moscow) Contradictions in scientific studies and many years of experience in the treatment: what should a practitioner do?
- **Tarasov A.** (Moscow). Modern view on the pathogenetic treatment of cardiac arrhythmias

09:00–10:30

CONFERENCE HALL №8 (B2)

**SATELLITE SYMPOSIUM
EXPERT DIALOGUES: NEW OPPORTUNITIES
FOR REDUCING CARDIOVASCULAR RISK IN
PATIENTS WITH DYSLIPIDEMIA. PROSPECTS FOR
COMBINATION THERAPY**

(supported by Abbott, CME credits are not accrued)

Chairperson: Arutiunov G. (Moscow)

- **Catapano A.** (Italy). Modern approaches to the treatment of dyslipidemia.
- **Alieva A.** (Saint-Petersburg). Residual risk and hypertriglyceridemia — approaches to correction.
- **Arutiunov G.** (Moscow). Expert`s discussion «Similarities and differences in the correction of dyslipidemia among doctors from different countries».
- **Mareev V.** (Moscow). The evolution of dyslipidemia treatment: from total cholesterol to combination therapy.

09:00–10:30

CONFERENCE HALL №9 (B6-B8)

**SYMPOSIUM
REHABILITATION OF CARDIAC PATIENTS: SPECIAL
GROUPS AND SPECIAL PANDEMIC CONDITIONS**

Chairpersons: Aronov D. (Moscow), **Bubnova M.** (Moscow)

- **Aronov D.** (Moscow). Rehabilitation of patients with IV functional class ischemic heart disease.
- **Bubnova M.** (Moscow), **Lyamina N.** (Moscow), **Ivanova G.** (Moscow). Rehabilitation of cardiac patients with COVID-19. Consensus of Russian societies.
- **Shugurova I.** (Saint-Petersburg), **Goryunova A.** (Saint-Petersburg), **Demchenko E.** (Saint-Petersburg), **Zobenko I.** (Saint-Petersburg), **Misura O.** (Saint-Petersburg), **Pavlenko A.** (Saint-Petersburg). Features of the second stage of rehabilitation of patients with cardiovascular diseases after COVID-19
- **Golovenkin S.** (Krasnoyarsk), **Nikulina S.** (Krasnoyarsk), **Ustyugov S.** (Krasnoyarsk). Arranging rehabilitation of patients with acute coronary syndrome in the Krasnoyarsk region. Special working features in pandemic conditions 2020-2021.

09:00–10:30

CONFERENCE HALL №10 (A1-A3)
**SATELLITE SYMPOSIUM
HOW TO INCREASE THE PATIENT'S ADHERENCE
TO TREATMENT? MODERN METHODS OF RAPID
AND RELIABLE DIAGNOSIS OF CARDIAC DISEASES
AND VARIOUS ASPECTS OF IMPROVING THE
AVAILABILITY OF MEDICAL CARE**

(supported by Roche, CME credits are not accrued)

Chairperson: Provatorov S. (Moscow)

- **Provatorov S.** (Moscow). Best practices in organizing clinical diagnostic units to improve the efficiency of the healthcare system and patient adherence to therapy.
- **Iltuga O.** (Saint-Petersburg). Anticoagulant therapy and methods of its control, digital assistant for doctor and patient.
- **Vinogradova N.G.** (Nizhny Novgorod). Patient-oriented model of providing medical care to patients with chronic cardiac diseases. Patient: Living with a Prosthetic Heart Valve
- Questions and answers.

09:00–10:30

CONFERENCE HALL №11 (A4-A5)
**SYMPOSIUM
RUSSIAN TRANSPLANT SOCIETY SYMPOSIUM**
Chairpersons: Shevchenko A. (Moscow), **Gautier S.** (Moscow), **Chernyavskiy A.** (Novosibirsk)

- **Shevchenko A.** (Moscow), **Gautier S.** (Moscow). 35 years' experience of heart transplantation in Russia: achievements and prospects.
- **Doronin D.** (Novosibirsk), **Chernyavskiy A.** (Novosibirsk), **Fomichev A.** (Novosibirsk). Expanding the heart donor pool by revising the critical ischemia time.
- **Sakhovsky S.** (Moscow). Interventional coronary correction after heart transplantation.

- **Koloskova N.** (Moscow), **Akopov G.** (Moscow), **Poptsov V.** (Moscow), **Shevchenko A.** (Moscow). Pediatric heart transplantation.
- **Stavenchuk T.** (Krasnodar), **Porhanov V.** (Krasnodar), **Kosmacheva E.** (Krasnodar). Follow-up of cardiac recipients.
- **Velikiy D.** (Moscow). MicroRNAs and proteomic biomarkers in heart transplant recipients: biological role and diagnostic efficacy.

09:00–10:30

CONFERENCE HALL №12 (A8-A9)
**SECTION SESSION
ACUTE CARDIOLOGY**
Chairpersons: Abdullaev A.A. (Makhachkala), **Cherevatiy G.G.** (Kaluga)

- **Medvedeva E.A., Gelis L.G., Polonetsky O.L., Kolyadko M.G., Lazareva I.V.** (Minsk, Belarus). Independent predictors of myocardial infarction and cardiovascular mortality in patients with unstable angina pectoris and coronary stenting over a seven-year follow-up period.
- **Chumachenko N.V., Tatarintseva Z.G., Kosmacheva E.D.** (Krasnodar). Features of the clinical and laboratory data of patients with COVID-19 who underwent emergency coronary artery bypass grafting.
- **Kononov S.K., Soloviev O.V.** (Kirov). Clinical features and outcomes in patients with pulmonary embolism and previous COVID-19 infection.
- **Solovieva M.V., Boldueva S.A.** (Saint-Petersburg). Preexisting atrial fibrillation as a predictor of a worse prognosis in patients with myocardial infarction.
- **Frolov A.A., Pochinka I.G., Mukhin A.S., Sharabrin E.G.** (Nizhny Novgorod). Predicting the development of the phenomenon of coronary microvascular obstruction ("no-reflow") during percutaneous coronary interventions in patients with myocardial infarction using an artificial neural network.
- **Morozova D.S., Nezhdanov K.S., Eliseeva O.O., Zateishchikov D.A., Minushkina L.O., Serebriyskiy I.I., Shakhidzhanov S.S., Protsenko D.N., Vasilyeva E Yu., Ataulakhanov F.I., Rumyantsev A.G.** (Moscow). Differences in risk factors in patients with arterial and venous thrombosis hospitalized with COVID-19.

09:00–10:30

CONFERENCE HALL №13 (F200)

**REPORTS OF THE WINNERS OF THE YOUNG
SCIENTISTS AWARD**

Jury: **Villevalde S.V.** (Saint-Petersburg), **Galagudza M.M.** (Saint-Petersburg), **Greenstein Yu.I.** (Krasnoyarsk), **Duplyakov D.V.** (Samara), **Kontsevaya A.V.** (Moscow), **Mayanskaya S.D.** (Kazan), **Melekhov A.V.** (Moscow), **Mikhailov E.N.** (Saint-Petersburg), **Nikulina S.Yu.** (Krasnoyarsk), **Osipova I.V.** (Barnaul), **Sumin A.N.** (Kemerovo), **Khaisheva L.A.** (Rostov-on-Don).

- **Kopyeva K.V.** (Tomsk). Endothelial dysfunction as a pathogenetic mechanism for the development of anthracycline-induced cardiotoxicity.
- **Kazantsev A.N.** (Saint-Petersburg). The first multicenter Russian study to study the results of selective use and deliberate refusal to use a temporary shunt during carotid endarterectomy.
- **Khanova M.Yu.** (Kemerovo). Cellular, biodegradable small diameter vascular prosthesis.
- **Berdibekov B.Sh.** (Moscow). The predictive role of quantitative assessment of fibrosis using magnetic resonance imaging in non-coronary ventricular arrhythmias.
- **Krivkina E.O.** (Kemerovo). Results of preclinical tests of biodegradable vascular prostheses with atrombogenic drug eluting on a model of large laboratory animals.
- **Vorobyova D.A.** (Tomsk). Interrelation of indicators of prothrombotic activity and myocardial perfusion in patients with myocardial infarction without coronary artery obstruction.

09:00–10:30

ONLINE HALL №1

**SYMPOSIUM
DIGITAL CARDIOLOGY**

Chairpersons: **Kopylov P.** (Moscow)

- **Kozlenok A.** (Saint-Petersburg), **Kurapeev D.** (Saint-Petersburg). Centralized system for storing and processing of ultrasound data. The first results.
- **Pogosova N.** (Moscow). Remote support for patients with arterial hypertension in social networks: results and new perspectives
- **Matskeplishvili S.** (Moscow). Information technologies in biomedicine — the experience of the Moscow university.
- **Koylov P.** (Moscow), **Gognieva D.** (Moscow), **Sagirova Z.** (Moscow), **Chomakhidze P.** (Moscow), **Kuznetsova N.** (Moscow). Diagnostic of arterial hypertension and heart failure by single-lead electrocardiography with photoplethysmography function.
- **Omboni S.** (Italy). Digital health and new frontiers in hypertension management.

09:00–10:30

ONLINE HALL №2

**SATELLITE SYMPOSIUM
MODERN APPROACHES AIMED AT IMPROVING
THE EFFICIENCY OF THE CARDIOLOGICAL
SERVICE**

(supported by Philips, CME credits are not accrued)

Chairperson: **Lensu A.** (Moscow)

- **Lensu A.** (Moscow). An overview of Philips integrated solutions to improve the efficiency of cardiac care from clinic to region.
- **Anisimov S.** (Moscow). Fractional blood flow reserve is a modern answer to the complex questions of patients with coronary heart disease.
- **Smirnov M.** (Moscow). Modern possibilities of computed tomography in cardiology.
- **Gonchar I.** (Moscow). The patient's journey through the prism of the architectural, clinical and business concepts of the medical center. Practical case.

11:00–12:30

PLENARY HALL

**PLENARY SESSION
OPENING CEREMONY OF THE CONGRESS**

On-line broadcasting/ Simultaneous translation

Chairpersons: **Shlyakhto E.V.** (Saint-Petersburg), **Pinto F.** (Portugal).

- **Pinto F.** (Portugal). The global burden of cardiovascular disease: the role of WHF.
- **Shlyakhto E.V. (St. Petersburg).** Cardiology of 21 of the XXI century — new challenges, new achievements.
- **Awarding of the winners of the Young Scientists Contest.**
- **RSC 2021 Award Ceremony.**

13:30–15:00

PLENARY HALL

**SATELLITE SYMPOSIUM
THE LIFE STORY OF ONE PATIENT. LOOKING
THROUGH TIME**

(supported by KRKA, CME credits are not accrued)

On-line broadcasting/ Simultaneous translation

Chairpersons: **Shlyakhto E.** (Saint-Petersburg)

- **Shlyakhto E.** (Saint-Petersburg). Arterial hypertension and dyslipidemia in patients of different age groups.
- **Nedoshivin A.** (Saint-Petersburg). 18, therapy for young patients with hypertension and dyslipidemia
- **Mareev V.** (Moscow). 20 years later, or how to control blood pressure and lipid levels using 1 tablet
- **Tkacheva O.** (Moscow). History of lost time. Therapy of hypertension and DLP as viewed by a gerontologist

13:30–15:00

CONFERENCE HALL №1 (E8-E9)

**SATELLITE SYMPOSIUM
ON THE WAY TO THE GOALS OF LIPID-LOWERING
THERAPY IN 2021. WHAT IS THERE IN DOCTORS
ARSENAL?**

(supported by Sanofi)

Chairpersons: **Drapkina O.** (Moscow)

- **Ezhov M.** (Moscow). Seeing the goal choosing means to achieve.
- **Yakovlev A.** (Saint-Petersburg). Patient after ACS with LDL 3,0 mmoll: choice of therapy.
- **Sergienko I.** (Moscow). Multi-level approach: patients history depends on each step.
- **Alieva A.** (Saint-Petersburg). The sooner the better concept — the way of implementation. A patient with genetically determined lipid metabolism disorders.

13:30–15:00

CONFERENCE HALL №2 (E7)

**SATELLITE SYMPOSIUM
SOLVING COMPLEX CLINICAL ISSUES IN THE
MANAGEMENT OF PATIENTS WITH ATRIAL
FIBRILLATION**

(supported by Bayer, CME credits are not accrued)

Chairpersons: **Zvartau N.** (Saint-Petersburg), **Villevalde S.** (Saint-Petersburg)

- **Shubik I.** (Saint-Petersburg). What do current guidelines for management of patients with AF say?
- **Villevalde S.** (Saint-Petersburg). Stroke protection in elderly patients with AF and a high bleeding risk
- **Gilyarevskiy S.** (Moscow). Ensuring adherence to life-saving therapy.
- **Bakulina N.** (Saint-Petersburg). Managing bleeding risks in patients taking DOAC
- **Koziolova N.** (Perm). Create nephroprotection for a patient with AF and type 2 diabetes mellitus.
- **Yakovlev A.** (Saint-Petersburg). Preventing cardiovascular complications in patients with AF

13:30–15:00

CONFERENCE HALL №3 (D1)

**SATELLITE SYMPOSIUM
ISGLT2 AND HF: WHAT THE GUIDELINES AND
CLINICAL PRACTICE SAY**

(supported by Boehringer Ingelheim, CME credits are not accrued)

Chairpersons: Lopatin Y. (Volgograd)

- **Nedogoda S.** (Volgograd). Implementing research data into real clinical practice: how to close the gap?
- **Arutyunov G.** (Moscow). EMPEROR-Reduced study: key findings and lessons learned.
- **Javed B.** (USA). International recommendations and new approaches to the therapy of CHF/NPF.

13:30–15:00

CONFERENCE HALL №4 (D2)

**SATELLITE SYMPOSIUM
ASK AN EXPERT. NON-RANDOM CLINICAL CASES
OF PATIENTS WITH CAD**

(supported by Servier, CME credits are not accrued)

Chairpersons: Glezer M. (Moscow), Ageev F. (Moscow)

- **Glezer M.** (Moscow). Patient with stable angina.
- **Ageev F.** (Moscow). Patient with CAD and IM in anamnesis.
- **Yakushin S.** (Ryazan). Patient with IHD and CHF.
- **Nifontov E.** (Saint-Petersburg). Patient with an acute heart attack.

13:30–15:00

CONFERENCE HALL №5 (D3)

**SATELLITE SYMPOSIUM
PAIN POINTS MANAGEMENT OF A PATIENT WITH
CARDIOVASCULAR DISEASE — 2021**

(supported by Teva, CME credits are not accrued)

Chairpersons: Belenkov Y. (Moscow)

- **Privalova E.** (Moscow), **Orlova Y.** (Moscow), **Belenkov Y.** (Moscow). Panel discussion of experts.

13:30–15:00

CONFERENCE HALL №6 (D4)

**SATELLITE SYMPOSIUM
ACS PATIENT JOURNEY 2021: FROM DIAGNOSTICS
TO REGULAR FOLLOW-UP**

(supported by AstraZeneca, CME credits are not accrued)

Chairpersons: Boytsov S. (Moscow)

- **Koziolova N.** (Perm). From diagnosis to the optimal P2Y12-inhibitor — 1 step.
- **Barbarash O.** (Kemerovo). Spotlight on the 2nd year after myocardial infarction.
- **Zhuravleva M.** (Moscow). DAPT impact on CV death rate decrease & KPIs achieving in frames of CVD prevention program.
- **Karpov Y.** (Moscow). To prevent 1st CV event: focus on T2D patients.

13:30–15:00

CONFERENCE HALL №7 (B1)

**SATELLITE SYMPOSIUM
WAYS TO OPTIMIZE HYPERTENSION THERAPY
FOR DIFFERENT GROUPS OF PATIENTS BY
CHOOSING A RATIONAL COMBINATION OF AN
INHIBITOR OF THE RENIN-ANGIOTENSIN SYSTEM
(IRAAS) AND A DIURETIC (D)**

(supported by Stada, CME credits are not accrued)

Chairpersons: Kobalava Z. (Moscow)

- **Konradi A.** (Saint-Petersburg). The place of the iRAAS D combination in the national clinical guidelines of different countries on hypertension. A brief overview of the clinical studies underlying the recommendations.
- **Karpov Y.** (Moscow). Possibilities of optimization of hypertension therapy via adequate control of nighttime blood pressure, using rational combinations of iRAAS + D.
- **Kobalava Z.** (Moscow). The need for a pragmatic clinical trial comparing iRAAS diuretic combinations chlorthalidone, hydrochlorothiazide and indapamide: insufficient evidence base available today.
- **Nedogoda S.** (Volgograd). Diuretic plus iRAAS is no longer a diuretic: the effect of the combination on water-electrolyte, carbohydrate and lipid metabolism.

13:30–15:00

CONFERENCE HALL №8 (B2)

**SATELLITE SYMPOSIUM
THE STRATEGY AND THE TACTIC OF CHOICE FOR
PATIENTS WITH ATRIAL FIBRILLATION. SURGICAL
VS DRUG TREATMENT: PRO CONTRA**

(supported by Olainfarm, CME credits are not accrued)

Chairpersons: Mihaylov E. (Saint-Petersburg)

- **Tarasov A.** (Moscow). Pharmacotherapy of patients with atrial fibrillation
- **Maikov E.** (Moscow). Surgical treatment of patients with atrial fibrillation

13:30–15:00

CONFERENCE HALL №9 (B6-B8)

**SATELLITE SYMPOSIUM
INTERVENTIONAL TECHNOLOGIES IN
CARDIOLOGICAL PATIENTS. HOW, WHEN AND
WHERE TO SEND A PATIENT?**

(supported by Cardiomedics, CME credits are not accrued)

Chairpersons: Davtyan K. (Moscow), **Merkulov E.** (Moscow), **Imaev T.** (Moscow)

- **Davtyan K.** (Moscow). Left atrial appendage occlusion in AF patients. World experience and our own results.
- **Merkulov E.** (Moscow). How to prevent a second stroke in young patients? When a cardiologist must not close his eyes to a problem.
- **Imaev T.** (Moscow). Endovascular treatment of critical aortic stenosis: affordable than it looks.
- **Sviridova A.** (Moscow). Sudden death prevention: endovascular and subcutaneous ICD systems.
- **Sapelnikov O.** (Moscow), **Uskach T.** (Moscow). Cardiac resynchronization and cardiac contractility modulation therapies in CHF patients.

13:30–15:00

CONFERENCE HALL №10 (A1-A3)

**SYMPOSIUM
CHRONIC CORONARY SYNDROME — WHAT'S NEW
IN DIAGNOSIS?**

Chairpersons: **Sumin A.** (Kemerovo), **Duplyakov D.** (Samara), **Bershtein L.** (Saint-Petersburg)

- **Sumin A.** (Kemerovo). Assessment of pre-test and clinical likelihood in the diagnosis of chronic coronary syndrome — what's new?
- **Duplyakov D.** (Samara). MSCT coronary angiography in the diagnosis of chronic coronary syndrome.
- **Bershtein L.** (Saint-Petersburg). Features of diagnostics of microvascular angina. A new look in the light of the results of the ISCHEMIA — CIAO study.
- **Sumin A.** (Kemerovo), **Shcheglova A.** (Kemerovo). Diagnosis of chronic coronary syndrome in real clinical practice: results from the EURECA register.

13:30–15:00

CONFERENCE HALL №11 (A4-A5)

**SYMPOSIUM
CME IN CARDIOLOGY. WHAT AWAITS US IN THE
FUTURE AND WHAT IS IN THE PRESENT?**

Chairpersons: **Shlyk S.** (Rostov-on-Don), **Balkizov Z.** (Moscow), **Drobotya N.** (Rostov-on-Don)

- **Balkizov Z.** (Moscow). Assessment of competencies in cardiology.
- **Drobotya N.** (Rostov-on-Don), **Shlyk S.** (Rostov-on-Don). Features of training and accreditation of cardiologists in the context of the COVID-19 pandemic.
- **Khaisheva L.** (Rostov-on-Don), **Pirozhenko A.** (Ростов-на-Дону). How to increase the survival rate of knowledge in a cardiologist?
- **Ratova L.** (Saint-Petersburg). Modern methods of training cardiologists in the new reality.
- **Nikulina S.** (Krasnoyarsk). Emergencies in cardiology with a robot-simulator.
- **Chernova A.** (Krasnoyarsk). Emergency training in ACS on a simulation dummy.

13:30–15:00

CONFERENCE HALL №12 (A8-A9)

**SECTION SESSION
IMAGING IN CARDIOLOGY, ULTRASOUND AND
CT TECHNOLOGIES**

Chairpersons: **Khludeeva E.A.** (Vladivostok), **Saidova M.A.** (Moscow)

- **Karpova D.V., Simakova M.A., Pishchulov K.A., Moiseeva O.M.** (Saint-Petersburg). The use of computed tomography in assessing the severity of chronic thromboembolic pulmonary hypertension.
- **Ozova M.A., Chomakhidze P.Sh., Poltavskaya M.G., Sedov V.P., Syrkin A.L.** (Moscow). Cardiac risk of surgical treatment of oncological urological pathology.
- **Usov V.Yu.** (Tomsk), **Bobrikova E.E., Chupakhin A.P., Bergen T.A.** (Novosibirsk), **Maksimova AS** (Tomsk), **Khovrin V.V.** (Moscow), **Kobelev E.V., Chernyavsky A.M.** (Novosibirsk). Mathematical modeling of the mechanoelastic qualities of the aortic wall in advanced atherosclerosis and the formation of aneurysms, according to dynamic ECG-synchronized MR-aortography.
- **Stepanova A.I., Radovan N.F., Alekhin M.N.** (Moscow). Evaluation of territorial longitudinal systolic deformity of the left ventricle in patients with coronary heart disease by stress echocardiography using the treadmill test.
- **Yaroslavskaya E.I., Krinochkin D.V., Shirokov N.E., Gulyaeva E.P., Mamarina A.V., Osokina N.A., Gorbatenko E.A., Petelina T.I.** (Tyumen). Echocardiographic indicators in patients with COVID-19 pneumonia three months after discharge from the hospital.
- **Omarov Yu.A., Veselova T.N., Shakhnovich R.M., Sukhinina T.S., Zhukova N.S., Merkulova I.N., Pevzner D.V., Atabaeva L.S., Shitov V N., Saidova M.A., Arutyunyan G.K., Mironov V.M., Merkulov E.V., Samko A.N., Ternovoy S.K., Staroverov I.I.** (Moscow). Diagnostic capabilities of myocardial perfusion computed tomography with transesophageal pacing as a stress test in patients with acute coronary syndrome.

13:30–15:00

CONFERENCE HALL №13 (F200)

SYMPOSIUM
A PATIENT WITH AORTIC AND/OR MITRAL VALVE
STENOSIS. HOW CAN GUIDELINES HELP US?

Chairpersons: **Irtuyuga O.** (Saint-Petersburg), **Gordeev M.** (Saint-Petersburg), **Barbuhatti K.** (Krasnodar), **Bogachev-Prokophiev A.** (Novosibirsk)

- **Irtuyuga O.** (Saint-Petersburg). Aortic stenosis. The cardiologist's view.
- **Gordeev M.** (Saint-Petersburg). Aortic stenosis. The surgeon's view.
- **Barbuhatti K.** (Krasnodar), **Babeshko S.** (Krasnodar). Mitral stenosis. The surgeon's view.
- **Belan I.** (Krasnodar), **Gavrilchik D.** (Krasnodar). Mitral stenosis. The cardiologist's view.
- **Bogachev Prokophiev A.** (Novosibirsk). Endovascular methods for the treatment of stenosis of the aortic and mitral valves.

13:30–15:00

ONLINE HALL №1

SATELLITE SYMPOSIUM
ELECTROLYTE DEFICIENCY IN THE AGE OF
COVID-19

(supported by Gedeon Richter, CME credits are not accrued)

Chairpersons: **Ostroumova O.** (Moscow)

- **Ostroumova O.** (Moscow), **Pereverzev A.** (Moscow). Medically-induced electrolyte deficiency: reasons and consequences.
- **Ostroumova O.** (Moscow), **Kochetkov A.** (Moscow). Electrolyte deficiency diagnostics and treatment among multimorbid patients.
- **Ostroumova O.** (Moscow), **Ebzeeva E.** (Moscow). Electrolyte deficiency associated with post-COVID asthenic syndrome.

13:30–15:00

ONLINE HALL №2

SYMPOSIUM
CARDIOGENETIC FORUM: HYPERTROPHIC
CARDIOMYOPATHY — 2021
 Simultaneous translation

Chairpersons: **Zateyshchikov D.** (Moscow), **Moiseeva O.** (Saint-Petersburg), **Pantazis A.** (UK)

- **Chumakova O.** (Moscow). HCM genetics for the cardiologist.
- **Kostareva A.** (Saint-Petersburg). Variety of clinical guidelines — what is applicable for the Russia.
- **Pantazis A.** (UK). Hypertrophic Cardiomyopathy: are we looking at the dawn of the disease-modifying management?
- **Arad M.** (Israel). Rare phenocopies of the HCM.
- **Sonicheva N.** (Moscow). Myocardial hypertrophy as an indication for molecular genetic testing — clinical case.

15:30–17:00

PLENARY HALL

PLENARY SESSION
NEW TRIALS AND REAL CLINICAL PRACTICE

On-line broadcasting/ Simultaneous translation

Chairpersons: **Achenbach S.** (Germany), **Nedoshivin A.O.** (Saint-Petersburg)

- **Achenbach S. (Germany).** Is CT the better coronary angiogram? Visions for the future.
- **Weidinger F.** (Austria). Myocardial Revascularization: how recent studies may impact our practice.
- **Catapano A. (Italy).** Lipid Lowering Therapies: Present and Future.
- **Lüscher T.F.** (UK). The spectrum of acute coronary syndromes from STEMI to MINOCA to Takotsubo syndrome and beyond.
- **Catapano A.** (Italy). Lipid lowering therapies: present and future.

15:30–17:00

CONFERENCE HALL №2 (E7)
**SATELLITE SYMPOSIUM
MANAGEMENT OF A CARDIAC PATIENT WITH
DIABETES MELLITUS: QUESTIONS AND ANSWERS**

(supported by Bayer, CME credits are not accrued)

Chairpersons: Belenkov Y. (Moscow)

- **Nedogoda S.** (Volgograd). Diabetes mellitus: more than a risk factor
- **Lopatin Y.** (Volgograd). Management of coronary artery disease in a patient with diabetes mellitus.
- **Belenkov Y.** (Moscow). Discussion. Why is it necessary to remember about atherothrombosis in patient with diabetes?
- **Arutyunov G.** (Moscow). AF in patient with diabetes: more than arrhythmia
- **Nifontov E.** (Saint-Petersburg). Key steps in protecting renal function in patient with AF and diabetes
- **Belenkov Y.** (Moscow). Discussion. Why is it important to remember about coronary risks in a patient with diabetes and AF?

15:30–17:00

CONFERENCE HALL №2 (E7)
**SATELLITE SYMPOSIUM
MANAGEMENT OF A CARDIAC PATIENT WITH
DIABETES MELLITUS: QUESTIONS AND ANSWERS**

(supported by Bayer, CME credits are not accrued)

Chairpersons: Belenkov Y. (Moscow)

- **Nedogoda S.** (Volgograd). Diabetes mellitus: more than a risk factor
- **Lopatin Y.** (Volgograd). Management of coronary artery disease in a patient with diabetes mellitus.
- **Belenkov Y.** (Moscow). Discussion. Why is it necessary to remember about atherothrombosis in patient with diabetes?
- **Arutyunov G.** (Moscow). AF in patient with diabetes: more than arrhythmia

- **Nifontov E.** (Saint-Petersburg). Key steps in protecting renal function in patient with AF and diabetes
- **Belenkov Y.** (Moscow). Discussion. Why is it important to remember about coronary risks in a patient with diabetes and AF?

15:30–17:00

CONFERENCE HALL №3 (D1)
**SATELLITE SYMPOSIUM
STATIN GALAXY, 10 YEARS LATER: JUPITER IS
CLOSER, TARGETS LOWER AND THE RIGHT DOSES
ARE NOT PRESTIGIOUS**

(supported by AstraZeneca, CME credits are not accrued)

Chairpersons: Susekov A. (Moscow)

- **Khadzegova A.** (Moscow). Primary prevention — it is important not to miss the moment
- **Susekov A.** (Moscow). Statins in secondary prevention: 30 years in 30 minutes.
- **Kobalava Z.** (Moscow). Statin safety: myths and reality.

15:30–17:00

CONFERENCE HALL №4 (D2)
**SATELLITE SYMPOSIUM
WOMAN'S "BROKEN HEART" FIND AND
NEUTRALIZE THE CULPRIT IN TIME**

(supported by Servier, CME credits are not accrued)

Chairpersons: Karpov Y. (Moscow и MO)

- **Karpov Y.** (Moscow и MO). Introduction: About women, hypertension and more
- **Lekareva T.** (Saint-Petersburg), **Rotar O.** (Saint-Petersburg). Woman's broken heart 1. Pressure spikes: is the man to blame or is it a hormone deficiency?
- **Ageev F.** (Moscow), **Esayan A.** (Moscow). Woman's broken heart 2. Is the burden of risk factors to blame?
- **Karpov Y.** (Moscow). Conclusion: Who is to blame and what to do?

15:30–17:00

CONFERENCE HALL №5 (D3)

**SATELLITE SYMPOSIUM
CHRONIC HEART FAILURE DIAGNOSTICS AND
MANAGEMENT TECHNOLOGIES — GLOBAL
EXPERIENCE**

(supported by Green Leaf Pharma, CME credits are not accrued)

Simultaneous translation

Chairpersons: **Matskeplishvili S.** (Moscow)

- **Matskeplishvili S.** (Moscow). Introduction
- **Matskeplishvili S.** (Moscow). Prediction of HF decompensation — from difficulties to simple things
- **Grinshtein Y.** (Krasnoyarsk). HF prevalence, therapy principles and causes of decompensation. Is it possible to escape negative outcomes?
- **Bensimhon D.** (USA). Using ReDS Pro Across the HF Continuum of Care: An Outcomes-Focused Approach.
- **Barbarash O.** (Kemerovo). HF decompensation: adequate patient monitoring for adequate treatment.
- **Lopatin Y.** (Volgograd). What new ESC/HFA 2021 Guidelines say about overloaded patients management?

15:30–17:00

CONFERENCE HALL №6 (D4)

**SATELLITE SYMPOSIUM
NEW ERA IN TREATMENT OF CARDIAC
AMYLOIDOSIS**

(supported by Pfizer, CME credits are not accrued)

Chairpersons: **Galyavich A.** (Kazan)

- **Andreev D.** (Moscow). The importance of early diagnosis for timely treatment of patients with ATTR-CM.
- **Adasheva T.** (Moscow). Diagnostic algorithm for ATTR amyloidosis. Digest of international guidelines and recommendations.

- **Zhirov I.** (Moscow). Red flags of transthyretin amyloid cardiomyopathy.
- **Galyavich A.** (Kazan). Practical aspects of the organization of diagnosis and treatment of amyloidosis of the heart in the region.
- **Moiseeva O.** (Saint-Petersburg). Transthyretin amyloidosis: from maintenance to disease — modifying therapy.

15:30–17:00

CONFERENCE HALL №7 (B1)

**SATELLITE SYMPOSIUM
TROMBOLYTIC THERAPY OF ACUTE CORONARY
SYNDROME WITH ST SEGMENT ELEVATION.
EXPERT OPINION**

(supported by Supragen, CME credits are not accrued)

Chairpersons: **Tereschenko S.** (Moscow), **Duplyakov D.** (Samara)

- **Tereschenko S.** (Moscow). Thrombolytic therapy as part of a pharmacoinvasive strategy against primary PCI.
- **Duplyakov D.** (Samara). Reperfusion therapy in the Russian clinical guidelines on acute coronary syndrome with ST segment elevation 2020.
- **Shakhnovich R.** (Moscow). Time to reperfusion as a major cause of increased risk of cardiogenic shock.
- **Oleynikov V.** (Пенза), **Kulucin A.** (Пенза). What can be changed to reduce mortality in patients with acute coronary syndrome with ST segment elevation.

15:30–17:00

CONFERENCE HALL №8 (B2)

**SATELLITE SYMPOSIUM
INTERNATIONAL EXPERIENCE IN THE TREATMENT
OF ARTERIAL HYPERTENSION**

(supported by Abbott, CME credits are not accrued)

Chairpersons: **Konradi A.** (Saint-Petersburg)

- **Schlaich M.** (Australia). Modern solution for blood pressure control.
- **Konradi A.** (Saint-Petersburg). Russian guidelines on arterial hypertension: national features and choice of therapy.
- **Baranova E.** (Saint-Petersburg). Problems and their solutions in the treatment of arterial hypertension in patients with metabolic disorders.
- **Nedogoda S.** (Volgograd). What can Physiotens give in combination?

15:30–17:00

CONFERENCE HALL №9 (B6-B8)

**SATELLITE SYMPOSIUM
WORKSHOP”HIGHLIGHTS OF HOLTER-ECG
INTERPRETATION IN PM-PATIENTS. A LOT
OF ALGORITHMS. A BORDER OF NORM AND
PATOLOGY”**

(supported by Cardiomedics, CME credits are not accrued)

Chairpersons: **Malkina T.** (Moscow), **Kostyleva O.** (Moscow)

*Workshop is not broadcasting online

15:30–17:00

CONFERENCE HALL №10 (A1-A3)

**SATELLITE SYMPOSIUM
FACE-TO-FACE WITH A PATIENT WITH
DYSLIPIDEMIA: A STRATEGY FOR ACHIEVING
LDL-C TARGETS**

(supported by Amgen, CME credits are not accrued)

Chairpersons: **Meshkov A.** (Moscow), **Sergienko I.** (Moscow), **Voznuk I.** (Moscow)

- **Meshkov A.** (Moscow). Strategy for achieving target LDL-C in patients without cardiovascular events: primary prevention.
- **Sergienko I.** (Moscow). Strategy for achieving the target level of LDL-C in patients with ACS: secondary prevention.
- **Voznuk I.** (Moscow). Strategy for achieving the target level of LDL-C in patients after stroke: secondary prevention.
- **Lebedeva A.** (Moscow). Experience of providing PCSK9 patients with hyperlipidemia in Moscow.
- **Cherepyansky M.** (Syktyvkar). Experience of using PCSK9 inhibitors in the acute period of ischemic stroke in the Komi Republic.
- **Skibitsky V.** (Krasnodar). Patient with hyperlipidemia: misconceptions, mistakes and questions — how to optimize therapy in real clinical practice.

15:30–17:00

CONFERENCE HALL №11 (A4-A5)

SYMPOSIUM
“SHAKE BUT NOT MIX”: DIFFERENT TARGETS
AND COMBINATIONS IN THE TREATMENT OF
DYSLIPIDEMIA

Chairpersons: **Zateyshchikov D.** (Moscow), **Kuznetsova T.** (Petrozavodsk), **Ezhov M.** (Moscow)

- **Korneva V.** (Петрозаводск). LDL — Battle Arsenal Optimization.
- **Konstantinov V.** (Saint-Petersburg). Triglycerides — Choosing the Trajectory of the Impact.
- **Ezhov M.** (Moscow). Lipoprotein a — mission feasible.
- **Sonicheva N.** (Spain). Pharmacogenetics — space weapons.

15:30–17:00

CONFERENCE HALL №12 (A8-A9)

SECTION SESSION
BASIC RESEARCH

Chairpersons: **Kostareva A.A.** (Saint-Petersburg), **Zharskiy S.L.** (Khabarovsk)

- **Smolyakova E.V., Skoblov Yu.S., Skoblova N.A., Masenko V.P., Zykov K.A.** (Moscow). Correlation between laboratory parameters and characteristics of β -adrenergic receptors in patients with cardiorespiratory pathology.
- **Sinitskiy M.Yu., Tsepokina A.V., Kutikhin A.G., Shishkova D.K., Ponasenko A.V.** (Kemerovo). Changes in the gene expression profile of primary arterial endothelial cells cultured under genotoxic stress.
- **Orlov P.S., Ivanoshchuk D.E., Nesterets A.A., Ivanova A.A., Kuznetsov A.A., Maksimova S.V., Maksimov V.N.** (Novosibirsk). The first results of sequencing of a new generation of men with borderline lengthening of the QT interval from the Novosibirsk population.
- **Shakhtshneider E.V., Ivanoshchuk D.E., Orlov P.S., Timoshchenko O.V., Voevoda M.I.** (Novosibirsk). Rare variants in lipid metabolism genes in patients with familial

hypercholesterolemia phenotype without mutations in genes LDLR, APOB, PCSK9, LDLRAP1.

- **Erdman V.V., Nasibullin T.R., Timasheva Ya.R., Tuktarova I.A.** (Ufa). The role of polymorphic markers of antioxidant system and inflammation genes in the development of cardiovascular diseases and survival.
- **Krivosheeva E.N., Kropacheva E.S., Titaeva E.V., Dobrovolsky A.B., Panchenko E.P.** (Moscow). Growth differentiation factor-15 (GDF-15), plasminogen activator inhibitor-1 (PAI-1) and the risk of cardiovascular complications in patients with atrial fibrillation after elective percutaneous coronary intervention.

15:30–17:00

CONFERENCE HALL №13 (F200)

SYMPOSIUM
DIFFERENT VIEWS ON ONE PROBLEM:
WHAT WE SHOULDN'T FORGET WHEN TREATING
A HEART FAILURE PATIENT

Chairpersons: **Gilarevsky S.** (Moscow), **Villevalde S.** (Saint-Petersburg)

- **Vinogradova N.** (Nizhny Novgorod). Quadruple therapy in HFrEF: how to navigate in the order of the drugs prescription and titration?
- **Soloveva A.** (Saint-Petersburg). HF with mildly reduced and preserved EF: treatment opportunities
- **Mareev Y.** (Moscow). Other treatment strategies of HF in case of symptoms persistence
- **Baymukanov A.** (Moscow). Interventional therapy of arrhythmias in HF
- **Kruchinova S.** (Krasnodar). Heart transplant: do not miss the moment
- **Galenko V.** (Saint-Petersburg). Physical rehabilitation in HF

15:30–17:00

ONLINE HALL №1

**SYMPOSIUM
PATIENT WITH AORTIC AND/OR MITRAL VALVE
REGURGITATION. HOW CAN GUIDELINES HELP
US?**
Chairpersons: Gordeev M. (Saint-Petersburg), **Bokeria L.** (Moscow)

- **Irtyuga O.** (Saint-Petersburg). Aortic regurgitation. The cardiologist's view
- **Uspenskiy V.** (Saint-Petersburg). Aortic regurgitation. The surgeon's view.
- **Gendlin G.** (Moscow). Mitral regurgitation. The cardiologist's view

15:30–17:00

ONLINE HALL №2

**SYMPOSIUM
CARDIOGENETIC FORUM: CARDIOLOGY OF
CHILDREN AND ADULTS — THE WAY TOWARDS**

Simultaneous translation

Chairpersons: Basargina E. (Moscow), **Arad M.** (Israel)

- **Ferro G.** (Spain). Genetics of dilated cardiomyopathy.
- **Basargina E.** (Moscow). The problem of continuity in cardiology — the viewpoint of a pediatric cardiologist.
- **Harlap M.** (Moscow). The problem of continuity in cardiology the viewpoint of an adult cardiologist.
- **Arad M.** (Israel). Danone disease — from genomics to the international registry.
- **Sonicheva N.** (Moscow). Genomic approach in determining the cause of long QT syndrome: a clinical case.

17:30–19:00

PLENARY HALL

**PLENARY SESSION
EPIDEMIOLOGY AND PREVENTION IN THE ERA OF
PANDEMIC**

On-line broadcasting/ Simultaneous translation

Chairpersons: Shlyakhto E.V. (Saint-Petersburg), **Boytsov S.A.** (Moscow)

- **Drapkina O.M.** (Moscow). Epidemiological monitoring as a control mechanism for measures aimed at reducing morbidity and mortality from cardiovascular diseases.
- **Gaita D.** (Romania). The ESC atlas of cardiology — much more than bearing the CVD burden.
- **Boytsov S.A.** (Moscow). Infection and cardiovascular diseases.
- **Kontsevaya A.V.** (Moscow). Economic aspects of the impact of the COVID-19 pandemic on cardiovascular morbidity and mortality.

17:30–19:00

CONFERENCE HALL №1 (E8-E9)

**SYMPOSIUM
SESSION 3D: DETAILED, DYNAMIC, PROVABLE.
EFFECT OF CARDIOVASCULAR DRUGS ON
MORBIDITY AND SEVERITY OF COURSE OF
COVID-19.**
Chairpersons: Arutyunov G. (Moscow)

- **Arutiunov A.** (Moscow). Parenteral anticoagulants.
- **Orlova Y.** (Moscow). Oral anticoagulants.
- **Petrova M.** (Krasnoyarsk). Antithrombotic preparations.
- **Kuznetsova T.** (Petrozavodsk). RAAS inhibitors.
- **Chesnikova A.** (Rostov-on-Don). Statines.
- **Tarlovskaia E.** (Nizhny Novgorod). Colchicine.
- **Koziova N.** (Perm). Antihyperglycemic drugs.
- **Grigorieva N.** (Nizhny Novgorod). Beta blockers.
- **Kuznetsova T.** (Petrozavodsk). Angiotensin receptors and neprilysin inhibitors.

17:30–19:00

CONFERENCE HALL №2 (E7)

**WORKSHOP
15 RARE ECG WITH RHYTHM AND MYOCARDIAL
CONDUCTION DISORDERS**

Chairpersons: **Lebedeva V.** (Saint-Petersburg), **Neminuschy N.** (Moscow), **Artemenko S.** (Novosibirsk)

- **Lebedev D.** (Tyumen). ECG with narrow QRS tachycardia.
- **Gorev M.** (Moscow). 3 ECG with wide QRS tachycardia.
- **Mareev Y.** (Moscow). 3 rare ECG in cardiology practice.
- **Lyubimtseva T.** (Saint-Petersburg). 3 difficult ECG in patient with pacemaker.
- **Garkina S.** (Saint-Petersburg). 3 unusual ECG in usual arrhythmias.

17:30–19:00

CONFERENCE HALL №3 (D1)

**SYMPOSIUM
MEDICAL AND SOCIAL EXPERTISE FOR DISEASES
OF CARDIOVASCULAR SYSTEM**

Chairpersons: **Yakushin S.** (Ryazan), **Puzin S.** (Moscow)

- **Yakushin S.** (Ryazan), **Lygina E.** (Ryazan). Disability recognition rules at the turn of decade 2020-2021. Discussion questions
- **Zotova L.** (Ryazan). Referral of the patients with cardiological pathology for medical and social expertise. The past and the present
- **Puzin S.** (Moscow), **Chandirli S.** (Moscow), **Potapov V.** (Moscow). Epidemiology, medical social and clinical expert characteristics of disability due to coronary heart disease
- **Lyalina I.** (Moscow), **Odebaeva R.** (Moscow), **Shurgaya M.** (Moscow), **Puzin S.** (Moscow). Essential hypertension as a pathology causing disability due to circulatory diseases of the adult population

17:30–19:00

CONFERENCE HALL №4 (D2)

**SYMPOSIUM
CARDIOVASCULAR RISKS OF PROFESSIONAL AND
POPULAR SPORTS**

Chairpersons: **Smolensky A.** (Moscow), **Mikhailova A.** (Moscow), **Bondarev S.** (Moscow), **Badtieva V.** (Moscow)

- **Smolensky A.** (Moscow). Cerebrovascular risks in athletes in a period remote from sports
- **Mikhailova A.** (Moscow). Risk factors for cardiovascular disease in sports veterans
- **Bondarev S.** (Moscow). The influence of physical activity on the cardiac prognosis of former athletes
- **Balykova L.** (Saransk). Stiffness of the vascular wall in young athletes — pupils of youth sports schools
- **Badtieva V.** (Moscow). Is it possible to prevent sudden cardiac death during organizing medical support for mass sports events?

17:30–19:00

CONFERENCE HALL №5 (D3)

**SYMPOSIUM
INFLAMMATORY HEART DISEASE: CURRENT
TREATMENT PROBLEMS**

Chairpersons: **Moiseeva O.** (Saint-Petersburg), **Paleev F.** (Moscow)

- **Moiseeva O.** (Saint-Petersburg), **Mayrina S.** (Saint-Petersburg), **Titov V.** (Saint-Petersburg). Steroids therapy in myocarditis: pro and contra.
- **Paleev F.** (Moscow). Myocarditis in the context of Russian clinical guidelines: development prospects.
- **Blagova O.** (Moscow), **Kogan E.** (Moscow). Myocarditis during a pandemic: diagnosis and approaches to the treatment of postcoid myocarditis, especially the management of dockyard patients.
- **Blagova O.** (Moscow), **Lutokhina J.** (Moscow). Giant cell myocarditis: clinical and morphological diagnosis, features, prognosis.

17:30–19:00

CONFERENCE HALL №6 (D4)

**SYMPOSIUM
COMORBIDITIES IN CHF — NEW AND OLD
PROBLEMS**

Chairpersons: **Kostenko V.** (Saint-Petersburg), **Kobalava Z.** (Moscow), **Sitnikova M.** (Saint-Petersburg)

- **Kostenko V.** (Saint-Petersburg). Characteristics of the infectious status in patients with acute decompensated chronic heart failure and its impact on the yearly prognosis
- **Dunaeva N.** (Saint-Petersburg). HIV- and HAART-associated cardiomyopathy
- **Kobalava Z.** (Moscow). Hyperuricemia in a CHF patient: is there any sense in correction?
- **Sitnikova M.** (Saint-Petersburg). Gynecomastia in CHF: causes, reversibility, therapy options
- **Sviryaev Y.** (Saint-Petersburg). Sleep-related breathing disorders in patients with CHF, approaches to management

17:30–19:00

CONFERENCE HALL №7 (B1)

**SYMPOSIUM
OBSERVATIONAL AND RANDOMIZED TRIALS IN
CARDIOLOGY**

Chairpersons: **Gendlin G.** (Moscow), **Galyavich A.** (Kazan)

- **Gilyarevskii S.** (Москва). Confounding factors in “real clinical practice” research as a source of systemic errors
- **Mareev Y.** (Moscow). The practical value of observational studies. Can statistical methods bring observational studies closer to RCTs?
- **Mareev V.** (Moscow). How size, choice of endpoint, and duration of RCTs can influence outcome
- **Yavelov I.** (Moscow). Are all RCTs Equally Beneficial: How Clinical and Statistical Significance Differs?

17:30–19:00

CONFERENCE HALL №8 (B2)

**TRAINING WORKSHOP
A PATIENT WITH DYSPNEA AND CHEST PAIN —
EXPERT OPINION**

Chairpersons: **Lopatin Y.** (Volgograd), **Zykov K.** (Moscow), **Nedogoda S.** (Volgograd)

- **Ratova L.** (Saint-Petersburg). A patient with dyspnea and chest pain at an outpatient appointment — what can and should be done?
- **Lopatin Y.** (Volgograd). Cardiac causes of dyspnea and chest pain.
- **Zykov K.** (Moscow). Respiratory causes of dyspnea and chest pain.
- **Nedogoda S.** (Volgograd). And if it is psychosomatics?

17:30–19:00

CONFERENCE HALL №9 (B6-B8)

**SYMPOSIUM
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES
IN SIBERIA: DEVELOPMENT PROSPECTS
FROM TRADITIONAL RISK FACTORS
TO NON-TRADITIONAL**

Chairpersons: **Gafarov V.** (Novosibirsk), **Repin A.** (Tomsk)

- **Ragino Y.** (Novosibirsk). Ischemic heart disease and its risk factors in a young Siberian population
- **Repkina T.** (Barnaul), **Osipova I.** (Барнаул), **Aleksentseva A.** (Барнаул). Five-year dynamics of the leading CVD risk factors in residents of the Altai Region
- **Panov D., Gromova E., Gafarova A.** (Novosibirsk). Social support and the risk of developing arterial hypertension in the population in Russia/Siberia (WHO program MONICA-psychosocial).
- **Akimov A., Kayumova M., Gakova E., Akimova E.** (Tyumen). Age trends of non-conventional risk factors for cardiovascular diseases in a mid-urbanized city of Western Siberia: prevalence, relationships, gender aspect.
- **Tsygankova O.** (Novosibirsk). Dynamics of cardiovascular risk factors after covidinfection in patients with type 2 diabetes, depending on the nature of antihyperglycemic therapy.

17:30–19:00

CONFERENCE HALL №10 (A1-A3)

THE BATTLE OF SCHOLARS

Presenter: Matskeplishvili S.T.

Jury: Garkina S.V., Dzhioeva O.N., Duplyakov D.V., Kozik V.A.,
Kosmacheva E.D., Lyapina I.N., Tatarsky R.B., Chernova A.A.,
Chulkov V S., Chumakova G.A.

Finalists:

Pulsars — 2021 team (Krasnoyarsk, Moscow, Saint-Petersburg, Tomsk)

Cardio troops: new blood (Krasnodar) — 2020 team

Quachlandia (Saint-Petersburg) — 2020 team

Kuzbass Hearts (Kemerovo) — 2020 team

17:30–19:00

CONFERENCE HALL №11 (A4-A5)

SYMPOSIUM

MODERN PROBLEMS OF ACUTE CARDIOLOGY

Chairpersons: Ryabov V. (Tomsk), Barbarash O. (Kemerovo)

- **Shtegman O.** (Krasnoyarsk). Acute decompensation of chronic heart failure and renal dysfunction. Diagnosis and treatment.
- **Vyshlov E.** (Tomsk). Problems of diagnosis of stress-induced cardiomyopathy.
- **Kashtalap V.** (Kemerovo). Diagnosis and treatment of type 2 myocardial infarction.
- **Ryabov V.** (Tomsk). Myocardial pathology as part of the MINOCA problem.
- **Barbarash O.** (Kemerovo). Atrial fibrillation in patients with myocardial infarction. How to properly assess and manage the risks of adverse outcomes?

17:30–19:00

CONFERENCE HALL №12 (A8-A9)

SECTION SESSION

EPIDEMIOLOGY, PREVENTION AND REHABILITATION. SPORTS MEDICINE

Chairpersons: Mikhin V.P. (Kursk), Nedbaikin A.M. (Bryansk)

- **Shapkina M.Yu., Ryabikov A.N., Mazdorova E.V., Avdeeva E.M., Shcherbakova L.V.** (Novosibirsk), **Bobak M., Pikhart H.** (London, UK), **Malyutina S.K.** (Novosibirsk). 13-year dynamics of the frequency of atrial fibrillation in the Russian population sample (Novosibirsk).
- **Zairova A.R., Rogoza A.N., Oshchepkova E.V., Yarovaya E.B., Kutsenko V.A., Shalnova S.A.** (Moscow), **Trubacheva I.A., Serebryakova V.N., Kaveshnikov V.S.** (Tomsk), **Boytsov S.A.** (Moscow). The value of the arterial stiffness index CAVI according to volumetric sphygmography for predicting cardiovascular events in the adult population of the Russian Federation (based on the ESSE-RF study in Tomsk).
- **Mukaneeva D.K., Kontsevaya A.V., Karamnova N.S., Balanova Yu.A., Drapkina O.M.** (Moscow). Evaluation of the impact of adherence to WHO recommendations on salt intake on cardiovascular mortality in Russia.
- **Yaroslavskaya E.I., Krinochkin D.V., Shirokov N.E., Gulyaeva E.P., Antipina N.S., Mamarina A.V., Sevoyan A.M., Gorbatenko E.A., Petelina T.I.** (Tyumen). Parameters of the cardiovascular profile of patients with COVID-19 pneumonia, three months after discharge from the hospital, depending on the initial severity of the lung injury.
- **Okrugin S.A., Lvova A.B., Repin A.N.** (Tomsk). WHO program — Registry of acute myocardial infarction — in Tomsk. 35-year follow-up data.
- **Tsygankova D.P., Bazdyrev E.D., Indukaeva E.V., Artamonova G.V., Barbarash O.L.** (Kemerovo). Nutritional stereotypes of Siberian residents: contribution to the development of risk factors for cardiovascular pathology.

17:30–19:00

CONFERENCE HALL №13 (F200)

**SYMPOSIUM
CONGENITAL HEART DISEASE — A LIFELONG
PROBLEM (CARDIAC ASPECTS AND DIAGNOSIS)****Chairpersons:** **Lezhnev A.** (Moscow), **Stovpyuk O.** (Saint-Petersburg),
Avramenko A. (Samara)

- **Stovpyuk O.** (Saint-Petersburg). Patient with congenital heart disease, difficulties in transition from pediatrics to adult medicine
- **Karev E.** (Saint-Petersburg). Cardiologist, attention! Meeting an adult patient with CHD
- **Avramenko A.** (Samara). Congenital heart defects: a variety of anatomical forms and a sectional approach to diagnosis
- **Korolev D.** (Moscow region). Computed and magnetic resonance imaging of congenital heart disease
- **Kuzmina-Krutetskaya S.** (Saint-Petersburg). Ultrasound diagnostics of congenital heart defects

17:30–19:00

ONLINE HALL №1

**SYMPOSIUM
COMORBIDITY IN CARDIOLOGY:
PRIORITIES OF SECONDARY PREVENTION****Chairpersons:** **Sayganov S.** (Saint-Petersburg), **Mamedov M.**
(Moscow)

- **Nikiforov V.** (Saint-Petersburg). Elderly and senile patients with cardiovascular pathology: emphasis on comorbidity
- **Mamedov M.** (Moscow). Comorbidity in cardiology: from concept to prevention
- **Kanorsky S.** (Krasnodar). Comorbid patient with heart failure
- **Arabidze G.** (Moscow). Modern possibilities of effective therapy of patients with resistant arterial hypertension, progressive atherosclerosis and type 2 diabetes mellitus from the standpoint of evidence-based medicine

09:00–10:30

PLENARY HALL

**PLENARY SESSION
NEW STUDIES AND REAL CLINICAL PRACTICE**

On-line broadcasting/ Simultaneous translation

Chairpersons: Baranova E.I. (Saint-Petersburg), **Vasyuk Yu. M.** (Moscow)

- **Anker S.** (Germany). News on Heart Failure from ESC Congress 2021: Focus on the new Guidelines and EMPEROR-Preserved.
- **Itchhaporia D. (USA).** Women and heart disease- emerging risk factors.
- **Priori S. (Italy).** Long QT syndrome: new risk stratification schema and new therapies on the horizon.
- **Vardas P. (Greece).** Precision medicine in Cardiology. From the Genome to the smart watch.

09:00–10:30

CONFERENCE HALL №1 (E8-E9)

**SATELLITE SYMPOSIUM
TARGET ADDRESS FOR CLINICIANS: HOW TO
CONTROL RISK FACTORS WITH AN IRON FIST?
(WITH INTERACTIVE QUESTIONNAIRE AND
CHAIRMANSHIP OF E.V. SHLYAKHTO).**

(supported by Sanofi, CME credits are not accrued)

Chairpersons: Shlyakhto E. (Saint-Petersburg)

- **Kobalava Z.** (Moscow). In the vanguard of antihypertensive therapy: how to reach goal BP numbers in most patients with HTN?
- **Arutyunov G.** (Moscow). When statins are not enough: ways to intensify lipid-lowering therapy in 2021
- **Mkrtumyan A.** (Moscow). Glycemic control in patient with CVD: what NON-endocrinologist should know?
- **Nedogoda S.** (Volgograd). Key directions in development of Russian clinical guidelines: how life of clinician will change?

09:00–10:30

CONFERENCE HALL №2 (E7)

**SATELLITE SYMPOSIUM
NEW HORIZONS OF HYPERTENSION THERAPY —
FOCUS ON ARNI CLASS**

(supported by Novartis, CME credits are not accrued)

Chairperson: Konradi A. (Saint-Petersburg)

- **Nedogoda S.** (Moscow). Evolution of clinical guidelines for hypertension: focus on practice
- **Ageev F.** (Moscow). A patient with AH and HF — focus on therapy.
- **Kobalava J.** (Moscow). ARNI — new approach in the treatment of hypertension

09:00–10:30

CONFERENCE HALL №3 (D1)

**SATELLITE SYMPOSIUM
OPPORTUNITIES TO PERSONILIZE
ANTITHROMBOTIC THERAPY IN CAD PATIENTS:
CLINICAL TRIALS, CLINICAL GUIDELINES, REAL
CLINICAL PRACTICE**

(supported by AstraZeneca, CME credits are not accrued)

Chairpersons: Galyavich A. (Kazan)

- **Yavelov I.** (Moscow). Current approaches to ischemic and bleeding risks stratification: what does a cardiologist need to know?
- **Duplyakov D.** (Samara). How to minimize bleeding risks: new evidence and current practice.
- **Shakhnovich R.** (Moscow). One size doesn't fit all: different approaches to antithrombotic therapy in patients with stable CAD.

09:00–10:30

CONFERENCE HALL №4 (D2)
**SATELLITE SYMPOSIUM
MEDICAL CONSULTATION. A PATIENT ON STAGE —
THE HEART AND THE BRAIN ARE UNDER THE RISK
OF HYPERTENSION**

(supported by KRKA, CME credits are not accrued)

Chairpersons: **Boytsov S.** (Moscow)

- **Boytsov S.** (Moscow). Introduction
- **Parfenov V.** (Moscow). Neurologist's opinion
- **Ageev F.** (Moscow). Cardiologist's opinion
- **Boytsov S.** (Moscow), **Ageev F.** (Moscow), **Parfenov V.** (Moscow). Medical consultation. Conclusion.

09:00–10:30

CONFERENCE HALL №5 (D3)
**SATELLITE SYMPOSIUM
HOW TO IMPROVE LIFE PROGNOSIS OF
CAD PATIENT WITH POLYVASCULAR
ATHEROTHROMBOTIC DISEASE?**

(supported by Bayer, CME credits are not accrued)

Chairpersons: **Karpov Y.** (Moscow)

- **Khasanov N.** (Kazan). Polyvascular atherothrombotic disease how to define and what to take into account?
- **Mareev V.** (Moscow). Correlation between the instability of an atherosclerotic plaque and the prognosis of the patient
- **Perepech N.** (Saint-Petersburg). Antithrombotic therapy of patient with polyvascular atherothrombotic disease perspective of cardiologist
- **Arakelyan V.** (Moscow). Antithrombotic therapy of patient with polyvascular atherothrombotic disease perspective of vascular surgeon
- **Koziolova N.** (Perm). Patient with MFA: Difficult questions of antithrombotic therapy choice — simple answers for the practitioner.

09:00–10:30

CONFERENCE HALL №6 (D4)
**SYMPOSIUM
THE ARRHYTHMOLOGIST COMPETENCY.
FOR WHOM AND FOR WHAT**

Chairpersons: **Nedoshivin A.** (Saint-Petersburg), **Popov S.** (Tomsk), **Golukhova E.** (Moscow)

- **Golukhova E.** (Moscow). The arrhythmologist's competency. Opinion of the Healthcare ministry chief specialist.
- **Yashin S.** (Saint-Petersburg). Assessment of the level of competencies: the role of the professional community.
- **Zenin S.** (Novosibirsk). Chief cardiology specialist of the region. A new conception.
- **Gilyarov M.** (Moscow). The profile section of RSC: opportunities and responsibilities.

09:00–10:30

CONFERENCE HALL №7 (B1)
**SATELLITE SYMPOSIUM
PAH: SYNERGY OF EXPERIENCE AND
KNOWLEDGE**

(supported by Johnson & Johnson, CME credits are not accrued)

Chairpersons: **Martynyuk T.** (Moscow), **Lebedeva A.** (Moscow), **Ivanov S.** (Novosibirsk)

- **Lebedeva A.** (Moscow). Treatment of PAH: focus on combined therapy.
- **Ivanov S.** (Novosibirsk). Specificities of therapy escalation through the prism of the register of E.Meshalkin National Medical Research Center.
- **Filippov E.** (Ryazan). Implementation of modern methods of PAH therapy in the regional PAH center.
- **Lyapina I.** (Kemerovo). Experience with the use of drugs acting on the prostacyclin pathway in patients with PAH.

09:00–10:30

CONFERENCE HALL №8 (B2)

**SATELLITE SYMPOSIUM
PANDEMIC OF ATHEROSCLEROSIS: HOW TO
ACHIEVE GOALS?**

(supported by Egis, CME credits are not accrued)

Chairpersons: Ezhov M. (Moscow)

- **Ezhov M.** (Moscow). Pandemic of atherosclerosis in Russia.
- **Sergienko I.** (Moscow). How to achieve ambitious goals? New opportunities
- **Gurevich V.** (Saint-Petersburg). Atherosclerosis: everything you wanted to know, but were afraid to ask.

09:00–10:30

CONFERENCE HALL №9 (B6-B8)

**SYMPOSIUM
RUSSIAN EPIDEMIOLOGY OF CVD.
MYTH OR REALITY: AN INVITATION
TO DISCUSSION**
Chairpersons: Yakushin S. (Ryazan), **Shalnova S.** (Moscow)

- **Karamnova N.** (Moscow). Nutritional factors as a forecast? Research results ESSE-RF.
- **Rotar O.** (Saint-Petersburg), **Boyarinova M.** (Saint-Petersburg). An obese patient in the population — is there a chance to stay metabolically healthy years later.
- **Kuntsevich A.** (Novosibirsk), **Simonova G.** (Novosibirsk). The predictive value of the carbohydrate component of nutrition for premature mortality of the Siberian population.
- **Balanova Y.** (Moscow). Reducing salt consumption in Russia is an important aspect of CVD prevention.
- **Shalnova S.** (Moscow). RSC section Cardiovascular Epidemiology and Prevention Development prospects. Discussion.

09:00–10:30

CONFERENCE HALL №10 (A1-A3)

**SYMPOSIUM
CARDIOVASCULAR RISKS
IN NON-CARDIOLOGICAL PATIENTS**
Chairpersons: Fomin I. (Nizhny Novgorod)

- **Chesnikova A.** (Rostov-on-Don). Heart rhythm disorders in patients with heart failure and chronic obstructive pulmonary disease: ways to solve problems.
- **Shaposhnik I.** (Chelyabinsk). Features of lipid metabolism disorders in HIV infection.
- **Ruzanov D.** (Gomel, Belarus). Acute respiratory infection: can cardio-vascular risks be reduced?
- **Nikitin I.** (Moscow). Influenza vaccine prophylaxis as a management element for cardiovascular mortality management.

09:00–10:30

CONFERENCE HALL №11 (A4-A5)

**SATELLITE SYMPOSIUM
EXPRESS ASSESSMENT OF CARDIAC RISK AND
STRESS USING MULTICHANNEL HARDWARE AND
SOFTWARE MONITORING IN ROUTINE PRACTICE**

(supported by Pharma 2030 Educational Center of Innovative Medicine, CME credits are not accrued)

Chairperson: **Khadartsev A.A.** (Tula)

- **Kireev S.S., Naumova E.M.** (Tula). The use of hardware and software systems for monitoring the function of the cardiovascular system in the ICU: a comparative characteristic.
- **Tokarev A.R.** (Tula). Stress tolerance index is a new prognostic marker for development of approach to the treatment of diseases using hardware-software monitoring.
- **R.V. Grachev** (Tula). Integral indicators of the function of the cardiovascular and respiratory systems in health and disease: modern technology of rapid assessment.
- **Kinyasheva N.B.** (Tula). The experience of using the Simona integral monitoring system in the diagnosis of CHF: a comparative assessment.
- **Khadartsev A.A.** (Tula), **Valentinov B.G.** (Moscow). Objectification of the effectiveness of biologically active agents of natural origin using a hardware-software complex for assessing the functional state of the body.

09:00–10:30

CONFERENCE HALL №12 (A8-A9)

**SECTION SESSION
ARTERIAL HYPERTENSION, METABOLIC
SYNDROME, DIABETES MELLITUS**

Chairpersons: **Nechaeva G.I.** (Omsk), **Simonova G.I.** (Novosibirsk)

- **Zyubanova I.V., Falkovskaya A.Yu., Mordovin V.F., Manukyan M.A., Tsoi E.I., Lichikaki V.A., Rebrova T.Yu., Muslimova E.F., Pekarsky S. E.** (Tomsk). Changes in the beta-adrenergic reactivity of erythrocytes after renal denervation as a prognostic factor for the long-term effectiveness of the intervention.
- **Timoshchenko O.V., Stakhneva E.M., Nikitin Yu.P., Simonova G.I., Ragino Yu.I.** (Novosibirsk). New protein Klotho in the blood of men with type 2 diabetes and its association with cardiovascular risk factors.
- **Ionov M.V., Emelyanov I.V., Yudina Yu.S., Panarina S.A., Zverev D.A., Avdonina N.G., Zvartau N.E., Konradi A.O.** (Saint-Petersburg). Long-term results of the use of renal denervation in patients with resistant arterial hypertension: a prospective observational single-center study in one group.
- **Losik D.V., Kozlova S.N. (Saint-Petersburg), Krivosheev Yu.S., Ponomarenko A.V., Ponomarev D.N., Pokushalov E.A. (Novosibirsk), Bolshakova O.O., Zhabina E.S., Lyasnikova E.A., Korelskaya N.A., Trukshina M.A., Tulintseva T.E.** (Saint-Petersburg). Results of a retrospective analysis of the choice of therapy using a medical decision support service in patients with arterial hypertension and atrial fibrillation (INTELLECT).
- **V.P. Podpalov (Vitebsk, Belarus), Ukla A.** (Gomel, Belarus), **Deev A.D.** (Moscow). The sum of the SV1 + RV5-V6 wave amplitudes as a risk factor for the development of arterial hypertension in randomized Belarusian populations.
- **Korolev A.I., Dadaeva V.A., Fedorovich A.A., Gorshkov A.Yu., Omelyanenko K.V., Mikhailova M.A., Drapkina O.M.** (Moscow). Functional state of skin microvessels according to non-invasive research methods in men with newly diagnosed arterial hypertension with low and moderate cardiovascular risk.

09:00–10:30

ONLINE HALL №1

**SYMPOSIUM
USING PERSONIFICATION IN VASCULAR SURGERY:
FOCUS ON THE PATIENT**

Chairpersons: **Alekyan B.** (Moscow), **Kavteladze Z.** (Moscow), **Chernyavskiy M.** (Saint-Petersburg)

- **Chernyavskiy A.** (Novosibirsk). Approaches to the treatment of patients with associated coronary and carotid arteries.
- **Alekyan B.** (Moscow). Carotid artery pathology: indications for surgical treatment, role of open and endovascular surgery.
- **Kavteladze Z.** (Moscow). “Real” hybrid surgery of the lower extremities arteries lesions.
- **Chernyavskiy M.** (Saint-Petersburg). Principles of fast track surgery in treatment patients with aortailiac artery occlusions: Almazov Centre experience.
- **Kolegaev A.** (Moscow). Own experience of treatment patients with critical limb ischemia: from recommendations to ulcers healing.

09:00–10:30

ONLINE HALL №2

**SYMPOSIUM
WEARABLES, ARTIFICIAL INTELLIGENCE —
TECHNOLOGIES OF THE FUTURE IN CARDIOLOGY**

Chairperson: **Tarlovskaia E.** (Nizhny Novgorod)

- **Matskeplishvili S.** (Moscow). Digital Medicine in 2021 — Hopes and Frustrations.
- **Arutiunov A.** (Moscow). Wearable devices — prospects for use in cardiovascular diseases.
- **Kuznetsova T.** (Petrozavodsk). Machine learning methods for assessing cardiovascular risk — current capabilities and real-world experience.
- **Grigoreva N.** (Nizhny Novgorod). Artificial Intelligence in Medicine: Risks and Concerns.

11:00–12:30

PLENARY HALL

**PLENARY SESSION
SMART CLINIC**

On-line broadcasting/ Simultaneous translation

Chairpersons: **Belenkov Yu. N.** (Moscow), **Zvartau N.E.** (Saint-Petersburg).

- **Belenkov Yu.N. (Moscow).** Smart clinic — clinic of the XXI century.
- **Kurapeev D.I. (Saint-Petersburg).** Artificial intelligence as the basis for smart clinic services.
- **Sinitsyn V.E. (Moscow).** Application of artificial intelligence systems in cardiovascular radiology.
- **Pavlov N.A. (Moscow).** Remote monitoring of patients with chronic diseases: opportunities and prospects.
- **Pogosova N.V. (Moscow).** Hybrid cardiac rehabilitation technologies for long-term support of patients with atrial fibrillation after interventional procedures.

11:00–12:30

CONFERENCE HALL №1 (E8-E9)

**SATELLITE SYMPOSIUM
CARDIOMYOPATHY: WHO TO CONSULT, HOW TO
DIAGNOSE AND MONITOR.**

(supported by Sanofi, CME credits are not accrued)

Chairperson: **Moiseev S.V.** (Moscow)

- **Moiseev S.** (Moscow). Left ventricular hypertrophy of unknown origin: 3 simple steps to find a true diagnosis.
- **Kharlap M.** (Moscow). NGS cardio: how to interpret conclusion of genetic test.
- **Senchikhin V.** (Saratov). Possibilities of remote support of patients with cardiac pathology on the example of Fabry disease.

11:00–12:30

CONFERENCE HALL №2 (E7)
**SATELLITE SYMPOSIUM
CONTRIBUTION OF THE THERAPIST AND
CARDIOLOGIST TO ACHIEVING NATIONAL TASK
OF REDUCING MORTALITY FROM DISEASES OF
THE CIRCULATORY SYSTEM**

(supported by Akrikhin, CME credits are not accrued)

Chairperson: Galyavich A.S. (Kazan)

- **Galyavich A.S.** (Kazan). New Opportunities for Risk Factor Management in Patients with Cardiovascular Diseases — A to D Concept.
- **Sitnikova M.** (Saint-Petersburg). Influence of the patient's phenotype on the choice of basic CHF therapy.
- **Zhirov I.** (Moscow). Help to a patient with a sudden increase in blood pressure.

11:00–12:30

CONFERENCE HALL №3 (D1)
**SATELLITE SYMPOSIUM
DOCTORS ASK — EXPERTS ANSWER**

(supported by Servier, CME credits are not accrued)

Chairperson: Karpov Y. (Moscow)

- **Karpov Y.** (Moscow), **Kobalava Z.** (Moscow), **Nedogoda S.** (Volgograd). Discussion.

11:00–12:30

CONFERENCE HALL №4 (D2)
**SATELLITE SYMPOSIUM
DIFFICULT PATIENT IN QUESTIONS AND
ANSWERS: FORMULATING A DIAGNOSIS AND
PRIORITIZING THERAPY**

(supported by Boehringer Ingelheim, CME credits are not accrued)

Chairpersons: Matskeplishvili S. (Moscow)**Baranova E.** (Saint-Petersburg). Questions for a cardiologist: AF and T2DM: the nuances of diagnosis and treatment.**Khasanova D.** (Kazan). Questions to a neurologist: How not to aggravate the clinical diagnosis? And what if the patient had TIA?**Esayan A.** (Saint-Petersburg). Questions to the nephrologist: is CKD a concomitant disease or complication?**Khalimov Y.** (Saint-Petersburg). Questions to the endocrinologist: "Citius, Altius, Fortius! Patient with T2DM and CVD".

11:00–12:30

CONFERENCE HALL №5 (D3)
**SYMPOSIUM
POLYMORBID PATIENTS WITH CARDIOVASCULAR
DISEASES IN THE COVID-19 PANDEMIC ERA:
DATA FROM THE INTERNATIONAL REGISTRY ATIV
SARS-COV-2**
Chairpersons: Arutyunov G. (Moscow)

- **Tarlovskaya E.** (Nizhny Novgorod). Features of the course of a new coronavirus infection in the Eurasian patient population.
- **Arutyunov A.** (Moscow). Anticoagulants, Hormones, Targeted Therapy — not all swans are white.
- **Shaposhnik I.** (Chelyabinsk). Post-COVID-19 syndrome, patient rehabilitation problems.
- **Petrova M.** (Krasnoyarsk). Comparative analysis of patients of the first and second wave of COVID-19.

11:00–12:30

CONFERENCE HALL №6 (D4)
**SATELLITE SYMPOSIUM
STEP BY STEP: HOW TO PROTECT AN ELDERLY
PATIENT WITH AF?**

(supported by Bayer, CME credits are not accrued)

Chairpersons: Boytsov S.A. (Moscow)

- **Gilyarevskiy S.** (Moscow). Simply about complex: how to use the results of observational studies in your daily practice?
- **Mareev V.** (Moscow). Comprehensive protection for elderly patients with AF: what is important to keep in mind when choosing an anticoagulant?
- **Glezer M.** (Moscow). What else can we do for a patient with AF? Coronary risk questions.
- **Koziolova N.** (Perm). Diabetic kidney disease in a patient with AF: how to prevent and avoid the consequences?

11:00–12:30

CONFERENCE HALL №7 (B1)
**SATELLITE SYMPOSIUM
TREATMENT OF STABLE CORONARY ARTERY
DISEASE: PROBABLE AND UNOBLIVIOUS FOR THE
PRACTITIONERS**

(supported by PIK-farma, CME credits are not accrued)

Chairpersons: Nedoshivin A. (Saint-Petersburg), **Barbarash O.** (Kemerovo)

- **Martsevich S.** (Moscow). Anti-ischaemic therapy of stable coronary artery disease. Unconditional and permissible approaches from the standpoint of evidence-based medicine
- **Nedoshivin A.** (Saint-Petersburg). Second-line anti-ischaemic drugs: when, to whom, and why
- **Soboleva G.** (Moscow). Percutaneous coronary intervention: how to prevent 4a type of myocardial infarction.
- **Barbarash O.** (Kemerovo). Preparing a patient for coronary artery bypass grafting. The role of effective drug therapy

11:00–12:30

CONFERENCE HALL №8 (B2)
**SATELLITE SYMPOSIUM
WE KNOW HOW TO TREAT, BUT THE GOALS ARE
NOT ACHIEVED**

(supported by Recordati, CME credits are not accrued)

Chairperson: Konradi A. (Saint-Petersburg)

- **Ezhov M.** (Moscow). What is real clinical practice?
- **Sergienko I.** (Moscow). Patients in the labyrinth of the information field.
- **Konradi A.** (Saint-Petersburg). Many pathological conditions — one patient.
- **Rudina L.** (Moscow). Doctor and patient. I want, I fear, I hope.

11:00–12:30

CONFERENCE HALL №9 (B6-B8)
**SYMPOSIUM
CARDIOGERIATRICS — A NEW ERA
IN CARDIOLOGY**
Chairperson: Tkacheva O. (Moscow)

- **Tkacheva O.** (Moscow). Integration of geriatric principles into management of cardiovascular diseases in older adults
- **Kotovskaya Y.** (Moscow). Arterial hypertension in a geriatric patient: primum non nocere.
- **Villevalde S.** (Saint-Petersburg). Heart failure in older adults: how to avoid mismanagement?
- **Duplyakov D.** (Samara), **Pavlova T.** (Samara), **Duplyakova P.** (Samara). Acute coronary syndrome in patients of 80 years and older: looking for optimal tactics.

11:00–12:30

CONFERENCE HALL №10 (A1-A3)
**SATELLITE SYMPOSIUM
IRON DEFICIENCY IN PATIENTS WITH HEART
FAILURE**

(supported by Vifor, CME credits are not accrued)

Chairperson: Tereshchenko S. (Moscow)

- **Anker S.** (Germany). Ferric carboxymaltose for patients with heart failure. AFFIRM-AHF trial.
- **Zhirov I.** (Moscow). Role of iron preparations in QoL improvement of heart failure patients.
- **Lopatin Y.** (Volgograd). Place of iron medications in guidelines on heart failure.

11:00–12:30

CONFERENCE HALL №11 (A4-A5)
**SYMPOSIUM
COMPLEX ISSUES OF ANTITHROMBOTIC
THERAPY: HOW ARE THEY SOLVED IN 2021?
SYMPOSIUM OF THE NATIONAL SOCIETY FOR
ATHEROTHROMBOSIS**
Chairpersons: Panchenko E. (Moscow), **Yavelov I.** (Moscow)

- **Panchenko E.** (Moscow). Coronary stenting in patients with indications for long-term use of anticoagulants: composition and duration of antithrombotic therapy.
- **Yavelov I.** (Moscow). Antithrombotic therapy in patients with high risk of coronary thrombosis: is it possible to understand the variety of approaches?
- **Komarov A.** (Moscow). Antithrombotic therapy and bleeding: the evolution of views on its significance and prognostic possibilities.

11:00–12:30

CONFERENCE HALL №12 (A8-A9)
**SECTION SESSION
HEART FAILURE/ LEFT VENTRICULAR
DYSFUNCTION**
Chairpersons: Nikitin I.G. (Moscow), **Lipatova T.E.** (Saratov)

- **Talibullin I.V., Lebedeva N.B., Temnikova T.B. (Kemerovo).** Analysis of the register of patients with an implanted cardioverter-defibrillator in the Kemerovo region. clinical and anamnestic data.
- **Podzolkov V.I., Dragomiretskaya N.A., Kucherova Yu.S. (Moscow).** Influence of congestive pneumonia on indicators of CHF biomarkers.
- **Simonenko M.A., Fedotov P.A., Kostomarov A.N., Sazonova Yu.V., Bortsova M.A., Bautin A.E., Marichev A.O., Nikolaev G.V., Gordeev M L., Karpenko M.A., Sitnikova M.Yu. (Saint-Petersburg).** Exclusion of patients with heart failure from the waiting list for heart transplantation: causes and results.
- **Gasparyan A.Zh., Shlevkov N.B., Tarasovsky G.S., Guseva E.V., Shitov V.N., Sharf T.V., Masenko V.P., Stukalova O.V., Skvortsov A A., Golitsyn S.P. (Moscow).** The place of NT-proBNP and SST2 biomarkers in predicting the “response” of patients with chronic heart failure to the use of implantable CPT and MCC devices.
- **Berezikova E.N., Shilov S.N., Popova A.A. (Novosibirsk), Teplyakov A.T., Grakova I.V., Kopyeva K.V. (Tomsk), Pankova I.V. (Novosibirsk).** Cytomegalovirus infection as a factor in the unfavorable course of chronic heart failure of ischemic genesis.
- **Shilov S.N., Berezikova E.N., Popova A.A., Ratushnyak E.T., Samsonova E.N. (Novosibirsk), Teplyakov A.T., Grakova E.V., Kopyeva K.V. (Tomsk).** Pharmacogenetic evaluation of the effectiveness of therapy for anthracycline-induced chronic heart failure.

11:00–12:30

ONLINE HALL №1
**SYMPOSIUM
LIFESTYLE MODIFICATION: EASY TO SAY, BUT
HOW TO DO IT?**
Chairpersons: Rotar O. (Saint-Petersburg), **Kontsevaya A.** (Moscow)

- **Chernova A.** (Krasnoyarsk). Lifestyle modification: what are our real possibilities?
- **Benimetskaya K.** (Novosibirsk). Obesity: is eating less and moving more enough?
- **Derevyanchenko M.** (Volgograd). Why run when you can lie down?
- **Ionin V.** (Saint-Petersburg). Insomnia: a beautiful term with an insidious meaning
- **Kopylova O.** (Moscow). Adherence or addiction — how to move to the light side
- **Benimetskaya K.** (Novosibirsk), **Semenova E.** (Omsk). Lifestyle in congenital connective tissue disorders: if there is a chance to change something?

11:00–12:30

ONLINE HALL №2
**SYMPOSIUM
GENETIC MARKERS IN URGENT CARDIOLOGY —
A MODERN INTERPRETATION OF THEIR MEANING**
Chairpersons: Skorodumova E. (Saint-Petersburg), **Gordienko A.** (Saint-Petersburg), **Kostenko V.** (Saint-Petersburg)

- **Siverina A.** (Saint-Petersburg), **Fedorov A.** (Saint-Petersburg), **Skorodumova E.** (Saint-Petersburg), **Rysev A.** (Saint-Petersburg). Features of the distribution of gene variants responsible for lipid metabolism, nitric oxide synthesis, and pharmacodynamics of antiplatelet drugs in the population of patients with acute coronary syndrome.

- **Gordienko A.** (Saint-Petersburg), **Serdyukov D.** (Saint-Petersburg). Initial atherosclerosis as a stage of development of coronary heart disease. Metabolic and genetic aspects.
- **Skorodumova E.** (Saint-Petersburg), **Kostenko V.** (Saint-Petersburg). Cardiorenal and renocardial syndromes in ACS-stratification of the risk of complications based on genetic factors.
- **Polunina E.** (Astrakhan), **Polunina O.** (Astrakhan), **Prokofieva T.** (Astrakhan), **Voronina L.** (Astrakhan). Effect of endothelial NO-synthase gene polymorphism on the functional state of the endothelium in CHF with preserved left ventricular ejection fraction.
- **Solodun M.** (Ryazan). The possibilities of a personalized approach to the appointment of antiplatelet agents in emergency cardiology.

13:30–15:00

PLENARY HALL
**PLENARY SESSION
JOINT SESSION WITH THE EUROPEAN HEART
JOURNAL: THE YEAR IN CARDIOVASCULAR
MEDICINE**
On-line broadcasting/ Simultaneous translation
Chairpersons: Shlyakhto E.V. (St. Petersburg), **Seferovic P.M.** (Serbia), **Crea F.** (Italy)

- **Lyon A.** (Great Britain). Cardio-oncology.
- **Baranova E.I.** (St. Petersburg). Diabetes and metabolic disorders.
- **Taddei S.** (Italy). Arterial hypertension.
- **Lopatin Yu.M.** (Volgograd). Heart failure.

13:30–15:00

CONFERENCE HALL №1 (E8-E9)
**SATELLITE SYMPOSIUM
PROSPECTS FOR REDUCING RESIDUAL RISKS
AFTER HFREF DECOMPENSATION EVENTS**

(supported by Bayer, CME credits are not accrued)

Chairperson: Kobalava Z. (Moscow)

- **Kobalava Z.** (Moscow). Introduction.
- **Villevalde S.** (Saint-Petersburg). The role of decompensation events in the clinical course of HFREF: the significance of the vulnerable period. Residual risks in the era of contemporary medical therapies.
- **Gilyarevskiy S.** (Moscow). Barriers for improvement of prognosis in patients after HF decompensation events.
- **Kobalava Z.** (Moscow). The role of NO-sGC-cGMP signal pathway in the pathogenesis of heart failure.
- **Lopatin Y.** (Volgograd). The implications of VICTORIA trial results: potential opportunities for optimizing the treatment of vulnerable HF patients.
- **Discussion.**

13:30–15:00

CONFERENCE HALL №2 (E7)
**SATELLITE SYMPOSIUM
POSSIBILITIES OF COMBINED THERAPY OF
DYSLIPIDEMIA IN PATIENTS WITH HIGH AND VERY
HIGH CARDIOVASCULAR RISK**

(supported by Akrikhin, CME credits are not accrued)

Chairpersons: Gurevich V. (Saint-Petersburg)

- **Susekov A.** (Moscow). Ezetimibe: 20 years later. Physiological and clinical aspects of ezetimibe efficacy.
- **Gurevich V.** (Saint-Petersburg). How to use effectively a combination of lipid-lowering drugs in a polymorbid patient.
- **Obrezan A.** (Saint-Petersburg). Practical aspects of the use of ezetimibe in combination therapy in patients with high and very high cardiovascular risk.

13:30–15:00

CONFERENCE HALL №3 (D1)
**SYMPOSIUM
CARDIOVASCULAR HEALTH IN REGIONS OF
RUSSIA**
Chairpersons: Konradi A. (Saint-Petersburg), **Shalnova S.** (Moscow)

- **Drapkina O.** (Moscow). Cardiovascular health of the megalopolis Moscow.
- **Efanov A.** (Tyumen). Cardiovascular health of the Urals.
- **Barbarash O.** (Kemerovo). Cardiovascular health in Siberia: PURE Study.
- **Kontsevaya A.** (Moscow). Cardiovascular health at the regional level: individual factors and the environment

13:30–15:00

CONFERENCE HALL №4 (D2)
**SATELLITE SYMPOSIUM
ALGORITHMS FOR THE DIAGNOSIS AND
TREATMENT OF PATIENTS WITH CHF AND T2DM
IN THE RUSSIAN FEDERATION**

(supported by Boehringer Ingelheim, CME credits are not accrued)

Chairpersons: Boytsov S. (Moscow), **Tereschenko S.** (Moscow)

- **Lopatin Y.** (Volgograd). Dynamics of HF treatment since 2016 in international guidelines
- **Zhirov I.** (Moscow). Clinical Practice Guidelines for Chronic Heart Failure: What's New?
- **Khalimov Y.** (Saint-Petersburg). Algorithms for managing patients with T2DM and CHF
- **Nedogoda S.** (Volgograd). Consensus document between the Russian Society of Cardiology and the Russian Association of Endocrinologists for the management of patients with heart failure and glucose metabolism disorders
- **Tereschenko S.** (Moscow). AF and CHF: choosing the optimal strategy for antithrombotic therapy

13:30–15:00

CONFERENCE HALL №5 (D3)

**SYMPOSIUM
CARDIOLOGICAL ASPECTS OF SOMATIC DISEASES
DURING PREGNANCY**

Chairpersons: **Irtyuga O.** (Saint-Petersburg), **Chumakova G.** (Barnaul), **Chulkov V.** (Chelyabinsk)

- **Irtyuga O.** (Saint-Petersburg), **Karelkina E.** (Saint-Petersburg), **Moiseeva O.** (Saint-Petersburg). Opportunities of planning and features of pregnancy management in patients with valvular heart diseases.
- **Veselovskaya N.** (Barnaul), **Chumakova G.** (Barnaul). Infective endocarditis in pregnant women: complex issues of diagnosis and treatment.
- **Moiseeva O.** (Saint-Petersburg), **Zaitsev V.** (Saint-Petersburg), **Pervunina T.** (Saint-Petersburg), **Karelkina E.** (Saint-Petersburg), **Konasov K.** (Saint-Petersburg), **Irtyuga O.** (Saint-Petersburg), **Bautin A.** (Saint-Petersburg), **Zazerskaya I.** (Saint-Petersburg). Pregnancy in women with a hypertrophic cardiomyopathy: data from 10 years experience.
- **Chulkov V.** (Chelyabinsk), **Vereina N.** (Chelyabinsk), **Chulkov V.** (Chelyabinsk). Cardiovascular risks factors in pregnant women with antiphospholipid syndrome.

13:30–15:00

CONFERENCE HALL №6 (D4)

**SATELLITE SYMPOSIUM
MASTER MANAGEMENT OF CARDIOVASCULAR
RISKS IN PATIENTS WITH ARTERIAL HYPERTENSION**

(supported by Teva, CME credits are not accrued)

Chairpersons: **Karpov Y.** (Moscow)

- **Nedogoda S.** (Volgograd). Personalization of arterial hypertension therapy — myth or reality.
- **Koziova N.** (Perm). “Life hacks” of a modern cardiologist in solving pressing issues of arterial hypertension treatment.
- **Karpov Y.** (Moscow). New world — new rules.

13:30–15:00

CONFERENCE HALL №7 (B1)

**SATELLITE SYMPOSIUM
CARDIOVASCULAR DISEASES IN THE XXI
CENTURY: CHALLENGING VICTORIES AND
INEVITABLE LOSSES?**

(supported by Canonpharma, CME credits are not accrued)

Chairpersons: **Ostroumova O.** (Moscow)

- **Ostroumova O.** (Moscow). Selection of antihypertensive therapy for arterial hypertension: false start cannot be allowed.
- **Adasheva T.** (Moscow). Arterial hypertension in older age groups. Therapeutic strategies.
- **Nedoshivin A.** (Saint-Petersburg). Pharmacotherapy of stable coronary heart disease: a victory over angina without loss.

13:30–15:00

CONFERENCE HALL №8 (B2)

**SATELLITE SYMPOSIUM
CARDIOLOGY MASKS OF RARE DISEASES**

(supported by Takeda, CME credits are not accrued)

Chairpersons: **Orlova Y.** (Moscow), **Kharlap M.** (Moscow)

- **Kharlap M.** (Moscow). What may be indicated by ventricular pre-excitation on the ECG.
- **Myasnikov R.** (Moscow). Cross phenotypes of cardiomyopathies.
- **Vasichkina E.** (Saint-Petersburg). Cardiac aspects of Fabry disease in children.

13:30–15:00

CONFERENCE HALL №9 (B6-B8)

**SYMPOSIUM
THE GENETICS OF MULTIFACTORIAL DISEASES —
A CLINICIAN'S VIEW**
Chairpersons: Minushkina L. (Moscow), **Nikulina S.** (Krasnoyarsk)

- **Nikulina S.** (Krasnoyarsk), **Chernova A.** (Krasnoyarsk), **Kryuchkova N.** (Krasnoyarsk). Clinical and genetic predictors of pulmonary embolism.
- **Zubova E.** (Moscow). Frailty syndrome and genetic polymorphism in patients with acute coronary syndrome.
- **Ivantsov E.** (Казань), **Khasanov N.** (Казань). Polymorphism of angiogenesis genes in patients with early development of acute coronary syndrome.
- **Dankovtseva E.** (Moscow). Genetic polymorphism and features of the course of pulmonary arterial hypertension.
- **Gavriliuk N.** (Saint-Petersburg), **Zhukov V.** (Saint-Petersburg), **Zhernakov A.** (Saint-Petersburg), **Uspenskiy V.** (Saint-Petersburg), **Moiseeva O.** (Saint-Petersburg). Non-familial non-syndrome aneurysms of the ascending aorta.

13:30–15:00

CONFERENCE HALL №10 (A1-A3)

**SYMPOSIUM
COVID-19 AND CARDIOVASCULAR DISEASES:
PECULIARITIES, COMPLICATIONS AND OUTCOMES**
Chairpersons: Pogosova N. (Moscow), **Matskeplishvili S.** (Moscow)

- **Ezhov M.** (Moscow). The role of cardiovascular diseases in COVID-19 course.
- **Pevzner D.** (Moscow). Comparison of conservative vs liberal approaches to mechanical ventilation in patients with COVID-19.
- **Orlova Y.** (Moscow). Anti-inflammatory treatment for COVID-19 and for cardiovascular diseases: what is in common.

13:30–15:00

CONFERENCE HALL №11 (A4-A5)

**SYMPOSIUM
ACHIEVEMENTS AND NEW ISSUES IN RUSSIAN
TRANSPLANTOLOGY**
Chairpersons: Pervunina T. (Saint-Petersburg), **Pustovoitov A.** (Krasnoyarsk), **Kosmacheva E.** (Krasnodar)

- **Pervunina T.** (Saint-Petersburg), **Vasichkina E.** (Saint-Petersburg), **Fedotov P.** (Saint-Petersburg). Transplantology in Pediatric Practice: Reality and Prospects.
- **Melnikov I.** (Chelyabinsk), **Nujdin M.** (Chelyabinsk), **Tsarkov A.** (Chelyabinsk). Immediate results and prospects for the heart transplantation programme development in the Urals.
- **Pustovoitov A.** (Krasnoyarsk), **Myznikov A.** (Krasnoyarsk), **Kaptyuk G.** (Krasnoyarsk). Heart transplant program in Krasnoyarsk region.
- **Thatl L.** (Krasnodar), **Pashkova I.** (Krasnodar), **Kosmacheva E.** (Krasnodar). Importance of HLA antibodies in the development of post-transplant complications in heart recipients.
- **Sazonova Y.** (Saint-Petersburg). Risk factors for allograft rejection in heart recipients: the role of clinical and immunological parameters.
- **Simonenko M.** (Saint-Petersburg). Dispensary observation of patients after heart transplantation.

13:30–15:00

CONFERENCE HALL №12 (A8-A9)**SECTION SESSION
ARRHYTHMOLOGY, PACING,
RESYNCHRONIZATION**

Chairpersons: Borovkova N.Yu. (Nizhny Novgorod), **Kuznetsov V.A.** (Tyumen)

- **Gogolashvili N.G., Tuchkov A.A., Yaskevich R.A. (Krasnoyarsk).** The rationale for prescribing small doses of direct oral anticoagulants in patients with atrial fibrillation according to the Krasnoyarsk registry of patients with atrial fibrillation “KRAF”.
- **Dzhaffarova O.Yu., Svintsova L.I., Plotnikova I.V., Krivolapov S.N., Kartofeleva E.O. (Tomsk).** Complications of constant pacing in children, depending on the method of implantation.
- **Dzaurova Kh.M., Mironov N.Yu., Yuricheva Yu.A., Vlodyanovskiy V.V., Sokolov S.F., Golitsyn S.P. (Moscow).** The first results of the efficacy and safety of the domestic antiarrhythmic drug Refralon in patients with paroxysmal atrial fibrillation.
- **Ionin V.A., Zaslavskaya E.L., Morozov A.N., Skuridin D.S., Baranova E.I. (Saint-Petersburg).** Procollagens of types I and III circulating in blood plasma and the severity of left atrial myocardial fibrosis in patients with atrial fibrillation and metabolic syndrome.
- **Shilenko P.A., Fomenko M.S., Tsoi M.D., Vygovskiy A.B., Shneider Yu.A. (Kaliningrad).** Thoracoscopic left atrial ablation in the structure of atrial fibrillation treatment.
- **Garkina S.V., Orshanskaya V.S., Simonova K.A., Arzhelas S.L., Golovina M.S., Zhiduleva E.V., Zlobina I.S., Stepanova E.V., Mineeva E.V., Lebedev D.S. (Saint-Petersburg).** Remote symptom management with wearable ECG recorders in COVID-19 patients.

13:30–15:00

ONLINE HALL №1**SATELLITE SYMPOSIUM
A PATIENT WITH HYPERTENSION AND CO-
MORBIDITY: CONTROVERSIAL AND UNRESOLVED
ISSUES OF THERAPY**

(supported by Berlin-Chemie, CME credits are not accrued)

Chairpersons: Arutyunov G. (Moscow)

- **Nedoshivin A.** (Saint-Petersburg). Risk factors in a patient with hypertension as possible targets for drug therapy.
- **Arutyunov G.** (Moscow). Nephroprotection in a patient with hypertension, possibilities and reality.
- **Nedoshivin A.** (Saint-Petersburg). Antihypertensive therapy: choosing effectiveness without compromising safety.
- **Ratova L.** (Saint-Petersburg). Cardiorespiratory patient in outpatient practice.
- **Arutyunov G.** (Moscow). Cerebroprotection in a patient with hypertension — our actions before and after stroke
- **Ratova L.** (Saint-Petersburg). Vascular disease in patients with hypertension.

13:30–15:00

ONLINE HALL №2**Satellite symposium
How to save a life of a patient with PE: what to take into account
when choosing anticoagulant therapy?**

(supported by Bayer, CME credits are not accrued)

Chairpersons: Duplyakov D. (Samara)

- **Obrezan A.** (Saint-Petersburg). The key issues of management of patient with PE at the hospital.
- **Lobastov K.** (Moscow). Safety issues of anticoagulant therapy in high-risk patients.
- **Erlikh A.** (Moscow). What to take into account in managing patient with PE in the ambulatory.

15:30–17:00

PLENARY HALL
**PLENARY SESSION
DIAGNOSTICS AND SURGICAL TREATMENT
OF MECHANICAL COMPLICATIONS OF ACUTE
INFARCTION**

On-line broadcasting/ Simultaneous translation

Chairpersons: **Golukhova E.Z.** (Moscow), **Skopin I.I.** (Moscow)

- **Sokolskaya N.O.** (Moscow). Imaging in mechanical complications of acute myocardial infarction.
- **Gordeev M.L.** (Saint-Petersburg). Operations of geometric reconstruction of the left ventricle in postinfarction aneurysm.
- **Skopin I.I.** (Moscow). Postinfarction mitral regurgitation.
- **Alshibaya M.D., Krymov K.V., Cheishvili Z.M., Musin D.E.** (Moscow). Postinfarction myocardial ruptures: rupture of the interventricular septum and rupture of the free wall of the left ventricle. Surgical tactics and results.

15:30–17:00

CONFERENCE HALL №1 (E8-E9)
**ROUNDTABLE
DISCUSSION OF THE PROJECT OF THE MINISTRY
OF HEALTH CLINICAL GUIDELINES ON THE
DIAGNOSIS AND TREATMENT OF DILATED
CARDIOMYOPATHY**
Chairpersons: **Belenkov Y.** (Moscow), **Sitnikova M.** (Saint-Petersburg), **Chesnikova A.** (Rostov-on-Don)

- **Gendlin G.** (Moscow), **Melechov A.** (Moscow). Etiology and pathogenesis of DCM. Epidemiology of the disease.
- **Obrezan A.** (Saint-Petersburg). Instrumental diagnostic studies
- **Garganeva A.** (Tomsk). Features of clinical and laboratory research.

- **Moiseeva O.** (Saint-Petersburg). Differential diagnosis.
- **Gilyarevsky S.** (Moscow). Drug therapy for DCM.
- **Mihailov E.** (Saint-Petersburg), **Fedotov P.** (Saint-Petersburg). Features of the treatment of rhythm and conduction disorders. Treatment of advanced heart failure in DCM. Indications for high-tech therapy methods.

15:30–17:00

CONFERENCE HALL №2 (E7)
**SATELLITE SYMPOSIUM
COMBINATION OF ARTERIAL HYPERTENSION
AND CORONARY HEART DISEASE. ARE WE DOING
EVERYTHING RIGHT?**

(supported by Merck, CME credits are not accrued)

Chairpersons: **Arutynov G.** (Moscow)

- **Kobalava Zh.** (Moscow). Combined cardiovascular pathology.
- **Arutynov G.** (Moscow). Sympathetic overdrive. Effects on the cardiovascular system.
- **Pathak A.** (Monaco). How to help a patient with hypertension and coronary heart disease? One pill strategy.

15:30–17:00

CONFERENCE HALL №3 (D1)
**SATELLITE SYMPOSIUM
IT'S TIME TO CHANGE THE PARADIGM OF CHF
TREATMENT**

(supported by AstraZeneca, CME credits are not accrued)

Chairpersons: **Boytsov S.** (Moscow)

- **Tereschenko S.** (Moscow). HFrEF: old problems — new solutions.
- **Matskeplishvili S.** (Moscow). DAPA-HF: two years later.
- **Petrie M.** (UK). A modern approach to the therapy of CHF.
- **Kobalava Z.** (Moscow). CHF and CKD: two poles of risk.

15:30–17:00

CONFERENCE HALL №4 (D2)

**SYMPOSIUM
MYOCARDIAL INFARCTION WITH
NONOBSTRUCTIVE CORONARY ARTERIES —
IMBOCA: STATE OF THE ART**

Chairpersons: **Boldueva S.** (Saint-Petersburg), **Kosmacheva E.** (Krasnodar)

- **Boldueva S.** (Saint-Petersburg). IMBOCA 2021: what the news?
- **Kosmacheva E.** (Krasnodar), **Raff S.** (Krasnodar), **Kruchinova S.** (Krasnodar). Prospects for imaging in patients with IMBOCA.
- **Protasov K.** (Irkutsk). Damage to the myocardium after extracardiac surgery: prognosis, prevention, treatment
- **Boldueva S.** (Saint-Petersburg), **Oblavatsky D.** (Saint-Petersburg). Clinical and pathogenetic variants of myocardial infarction of the second type according to the results of a retrospective analysis of the data of a multidisciplinary hospital for 10 years.

15:30–17:00

CONFERENCE HALL №5 (D3)

**SYMPOSIUM
CARDIOVASCULAR SCREENING: PROS AND CONS**

Chairpersons: **Drapkina O.** (Moscow), **Konradi A.** (Saint-Petersburg)

- **Drozdova L.** (Moscow). Cardiovascular screening: pros.
- **Rotar O.** (Saint-Petersburg). Cardiovascular screening: cons.
- **Kontsevaya A.** (Moscow). Cardiovascular screening: economic arguments.

15:30–17:00

CONFERENCE HALL №6 (D4)

**SATELLITE SYMPOSIUM
CLINICAL REVIEWS: COMPLEX AND UNSOLVED
PROBLEMS OF PRESCRIBING ANTICOAGULANT
THERAPY IN NVAF**

(supported by Pfizer, CME credits are not accrued)

Chairpersons: **Andreev D.** (Moscow)

- **Andreev D.** (Moscow). Complex issues of diagnosis and treatment of NVAF
- **Dzhioeva O.** (Moscow). Perioperative AF: principles of diagnosis and treatment
- **Vinogradov O.** How to avoid losing efficiency in the pursuit of safety?

15:30–17:00

CONFERENCE HALL №7 (B1)

**SATELLITE SYMPOSIUM
UNIFIED CARDIO-METABOLIC APPROACH
TO RISK MANAGEMENT IN PATIENTS WITH
CARDIOVASCULAR DISEASES AND TYPE 2
DIABETES**

(supported by NovoNordisk, CME credits are not accrued)

Chairpersons: **Villevalde S.** (Saint-Petersburg)

- **Villevalde S.** (Saint-Petersburg). Correlation between hypoglycemic drugs and cardiovascular outcomes.
- **Karpov Y.** (Moscow). Beyond Glycemic Control: Time to choose a therapy with proven cardiovascular benefits.
- **Matskeplishvili S.** (Moscow). Pleiotropic effects of GLP-1 receptor agonists.

15:30–17:00

CONFERENCE HALL №8 (B2)

**SATELLITE SYMPOSIUM
ASYMPTOMATIC HYPERURICEMIA. ARTERIAL
HYPERTENSION. CARDIOVASCULAR RISK.
SEPARATE PUZZLES OR A SINGLE PICTURE?**

(supported by Egis, CME credits are not accrued)

Chairpersons: Mazurov V. (Saint-Petersburg), **Nedogoda S.** (Volgograd), **Galyavich A.** (Kazan)

- **Mazurov V.** (Saint-Petersburg). Asymptomatic hyperuricemia as an interdisciplinary problem, unresolved issues
- **Nedogoda S.** (Volgograd). Pathogenetic aspects of hyperuricemia for patients with arterial hypertension
- **Galyavich A.** (Kazan). Hyperuricemia: a risk factor and predictor of poor prognosis in high CV risk patients.

15:30–17:00

CONFERENCE HALL №9 (B6-B8)

**SYMPOSIUM
GENETIC ASPECTS IN CARDIOLOGY**
Chairpersons: Yakushin S. (Ryazan), **Barbarash O.** (Kemerovo), **Sychev D.** (Moscow)

- **Nikulina S.** (Krasnoyarsk), **Demkina A.** (Krasnoyarsk). Genetic predictors of myocardial infarction in young adults.
- **Pereverzeva K.** (Ryazan), **Yakushin S.** (Ryazan). Genetic factors that determine unfavorable outcome among highly adherent to drug treatment patients with myocardial infarction.
- **Barbarash O.** (Kemerovo), **Pecherina T.** (Kemerovo). Genetic markers in the evaluation of the severity of postinfarction myocardial remodeling.
- **Mirzaev K.** (Moscow). Prediction of the efficiency of antiplatelet therapy among patients with cardiovascular pathology: from the study of particular omics biomarkers to complex methods based on machine learning.
- **Sychev D.** (Moscow), **Rytkin E.** (Moscow). Plasmatic microRNA as biomarkers to predict individual characteristics of the pharmacokinetics and pharmacodynamics of antithrombotic drugs.

15:30–17:00

CONFERENCE HALL №10 (A1-A3)

**SYMPOSIUM
MODERN APPROACHES TO PHYSIOLOGICAL
PACING IN CHRONIC HEART FAILURE**
Chairpersons: Lebedev D. (Saint-Petersburg), **Popov S.** (Tomsk)

- **Krivolapov S.** (Tomsk). Modern view of physiological pacing.
- **Kalemberg A.** (Moscow). Is there a place for non-selective His bundle pacing?
- **Gorev M.** (Moscow). Indications and approaches for the correction of left bundle branch block.
- **Kolunin G.** (Tyumen). Indications and approaches for the correction of right bundle branch block.
- **Lyubimtseva T.** (Saint-Petersburg). Dynamic monitoring of patients with His bundle and left bundle branch pacing.

15:30–17:00

CONFERENCE HALL №11 (A4-A5)

**SYMPOSIUM
NEW HORIZONS FOR THERAPEUTIC CORRECTION
OF CARDIOVASCULAR RISK IN OBESE PATIENTS**
Chairpersons: Kuznetsova T. (Petrozavodsk), **Chumakova G.** (Barnaul)

- **Kuznetsova T.** (Petrozavodsk). New target — “incretin axis”.
- **Chumakova G.** (Barnaul). New candidates — SGLT2 inhibitors.
- **Gruzhirov M.** (Petrozavodsk). New rational combinations.

15:30–17:00

CONFERENCE HALL №12 (A8-A9)
**SECTION SESSION
CARDIOVASCULAR AND HYBRID SURGERY**
Chairpersons: Osipova O.A. (Belgorod), Batyrov Z.S. (Nalchik)

- **Shneider Yu.A., Antipov G.N., Postol A.S. (Kaliningrad).** Surgical treatment options for atrial fibrillation in concomitant cardiac surgeries.
- **Grinчук I.I., Shumovets V.V., Andraloit I.E., Krutov V.G., Ostrovsky Yu.P. (Minsk, Belarus).** Long-term results of surgical treatment of moderate ischemic mitral regurgitation: propensity-matching analysis.
- **Bezdenzhnykh N.A., Sumin A.N., Bezdenzhnykh A.V., Osokina A.V., Kuzmina A.A., Tsepokina A.V., Barbarash O.L. (Kemerovo).** The role of the DISSE insulin resistance index and free fatty acids in determining the hospital prognosis of coronary artery bypass grafting in patients with carbohydrate metabolic disorders.
- **Sorokin A.A., Kazantsev A.N. (Saint-Petersburg), Vinogradov R.A. (Krasnodar), Kravchuk V.N., Shmatov D.V., Artyukhov S.V., Bagdavazde G.Sh. (Saint-Petersburg), Lider R.Yu. (Kemerovo), Khubulava G.G. (Saint-Petersburg).** The course of resistant arterial hypertension in the hospital period after eversion and classical carotid endarterectomy.
- **Kudaev Yu.A., Panov A.V., Kuleshova E.V., Chernyavsky M.A., Lokhovinina N.L., Abesadze I.T., Alugishvili M.Z. (Saint-Petersburg).** Risk factors in patients with atherosclerosis of the arteries of the lower extremities, referred for surgical intervention.
- **Eraliev T.K. (Osh, Kyrgyzstan), Krestyaninov O.V., Khelimsky D.A. (Novosibirsk).** A prospective, randomized study of the use of drug-eluting balloon catheters for the treatment of a lateral branch in patients with true bifurcation lesions.

15:30–17:00

ONLINE HALL №1
**SATELLITE SYMPOSIUM
MODERN CHALLENGES IN THE TREATMENT OF
PATIENTS WITH CORONARY ARTERY DISEASE**

(supported by Berlin-Chemie, CME credits are not accrued)

Chairpersons: Bubnova M. (Moscow)

- **Karpov Y. (Moscow).** New recommendations for the treatment of stable coronary artery disease: personalization of therapy.
- **Shakhnovich R. (Moscow).** Differentiated approach in the management of patients with type 2 myocardial infarction.
- **Bubnova M. (Moscow).** Cardioprotective effects of rehabilitation of patients with acute and chronic coronary syndrome.

15:30–17:00

ONLINE HALL №2
**SATELLITE SYMPOSIUM
METABOLIC THERAPY AND CO-MORBIDITIES**

(supported by Grindex, CME credits are not accrued)

Chairperson: Statsenko M.E. (Volgograd)

- **Nedoshivin A.O. (Saint-Petersburg).** Mildronate in cardiology: past, present and future.
- **Statsenko M.E. (Volgograd).** A patient with CHF of ischemic genesis and COPD.
- **Mikhin V.P. (Kursk).** A patient with coronary artery disease and hypertension: focus on cyto- and vasoprotection.
- **Shishkova V.N. (Moscow).** Pathogenetic features of cardiomyopathy and heart failure with insulin resistance and type 2 diabetes.

09:00–10:30

PLENARY HALL

**PLENARY SESSION
ARTERIAL HYPERTENSION AND METABOLIC
SYNDROME. NEW DATA**

On-line broadcasting/ Simultaneous translation

Chairpersons: **Chumakova G.A. (Barnaul), Libis R.A. (Orenburg)**

- **Nedogoda S.V.** (Volgograd). Same meaning of target blood pressure — myth or reality?
- **Chumakova G.A.** (Barnaul). Is hypertension secondary to obesity?
- **Kobalava Zh.D. (Moscow)**. Diastolic BP — neoclassicism of modern hypertension.
- **Konradi A.O.** (Saint-Petersburg). BP in stroke.

09:00–10:30

CONFERENCE HALL №1 (E8-E9)

**SYMPOSIUM
PSYCHO-CARDIOLOGY**
Chairpersons: **A.L. Syrkin** (Moscow), **Neznanov N.G.** (St. Petersburg), **Smulevich A.B.** (Moscow)

- **Vasilyeva A.V.** (Saint-Petersburg). Cardiophobia in cardiology. Possibilities of psychotherapy.
- **Pogosova N.V.** (Moscow). Perception of the disease and psychological profile of patients with atrial fibrillation after catheter ablation.
- **Shchekochikhin D.Yu.** (Moscow), **Gognieva D.G.** (Moscow), **Fomicheva A.V. (Moscow), Kopylov F.Yu. (Moscow), Volel B.A. (Moscow), Bogdanova R.S. (Moscow)**. Anxiety disorders and adherence to treatment in patients with atrial fibrillation.
- **Ivanov S.V. (Moscow)**. Rational pharmacotherapy of mental disorders in cardiology.

09:00–10:30

CONFERENCE HALL №2 (E7)

**SCIENTIFIC SESSION
ATHEROSCLEROSIS AS A DISEASE OF MIDDLE
AGE**
Chairpersons: **Konstantinov V.** (Saint-Petersburg), **Urazgildeeva S.** (Saint-Petersburg)

- **Kuznetsova T.** (Petrozavodsk), **Korneva V.** (Petrozavodsk). Multifactorial role of dyslipidemia in the development of atherosclerosis
- **Urazgildeeva S.** (Saint-Petersburg), **Baranova E.** (Saint-Petersburg), **Muzalevskaya M.** (Saint-Petersburg), **Shugurova I.** (Saint-Petersburg). Non-lipid markers of early and progressive atherosclerosis
- **Serdiukov D.** (Saint-Petersburg). A male older than 40 years: an active maturity or premature vascular aging?

09:00–10:30

CONFERENCE HALL №3 (D1)

**SYMPOSIUM
ACUTE CARDIAC CARE — 2021**
Chairpersons: **Tereschenko S.** (Moscow)

- **Averkov O.** (Moscow). Myocardial infarction — 2021
- **Zhirov I.** (Moscow). Acute heart failure — 2021
- **Golitsyn S.** (Moscow). Cardiac arrhythmias — 2021
- **Yavelov I.** (Moscow). Pulmonary embolism — 2021

09:00–10:30

CONFERENCE HALL №4 (D2)

**SYMPOSIUM
OPTIMIZATION OF SECONDARY
CARDIOVASCULAR PREVENTION DURING THE
COVID-19 PANDEMIC IN GENERAL PRACTITIONER
PRACTICE**
Chairpersons: Drapkina O. (Moscow)

- **Drapkina O.** (Moscow). The tasks of improving the quality of regular medical check-up for patients with cardiovascular diseases during the COVID-19 pandemic.
- **Drozdova L.** (Moscow). Organizational form of regular medical check-up in general practitioner practice for cardiovascular diseases during the COVID-19 pandemic.
- **Chesnikova A.** (Rostov-on-Don). Applied aspects of regular medical check-up of patients with cardiovascular diseases.

09:00–10:30

CONFERENCE HALL №5 (D3)

**SYMPOSIUM
CARDIO-ONCOLOGY: LIGHT IN THE LABYRINTH
OF PROBLEMS?**
Chairpersons: Ballyuzek M. (Saint-Petersburg), **Vasyuk Y.** (Moscow)

- **Vasyuk Y.** (Moscow). Chemotherapy cardiotoxicity isn't just heart failure.
- **Poltavskaya M.** (Moscow). Why does a patient cured of childhood cancer need lifelong supervision by a cardiologist?
- **Emelina E.** (Moscow). Prescribing an anticoagulant to an oncological patient — what will be the path?
- **Emelina E.** (Moscow), **Gendlin G.** (Moscow). Is cardiac monitoring of an oncological patient necessary?

09:00–10:30

CONFERENCE HALL №6 (D4)

**SYMPOSIUM
COVID-19 — RAPID PANDEMIC ON TOP OF SLOW
CARDIOVASCULAR DISEASE PANDEMIC**
Chairpersons: Garganeeva A. (Tomsk), **Orlova Y.** (Moscow)

- **Arutynov G.** (Moscow). CVD and COVID-19 Risk Factors: Intersection Points. Data from international registers ACTIVE and ACTIVE-2.
- **Orlova Y.** (Moscow). Impact of the COVID-19 pandemic on approaches to correcting risk factors for cardiovascular diseases.
- **Begrambekova Y.** (Moscow). Evolutionary human biology in the context of the development of functional abilities and “hypodynamic disease” in modern society.

09:00–10:30

CONFERENCE HALL №7 (B1)

**SYMPOSIUM
DIFFICULT PATIENT WITH CAD AND
OPPORTUNITIES OF INTERVENTIONAL
CARDIOLOGY: THE BALANCE OF RISK AND
BENEFIT**
Chairpersons: Babunashvili A. (Moscow), **Yakushin S.** (Ryazan)

- **Babunashvili A.** (Moscow). Chronic occlusions of coronary arteries: Percutaneous coronary intervention? Coronary shunting? Optimal drug therapy?
- **Barbarash O.** (Kemerovo). Opportunities of endovascular interventions after coronary shunting.
- **Galyavich A.** (Kazan). Patient with stable angina pectoris and multivessel coronary artery disease: the individualized approach.
- **Yakushin S.** (Ryazan). Multivessel coronary artery disease of a patient with myocardial infarction: to stent or to halt.

09:00–10:30

CONFERENCE HALL №8 (B2)
**SATELLITE SYMPOSIUM
INTERNATIONAL MULTIDISCIPLINARY FORUM
HIGH CV RISK PATIENT — FOCUS ON RESULTS.
CORRECTION OF DYSLIPIDEMIA IN THE CLINICAL
PRACTICE OF A CARDIOLOGIST, PEDIATRICIAN,
NEUROLOGIST AND ENDOCRINOLOGIST. PART 1.**

(supported by Amgen, CME credits are not accrued)

Chairpersons: **Ezhov M.** (Moscow), **Gurevich V.** (Saint-Petersburg)

- **Shlyakhto E.** (Saint-Petersburg). Opening, greetings.
- **Gurevich V.** (Saint-Petersburg). Management of cardiovascular risks in patients with ACS. Combined lipid-lowering therapy: from recommendations to real clinical practice.
- **Dobrecky Mery I.** (Israel). Optimization of lipid-lowering therapy in ACS. Clinical experience in Israel with PCSK9 inhibitors.
- **Voznjouk I.** (Saint-Petersburg). Welcome, greetings. Moderation.
- **Ntaios G.** (Greece). Optimization of lipid-lowering therapy in patients after ischemic stroke or transient ischemic attack.
- **Shamalov N.** (Moscow). Management of ischemic stroke in the Russian Federation: issues and prospects.

09:00–10:30

CONFERENCE HALL №9 (B6-B8)
**SYMPOSIUM
RUSSIAN JOURNAL OF CARDIOLOGY.
EDUCATION — RESULTS OF THE FIRST YEAR**
Chairpersons: **Duplyakov D.** (Samara), **Villevalde S.** (Saint-Petersburg)

- **Duplyakov D.** (Samara). RJC. Education — we are 1 year old.
- **Zagidullin N.** (Ufa). My experience as a copy editor — the best articles over the past year.
- **Villevalde S.** (Saint-Petersburg). What is the difference between a classical and a systematic review, how to make a meta-analysis,

what is the difference between RCTs, observational and cohort studies?

- **Rodionova Y.** (Moscow). Requirements for incoming articles: the main stumbling blocks.
- **Kercheva M.** (Tomsk), **Mullova I.** (Samara), **Namitokov A.** (Krasnodar), **Lyapina I.** (Kemerovo). Planet “RCJ. Education” — the integration of your achievements into the world around you.

09:00–10:30

CONFERENCE HALL №10 (A1-A3)
**SYMPOSIUM
PERSONALIZED ARRHYTHMOLOGY: MYTH OR
REALITY?**
Chairpersons: **Lebedev D.** (Saint-Petersburg), **Popov S.** (Tomsk), **Boldueva S.** (Saint-Petersburg)

- **Kostareva A.** (Saint-Petersburg). Genetic test to everybody Is this needed? Is it real?
- **Nikiforov V.** (Saint-Petersburg). Examination standards for patients with arrhythmia. Is personalization possible?
- **Chapurnykh A.** (Moscow). Personalization of interventional treatment for atrial fibrillation. Does it work?
- **Mikhaylov E.** (Saint-Petersburg). Can we really affect the arrhythmia substrate?
- **Shubik Y.** (Saint-Petersburg). Personalized antiarrhythmic therapy. XXI century — the century of evidence-based medicine.

09:00–10:30

CONFERENCE HALL №11 (A4-A5)**CLINICAL CASES
CARDIOMYOPATHY**

Chairpersons: Kosmacheva E.D. (Krasnodar), **Moiseeva O.M.** (Saint-Petersburg)

- **Khorolets E.V., Pasechnik A.A. (Rostov-on-Don).** Stress-induced cardiomyopathy.
- **Golovina G.A., Stavenchuk T.V., Kizhvatova N.V., Kosmacheva E.D.** (Krasnodar). Hypertrophic cardiomyopathy of the transplanted heart: a case report.
- **Bratilova E.S., Kachnov V.A., Tyrenko V.V., Vasiliev M.V., Kushnarev S.V.** (Saint-Petersburg). A clinical case of heart failure in a young man: dilated cardiomyopathy, non-compact left ventricular myocardium, or a consequence of anabolic androgenic steroids?
- **A.S. Zamshina, E.V. Khorolets** (Rostov-on-Don). Heart transplantation for secondary dilated cardiomyopathy.

09:00–10:30

CONFERENCE HALL №12 (A8-A9)**SECTION SESSION
ISCHEMIC HEART DISEASE, LIPIDS AND
ATHEROSCLEROSIS. IMAGING IN CARDIOLOGY,
ULTRASOUND AND TOMOGRAPHIC
TECHNOLOGIES**

Chairpersons: Greenstein Yu.I. (Krasnoyarsk), **Eregin S.Ya.** (Yaroslavl)

- **Nekrasova E.V., Orlov S.V.** (Saint-Petersburg). APOA-1 affects the migration activity of human macrophages induced by the chemokine C5A.
- **Trusov I.S., Nifontov E.M., Trotsenko A.I.** (Saint-Petersburg). Influence of thyroid status on long-term outcomes of percutaneous coronary interventions.

- **Zarudskiy A.A., Vinyukov V.A., Puchenkova O.A., Suslov S.S. (Belgorod).** Possibilities of modern cholesterol-lowering therapy and the real state of affairs based on the results of the HUNT study (assessment of cholesterol-lowering therapy at the outpatient stage).
- **Rogozhina A.A., Minushkina L.O., Alesenko A.V., Gutner U.A., Shupik M.A., Kurochkin I.N., Maloshitskaya O.A., Sokolov S.A., Zateishchikov D.A. (Moscow).** Study of the dynamics of sphingolipids in patients with early atherosclerosis against the background of lipid-lowering therapy.
- **Shneider Yu.A., Tsoi V.G., Fomenko M.S., Pavlov A.A., Shilenko P.A. (Kaliningrad).** The use of two HAVs in the surgical treatment of coronary artery disease.
- **Krivoshapova K.E., Wegner E.A., Terentyeva N.A., Masenko V.L., Kokov A.N., Barbarash O.L. (Kemerovo).** Senile asthenia syndrome as an independent predictor of poor prognosis for patients undergoing coronary artery bypass grafting.

09:00–10:30

ONLINE HALL №1**SYMPOSIUM
MOLECULAR AND TRANSLATIONAL BIOMEDICINE
IN CARDIOVASCULAR DISORDERS**

Chairpersons: Kzhyshkowska J. (Germany), **Ryabov V.** (Tomsk)

- **Kzhyshkowska J.** (Germany). Programming of innate immunity in metabolic and cardiovascular diseases.
- **Sobenin I.** (Moscow). Atherosclerosis and mitochondrial genome damage: research prospects.
- **Ragino Y.** (Novosibirsk). Inflammatory cytokines-chemokines and early coronary heart disease in a young Siberian population.
- **Sirotnina M.** (Tomsk), **Tsibulnikov S.** (Tomsk), **Mukhomedzyanov A.** (Tomsk), **Maslov L.** (Tomsk). Activation of opioid and cannabinoid receptors increases cardiac tolerance to the pathogenic effect of reperfusion.
- **Kercheva M.** (Tomsk), **Gombozhapova A.** (Tomsk), **Ryabov V.** (Tomsk). Innate immunity in the development of cardiorenal syndrome in patients with acute myocardial infarction.

09:00–10:30

ONLINE HALL №2

**SYMPOSIUM
PCR SEMINARS RUSSIA
PCI IN PATIENTS AT HIGH RISK OF BLEEDING**

Simultaneous translation

Presenter: Stankovic G. (Serbia)
Chairpersons: Fajadet J. (France), Babunashvili A.M. (Moscow),
Zverev D.D. (Saint-Petersburg), Sozykin A. (Moscow),
Shugushev Z.Kh. (Moscow)

11:00–12:30

PLENARY HALL

**PLENARY SESSION
PRESENTATIONS OF THE DRAFTS OF THE NEW
CLINICAL GUIDELINES OF THE MINISTRY OF
HEALTH**

On-line broadcasting/ Simultaneous translation

Chairpersons: Shlyakhto E.V. (Saint-Petersburg), Nedogoda S.V.
(Volgograd).

- **Kobalava Zh.D. (Moscow).** Presentation of the draft clinical guidelines "Infective endocarditis and infections of intracardiac devices".
- **Arutyunov G.P. (Moscow).** Presentation of the draft clinical guidelines "Pericarditis".
- **Sergienko I.V. (Moscow).** Presentation of the draft clinical guidelines "Lipid Metabolism Disorders".
- **Discussion**

11:00–12:30

CONFERENCE HALL №1 (E8-E9)

**SYMPOSIUM
MODERN OPPORTUNITIES OF
ECHOCARDIOGRAPHY IN CARDIOLOGY PRACTICE**
Chairpersons: Pavlyukova E. (Saint-Petersburg), Nikiforov V.
(Saint-Petersburg)

- **Pavlyukova E.** (Saint-Petersburg). The deformation of the papillary muscles in secondary mitral regurgitation.
- **Nikiforov V.** (Saint-Petersburg). Current trends in echocardiographic assessment of dissynchrony in clinical practice.
- **Davydova A.** (Petropavlovsk-Kamchatskiy). Diagnostic capabilities of echocardiography in acute coronary syndromes.
- **Sklyarova V.** (Saint-Petersburg). Echocardiographic evaluation of the mitral valve in valve-preserving interventions.
- **Mamaeva O.** (Saint-Petersburg), **Davydova E.** (Saint-Petersburg). Evaluation of myocardial function using 3D echocardiography.

11:00–12:30

CONFERENCE HALL №2 (E7)

**SYMPOSIUM
ECG DIAGNOSTICS: NEW AND WELL
OVERLOOKED OLD**
Chairpersons: Treshkur T. (Saint-Petersburg), Yakushin S. (Ryazan)

- **Treshkur T.** (Saint-Petersburg), **Chmelevsky M.** (Saint-Petersburg). ECG from classics to new diagnostic aspects.
- **Yakushin S.** (Ryazan). Long and short QT syndromes: theory and practical significance.
- **Parmon E.** (Saint-Petersburg). Risk-stratification of BER and QRS fragmentation.
- **Wisne E.** (USA), **Chmelevsky M.** (Saint-Petersburg). Noninvasive ECG mapping of polymorphic ventricular arrhythmias in routine clinical practice.
- **Pereverzeva K.** (Ryazan). Difficulties of ECG diagnosis of myocardial infarction.

11:00–12:30

CONFERENCE HALL №3 (D1)

**SYMPOSIUM
COVID-19 AND CARDIOVASCULAR
COMPLICATIONS: EXPERIENCE OF THE RUSSIAN
FEDERATION**
Chairpersons: Konradi A. (Saint-Petersburg), **Belenkov Y.** (Moscow)

- **Villevalde S.** (Saint-Petersburg). Russian Cardiovascular Registry of COVID-19: preliminary results.
- **Kopylov F.** (Moscow), **Gognieva D.** (Moscow). Cardiovascular Risk in Hospitalized COVID-19 Patients: CAPACITY Registry.
- **Zagidullin N.** (Ufa). Investigation of cardiovascular markers of adverse outcome in COVID-19.
- **Lopatin Y.** (Volgograd). Heart failure and COVID-19.
- **Sitnikova M.** (Saint-Petersburg). Principles of heart transplantation and post-transplant patient management in the COVID-19 pandemic.
- **Nedogoda S.** (Volgograd). Rehabilitation after COVID-19.

11:00–12:30

CONFERENCE HALL №4 (D2)

**SATELLITE SYMPOSIUM
VTE: HOW TO TURN TRAGEDY INTO HOPE**

(supported by Pfizer, CME credits are not accrued)

Chairperson: Zolotukhin I. (Moscow)

- **Andreev D.** (Moscow). How views on the treatment of VTE are changing in the era of DOAC.
- **Zolotukhin I.** (Moscow). VTE: where are we now and where do we go?
- **Gromova E.G.** (Moscow). Cancer thrombosis: that really is too much!

11:00–12:30

CONFERENCE HALL №5 (D3)

**SATELLITE SYMPOSIUM
INTERACTION BETWEEN PHYSICIAN AND HF
PATIENT: HOW TO UNDERSTAND EACH OTHER?**

(supported by Green Leaf Pharma, CME credits are not accrued)

Chairpersons: Matskeplishvili S. (Moscow)

- **Matskeplishvili S.** (Moscow). Introduction.
- **Matskeplishvili S.** (Moscow). HF patient treatment adherence: necessity of physician-patient cooperation for success achieving.
- **Grinshtein Y.** (Krasnoyarsk). HF and COVID-19 comorbidity: disease course features, timely diagnostics and outcomes.
- **Galyavich A.** (Kazan). Hospital management of a HF patient real practice.
- **Tereschenko S.** (Moscow). Perfection of the health care system for HF patients.
- **Sitnikova M.** (Saint-Petersburg). RusHF HF patients registry: a tool for patients management and interaction with them.

11:00–12:30

CONFERENCE HALL №6 (D4)

**SYMPOSIUM
WITHOUT A NURSE — AS WITHOUT HANDS:
THE ROLE AND FUNCTIONS OF A NURSE IN THE
SYSTEM OF OUTPATIENT MANAGEMENT OF PATIENTS
WITH CHF**
Chairperson: Ageev F.T. (Moscow)

- **Mareev Yu.V.** (Moscow). The role of the nurse in the treatment of CHF in different countries.
- **Svirida O.N.** (Moscow). The role of a nurse in the provision of outpatient care for patients with CHF.
- **Blankova Z.N.** (Moscow). Practical aspects of the work of a nurse in the CHF cabinet.
- **Begrambekova Yu.L.** (Moscow). Dialogue with the patient: diet and exercise.

11:00–12:30

CONFERENCE HALL №7 (B1)
**SATELLITE SYMPOSIUM
CURRENT PROSPECTS FOR THE USE OF
ACETYLSALICYLIC ACID IN WIDE CLINICAL
PRACTICE FROM THE PREVENTIVE MEDICINE
POINT OF VIEW**

(supported by Stada, CME credits are not accrued)

Chairpersons: Vavilova T. (Moscow)

- **Vavilova T.** (Moscow). Primary prevention of CVD: are all the i's dotted and the t's crossed?
- **Lomakin N.** (Moscow). Arterial thrombosis prevention in the Post-Covid era.
- **Gilyarevskiy S.** (Moscow). Clinical and pharmacological aspects of acetylsalicylic acid use in patients with chronic coronary artery disease: form and content.

11:00–12:30

CONFERENCE HALL №8 (B2)
**SATELLITE SYMPOSIUM
INTERNATIONAL MULTIDISCIPLINARY FORUM
HIGH CV RISK PATIENT — FOCUS ON RESULTS.
CORRECTION OF DYSLIPIDEMIA IN THE CLINICAL
PRACTICE OF A CARDIOLOGIST, PEDIATRICIAN,
NEUROLOGIST AND ENDOCRINOLOGIST. PART 2.**

(supported by Amgen, CME credits are not accrued)

Chairpersons: Gurevich V. (Saint-Petersburg), **Ezhov M.** (Moscow)

- **Ezhov M.** (Moscow). Welcome, greetings. Moderation.
- **Konovalov G.** (Moscow). Familial hypercholesterolemia as a target for reducing cardiovascular mortality.
- **Sadykova D.** (Kazan). Dyslipidemia in the practice of a pediatric cardiologist: basic approaches to diagnosis and treatment.

- **Wiegman A.** (Netherlands). Familial Hypercholesterolemia in children and adolescents: gaining decades of life by optimizing detection and treatment.
- **Galstyan G.** (Moscow). Management of cardiovascular risks in patients with diabetes. Combined lipid-lowering therapy: from recommendations to real clinical practice.
- **Alieva A.** (Saint-Petersburg). Management of cardiovascular risks in dyslipidemias as part of primary prevention. The role of the decision support system.

11:00–12:30

CONFERENCE HALL №9 (B6-B8)
**SATELLITE SYMPOSIUM
INTERNATIONAL PANORAMA**

(supported by Boehringer Ingelheim, CME credits are not accrued)

Chairpersons: Glezer M. (Moscow)

- **Tyrenko V.** (Saint-Petersburg). Neutralizing Anticoagulant Therapy: Pride and Prejudice. World Practical Experience
- **Villevalde S.** (Saint-Petersburg). News from the European Congress of Cardiology 2021.
- **Babenko A.** (Saint-Petersburg). News from the European Congress of Endocrinology 2021.

11:00–12:30

CONFERENCE HALL №10 (A1-A3)
**JOINT RUSSIAN-TURKISH SYMPOSIUM (TOGETHER
WITH THE TURKISH SOCIETY OF CARDIOLOGY)
PATIENTS WITH STENOSIS OF THE LEFT
CORONARY ARTERY OR WITH AORTIC STENOSIS.
ANSWERS TO DIFFICULT QUESTIONS**

Simultaneous translation

Chairpersons: **Aytekin V.** (Turkey), **Uspenskiy V.E.** (Saint-Petersburg),
Duplyakov D.V. (Samara)

- **Degertekin M.** (Turkey). Left Main Coronary Stenting-New Concepts.
- **Kavteladze Z.A.** (Moscow). Stenting of the left coronary artery in ACS and chronic coronary artery disease.
- **Okuyan E.** (Turkey). Transcatheter aortic valve replacement-new concepts.
- **Uspensky V.E.** (St. Petersburg). Surgical replacement of the aortic valve. Where to go?

11:00–12:30

CONFERENCE HALL №11 (A4-A5)
**SYMPOSIUM
A PATIENT WITH PULMONARY HYPERTENSION.
IS EVERYTHING SO UNAMBIGUOUS?**

Chairpersons: **Avdeev S.** (Moscow), **Moiseeva O.** (Saint-Petersburg)

- **Avdeev S.** (Moscow). Differential diagnosis of IPH from CTPH. Two sides of the same coin.
- **Moiseeva O.** (Saint-Petersburg). From Pulmonary embolism to CTPH. How not to miss precious time.
- **Vasiltseva O.** (Novosibirsk). Cancer patient with CTPH. Is everything so unambiguous.

11:00–12:30

CONFERENCE HALL №12 (A8-A9)
**SECTION SESSION
INTERDISCIPLINARY PROBLEMS IN CARDIOLOGY**

Chairpersons: **Belyalov F.I.** (Irkutsk), **Garganeeva N.P.** (Tomsk)

- **Shilov S.N.** (Novosibirsk), **Kopyeva K.V.** (Tomsk), **Berezikova E.N.**, **Popova A.A.**, **Neupokoeva M.N.**, **Ratushnyak E.T.** (Novosibirsk), **Teplyakov A.T.** (Tomsk). Anthracycline-induced cardiotoxicity: molecular genetic predictors.
- **Smirov V.V.**, **Bondarev S.A.** (Saint-Petersburg). High sports results and the problem of arterial hypertension in women. Development mechanisms, diagnostics, ways of correction.
- **Yaroslavskaya E.I.**, **Krinochkin D.V.**, **Shirokov N.E.**, **Gulyaeva E.P.**, **Garanina V.D.**, **Mamarina A.V.**, **Osokina N.A.**, **Gorbatenko E.A.**, **Petelina T. I.** (Tyumen). Dynamics of indicators of the cardiovascular profile of patients with COVID-19 pneumonia three months after discharge from the hospital.
- **Shpagina L.A.**, **Likhenko-Logvinenko K.V.**, **Shpagin I.S.**, **Kotova O.S.**, **Gerasimenko D.A.**, **Kamneva N.V.**, **Anikina E.V.** (Novosibirsk). Cardiorespiratory continuum in patients with a new coronavirus infection.
- **Efimova O.I.**, **Pavlova T.V.**, **Khokhlunov S.M.** (Samara). Evaluation of treatment outcomes in patients with atrial fibrillation after cardioembolic stroke depending on the outpatient monitoring strategy.
- **Trofimova T.A.**, **Polyakova E.B.** (Moscow). Application of ECG event recorders in the diagnosis of cardiac arrhythmias in children.
- **Magomedova K.A.**, **Komarov R.N.**, **Fomin V.V.**, **Shcheglov M.I.**, **Isaev R.M.** (Moscow). Operation "Russian conduit": a view of a cardiologist.

11:00–12:30

ONLINE HALL №1

**TRAINING WORKSHOP
NUTRITION IN CARDIOVASCULAR DISEASES —
UNDERESTIMATED OPPORTUNITIES FOR SAVING
LIVES**

Chairpersons: **Nikulina S.** (Krasnoyarsk), **Benimetskaya K.** (Novosibirsk), **Chernova A.** (Krasnoyarsk)

- **Ionin V.** (Saint-Petersburg). Polyunsaturated fatty acids: myths and reality.
- **Kopylova O.** (Moscow). Mono diets in patients with CVD: what are the benefits and dangers for cardiac patients?
- **Benimetskaya K.** (Novosibirsk), **Semenova E.** (Omsk). Vitamins and minerals in cardiovascular diseases. Nutrition in congenital connective tissue disorders.
- **Derevyanchenko M.** (Volgograd). Nutrition in CHF: new data against the old concepts.
- **Benimetskaya K.** (Novosibirsk). Dietary patterns in CVD: mediterranean, DASH, and PORTFOLIO diets. How to use all the opportunities?
- **Chernova A.** (Krasnoyarsk). Management of overweight and obesity in CVD.

11:00–12:30

ONLINE HALL №2

**TRAINING WORKSHOP
GUIDELINES AND REAL CLINICAL PRACTICE:
MANAGEMENT OF COMORBID PATIENTS
WITH CORONARY ARTERY DISEASE DURING
MYOCARDIAL REVASCULARIZATION**

Chairpersons: **Drobotya N.** (Rostov-on-Don), **Khaisheva L.** (Rostov-on-Don), **Ratova L.** (Saint-Petersburg)

- **Drobotya N.** (Rostov-on-Don). Preparing a polymorbid patient for CAG and PCI — what do the guidelines say and what should a doctor do?
- **Khaisheva L.** (Rostov-on-Don). Patient with arterial hypertension and CKD — how to minimize the risks.
- **Ratova L.** (Saint-Petersburg). Patient with diabetes mellitus before and after PCI — how to minimize the risk of cardiovascular death.
- **Baryshnikova G.** (Moscow). Patient with atrial fibrillation before and after PCI — features of the clinical use of DOAC.

12:40–13:20

PLENARY HALL

PLENARY LECTURES

On-line broadcasting/ Simultaneous translation

- **Zamorano J.L.** (Spain). New approaches in treatment of Tricuspid Regurgitation, from Anatomy to Intervention.
- **Atar D.** (Norway). The new ESC Heart Failure Guidelines OR What is new in antithrombosis?

Moderator: **Matskeplishvili S.T.** (Moscow)

13:30–15:00

PLENARY HALL
**PLENARY SESSION
HYBRID TECHNOLOGIES AT THE INTERSECTION
OF SPECIALTY**

On-line broadcasting/ Simultaneous translation

Chairpersons: Shevchenko Yu.L. (Moscow), **Chernyavskiy M.A.** (Saint-Petersburg)

- **Chernyavsky A.M.** (Novosibirsk). Open and endovascular treatment of chronic postembolic pulmonary hypertension.
- **Kavteladze Z.A. (Moscow)**. The brilliance and poverty of endovascular surgery.
- **Chernyavsky M.A.** (Saint-Petersburg). A paradigm shift in Aortic and Non-Branching Surgery in High Cardiac Risk Patients.
- **Shevchenko Yu.L.** (Moscow). Hybrid cardiac rehabilitation technologies for long-term support of patients with atrial fibrillation after interventional procedures.

13:30–15:00

CONFERENCE HALL №1 (E8-E9)
**SYMPOSIUM
POSSIBILITIES OF INITIATING MYOCARDIAL
REMODELING INVERSION IN HEART FAILURE**
Chairpersons: Skibitskiy V. (Krasnodar), **Lelyavina T.** (Saint-Petersburg), **Sitnikova M.** (Saint-Petersburg)

- **Skibitskii V.** (Krasnodar). Remodeling of the left ventricular myocardium in CHF patients with metabolic disorders: the possibilities of drug therapy.
- **Lelyavina T.** (Saint-Petersburg). Effect of personalized physical rehabilitation on the morphofunctional parameters of the myocardium in patients with heart failure.
- **Fendrikova A.** (Krasnodar). Arterial hypertension, depression and myocardial remodeling in CHF patients: are there any features of pharmacotherapy?

- **Galenko v.** (Saint-Petersburg). Inversion of remodeling in CHF against the background of various modes of physical rehabilitation.
- **Sitnikova M.** (Saint-Petersburg). Management strategy for patients with “improved” and “corrected” ejection fraction.

13:30–15:00

CONFERENCE HALL №2 (E7)
**SYMPOSIUM
PREVENTION OF CEREBRAL ACCIDENTS BY
TREATING STRUCTURAL HEART DISEASES.
SESSION “STROKE AND HEART”**
Chairpersons: Kulesh A. (Perm), **Ognerubov D.** (Moscow), **Merkulov E.** (Moscow)

- **Kulesh A.** (Perm). Features of ischemic strokes associated with patent foramen ovale and atrial fibrillation.
- **Shchekochihin D.** (Moscow). Patent foramen ovale and atrial fibrillation in the cardiologist practice.
- **Chechetkin A.** (Moscow). Ultrasound diagnostics of the patent foramen ovale and the left atrial appendage as a first step of the correct diagnosis.
- **Ognerubov D.** (Moscow). Decompression illness. Common features with stroke and the pathogenetic role of the patent foramen ovale. Clinical case presentation.
- **Merkulov E.** (Moscow). Percutaneous intervention as a treatment of structural heart diseases — as prevention of ischemic strokes.

13:30–15:00

CONFERENCE HALL №3 (D1)
**SATELLITE SYMPOSIUM
HOW TO TREAT CHF AT THE BEGINNING OF THE
NEW DECADE — WHAT THE LATEST RESEARCH
AND EXPERIENCE HAS LED US TO**

(supported by Novartis, CME credits are not accrued)

Chairpersons: Villevalde S. (Saint-Petersburg)

- **Villevalde S.** (Saint-Petersburg). System of organization of care for patients with heart failure: present and future
- **Mareev V.** (Moscow). Lifehacks in the treatment of heart failure: what the indicators of heart remodeling tell about
- **Zhirov I.** (Moscow). If a patient with CHF hospitalized: priorities at hospital and outpatient stages
- **Glezer M.** (Moscow). CHF and comorbid conditions: how to cope with a complex of diseases.

13:30–15:00

CONFERENCE HALL №4 (D2)
**SYMPOSIUM
D. D. PLETNEV IS A FOUNDER OF THE CLINICAL
AREA OF PSYCHOSOMATIC MEDICINE IN RUSSIA:
TRAGIC FATE AND VICTORY OF THOUGHT.
THE SYMPOSIUM IS DEDICATED TO THE 150TH
ANNIVERSARY SINCE THE BIRTHDAY OF THE
PROMINENT RUSSIAN SCIENTIST**
Chairpersons: Barbarash O. (Kemerovo), **Garganeeva N.** (Tomsk)

- **Garganeeva N.** (Tomsk). Great vision of the future: D. D. Pletnev about mental symptoms in the clinical picture of pure somatic diseases: the lessons of history and modern times.
- **Petrova M.** (Krasnoyarsk). Mental health and active longevity: together or apart?
- **Sumin A.** (Kemerovo). Is the concept of type D personality a component of personalized medicine or a prognostic factor in the treatment of cardiovascular diseases?

- **Belialov F.** (Irkutsk). Cardiac Arrhythmias and Anxiety: Therapeutic Solutions.
- **Trubnikova O.** (Kemerovo), **Syrova Irina S.** (Kemerovo), **Lozhkin I.** (Kemerovo), **Maleva O.** (Kemerovo), **Tarasova I.** (Kemerovo). Features of the cognitive status of patients in the long term after coronary artery bypass grafting five-year observation.

13:30–15:00

CONFERENCE HALL №5 (D3)
**WORKING MEETING OF EXPERTS OF THE RSC
WORKING GROUPS ON THE DEVELOPMENT
OF CLINICAL GUIDELINES**
Chairperson: Shlyakhto E.V. (Saint-Petersburg)

- **Nedogoda S.V. (Volgograd).** Report on the work of the committee and working groups on the preparation of clinical guidelines.
- **Nedogoda S.V. (Volgograd).** Implementation of clinical guidelines in the practice of doctors.
- **Irtyuga O.B. (Saint-Petersburg).** Discussion of the main issues arising in the development of clinical guidelines. Possible solutions.
- **Irtyuga O.B. (Saint-Petersburg).** Plans for the development and updating of clinical guidelines developed by experts of the RCS.
- Discussion of the Team Leaders on the plan for revising the previously developed clinical guidelines.

13:30–15:00

CONFERENCE HALL №6 (D4)

**SCIENTIFIC SESSION
DIGITAL PREVENTION OF CARDIOVASCULAR
DISEASES: REALITY AND PROSPECTS**

Chairpersons: **Demkina A.** (Moscow), **Benimetskaya K.** (Novosibirsk)

- **Demkina A.** (Moscow). World experience: the present and the future of social networks in the prevention of cardiovascular diseases.
- **Benimetskaya K.** (Novosibirsk). Methods and services for remote monitoring of patient nutrition.
- **Bezzubtseva M.** (Voronezh). Social networks in stroke prevention: results and prospects of the online medical school “Stroke in young people”.
- **Lobzhanidze F.** (Stavropol). Features of the perception of medical information about risk factors for arterial hypertension in social networks.
- **Isaeva A.** (Ekaterinburg). Results of testing an electronic medical platform for remote monitoring of patients with chronic heart failure, created on the territory of the Russian Federation.

13:30–15:00

CONFERENCE HALL №7 (B1)

**SYMPOSIUM
BIOMARKERS IN CLINICAL CARDIOLOGY
PRACTICE**

Chairpersons: **Belenkov Y.** (Moscow), **Drapkina O.** (Moscow)

- **Drapkina O.** (Moscow). Epigenetics and cardiovascular diseases.
- **Kozhevnikova M.** (Moscow). Biomarkers of Heart Failure: present and future.
- **Ilgisonis I.** (Moscow). Proven biomarkers of cardiotoxicity of anticancer therapy in the management of cardio-oncological patients.
- **Duplyakov D.** (Samara). Biomarkers in acute coronary syndrome: possibilities and clinical algorithms.

13:30–15:00

CONFERENCE HALL №8 (B2)

**SATELLITE SYMPOSIUM
CLINICAL TRIALS IN RUSSIA: WHAT IS IMPORTANT
FOR SUCCESS IN THE TIMES OF CHANGES?**

(Satellite symposium, CME credits are not accrued)

- **Opening.**
- **Semenova Y. (Novartis).** Modern trends in cardiac research. Innovations introduced during COVID-19 constraints that will stay with us in the new reality.
- **Andreev A. (Servier).** How can the center remain competitive in the face of current trends in research in cardiology? Innovations introduced during COVID-19 constraints: what should you look out for?
- Discussion. Are we ready for changes in the organization of clinical trials in cardiology in the near future?
- **Closing.**

13:30–15:00

CONFERENCE HALL №9 (B6-B8)

**SYMPOSIUM
MODERN ISSUES OF STRESS
ECHOCARDIOGRAPHY TECHNIQUE**

Chairpersons: **Alekhin M.** (Moscow), **Boshchenko A.** (Tomsk), **Bobrov A.** (Saint-Petersburg)

- **Alekhin M.** (Moscow). Current issues of exercise stress echocardiography.
- **Boshchenko A.** (Tomsk). Stress echocardiography with pharmacological agents: advantages, disadvantages and unresolved issues.
- **Bobrov A.** (Saint-Petersburg). Stress echocardiography with pacing: capabilities and features of the method.
- **Ovchinnikov A.** (Moscow). Diastolic stress test — who, when, and why.

13:30–15:00

CONFERENCE HALL №10 (A1-A3)
**JOINT RUSSIAN-TURKISH SYMPOSIUM
(TOGETHER WITH THE TURKISH
CARDIOVASCULAR ACADEMY SOCIETY)
DIFFICULT PATIENTS: WHAT THE GUIDELINES
SAY?**

Simultaneous translation

Chairpersons: Galyavich A.S. (Kazan), **Kozan Ö.** (Turkey)

- **Kalemberg A.A.** (Moscow). New recommendations in management of AF.
- **Zoghi M.** (Turkey). Universal heart failure definition and new treatment recommendations for patients with HF_{rEF}.
- **Ekici B.** (Turkey). SGLT2 inhibitors in non-diabetics.
- **Prokhorikhin A.A.** (Saint-Petersburg). Controversies in revascularisation for chronic coronary syndrome.

13:30–15:00

CONFERENCE HALL №11 (A4-A5)
**CLINICAL CASES
DIFFICULT PATIENTS ON THE CARDIOLOGIST'S
APPOINTMENT**
Chairpersons: Oleinikov V.E. (Penza), **Libis R.A.** (Orenburg)

- **Devyatova M.D., Isaeva A.V. (Ekaterinburg), Demkina A.E. (Moscow).** Identification of a case of familial hypercholesterolemia at the outpatient stage using cascade screening.
- **Chernysheva S.G., Hasanova R.M. (Moscow).** Pregnancy and coronary heart disease.
- **Zolotareva E.V., Runkova O.M. (Ekaterinburg).** A clinical case of postmyocarditis sclerosis associated with SARS-COV-2.
- **Karanadze N.A., Begrambekova Yu.L., Orlova Ya.A., Filatova D.A. (Moscow).** The effectiveness of complex training of respiratory muscles (RM) with a sequential connection of aerobic training and their impact on the functional parameters of a patient with chronic heart failure (CHF).

13:30–15:00

CONFERENCE HALL №12 (A8-A9)
**SECTION SESSION
NON-CORONARY DISEASES, VALVULAR
PATHOLOGY, CONGENITAL DISEASES, PEDIATRIC
CARDIOLOGY, PULMONARY HYPERTENSION**
Chairpersons: Demin A.A. (Novosibirsk), **Pavlyukova E.N.** (Tomsk)

- **Chumakova O.S., Reznichenko N.E., Voloshina N.M., Arkhipkina T.S., Ukhova L.V., Petrashevich T.V., Mirzoev E.E., Spektor V.I., Kozachuk L.T., Alkam D.M., Arutyunyan R.R., Ilyenkova N.A., Drobyazko O.A., Isaeva M.Yu., Abushenko M.I., Zotov A.S., Baklanova T.N., Zateyshchikov D.A. (Moscow).** Hypertrophic cardiomyopathy and arterial hypertension — features of the clinical profile and prognosis.
- **Kotova E.O., Domonova E.A., Pisaryuk A.S., Karaulova Yu.L., Moiseeva A.Yu., Kobalava Zh.D. (Moscow).** The diagnostic advantage of PCR studies in the etiological diagnosis of infective endocarditis.
- **Gorbunova E.V., Rozhnev V.V., Bezgans A.V., Taran I.N., Barbarash O.L. (Kemerovo).** Educational program for patients with prosthetic heart valves (10 years of follow-up).
- **Goncharova N.S., Simakova M.A., Marichev A.O., Malikov K.N., Zaitsev V.V., Moiseeva O.M. (Saint-Petersburg).** Peculiarities of the course of idiopathic pulmonary arterial hypertension in patients over 60 years of age according to the data of the Northwestern Register of Pulmonary Hypertension.
- **Lyapina I.N. (Kemerovo), Belevskaya A.A., Valieva Z.S., Saidova M.A., Martynyuk T.V. (Moscow).** Modern markers of cardiac remodeling in different phenotypes of patients with idiopathic and chronic thromboembolic pulmonary hypertension.
- **Lutokhina Yu.A., Blagova O.V., Shestak A.G., Polyak M.E., Bukaeva A.A., Zaklyazminskaya E.V., Varionchik N.V., Sedov V.P., Kogan E. A., Alexandrova S.A., Nedostup A.V. (Moscow).** Combination of arrhythmogenic right ventricular dysplasia and non-compact left ventricular myocardium: clinical picture, diagnosis, genetic nature, course.

13:30–15:00

ONLINE HALL №1

**SATELLITE SYMPOSIUM
INNOVATIVE APPROACH TO CARDIO-VASCULAR
RISK PREDICTION: HS-TROPONIN-I IN PRIMARY
PREVENTION, INTERNATIONAL EXPERIENCE AND
RUSSIAN STUDIES**

(supported by Abbott, CME credits are not accrued)

Chairpersons: Arutyunov G. (Moscow)

- **Arutyunov G.** (Moscow). Risk stratification of MI, HF and stroke — new tools available to physicians.
- **Ezhov M.** (Moscow). Atherosclerosis and hs-Troponin-I: is there a link?
- **Kontsevaya A.** (Moscow). Troponin-I in the Russian population: risk prognosis of fatal and non-fatal cardiovascular events.
- **Farmakis D.** (Greece). Role and place of hs-troponin in population screening of CVD.

13:30–15:00

ONLINE HALL №2

**SYMPOSIUM
PATIENT MANAGEMENT WITH PE:
ANALYSIS OF COMPLEX CASES**
Chairpersons: Averkov O. (Moscow), **Martynyuk T.** (Moscow)

- **Averkov O.** (Moscow). Venous thrombosis and pulmonary embolism in inpatients with COVID-19.
- **Iakushin S.** (Ryazan). Inpatient management of a patient with recurrent pulmonary embolism.
- **Martynyuk T.** (Moscow). PE in a patient with chronic thromboembolic pulmonary hypertension.
- **Vinogradov O.** (Moscow). PE in a patient with ischemic stroke.
- **Filippov E.** (Ryazan). PE in the early stages after surgery.

15:30–17:00

PLENARY HALL

**PLENARY SESSION
CLOSING OF THE CONGRESS**

On-line broadcasting/ Simultaneous translation

Chairpersons: Shlyakhto E.V. (Saint-Petersburg), **Ferrari R.** (Italy), **Galyavich A.S.** (Kazan)

- **Ferrari R.** (Italy). How will the near future change in terms of cardiovascular research?
- **Matskeplishvili S.T.** (Moscow). Cardiovascular imaging — what's new?
- **Casadei B.** (UK). Atrial fibrillation: what's new?
- **Arutyunov G.P.** (Moscow). Chronic Kidney Disease in Cardiology — What's New?
- **Closing ceremony.**

GENERAL PARTNERS



PRINCIPAL PARTNERS



PARTNERS



EXHIBITORS



GENERAL INFORMATION PARTNER



НАУЧНО-ПРАКТИЧЕСКИЙ РЕЦЕНЗИРУЕМЫЙ МЕДИЦИНСКИЙ ЖУРНАЛ

РОССИЙСКОЕ КАРДИОЛОГИЧЕСКОЕ ОБЩЕСТВО

INFORMATION PARTNERS



ИЗДАТЕЛЬСКАЯ ГРУППА
«ГЭОТАР-Медиа»



OmniDoctor

Medical Journal
Лечащий Врач



МЕДФОРУМ



Рациональная
Фармакотерапия
в Кардиологии



**МЕДИЦИНСКИЙ
ВЕСТНИК**

МЕДИЦИНСКИЙ
ОППОНЕНТ

БРИЛАНТА® ДОСТУПНО
БЕСПЛАТНО
НА 12 МЕСЯЦЕВ

БРИЛАНТА® ПРЕДОТВРАЩАЕТ БОЛЬШЕ СЕРДЕЧНО-СОСУДИСТЫХ СОБЫТИЙ У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ

ВНЕ ЗАВИСИМОСТИ
ОТ НАЛИЧИЯ

В АНАМНЕЗЕ

СПАСАЕМ БОЛЬШЕ
СЕГОДНЯ И ЗАВТРА

БРИЛАНТА®
тикагрелор таблетки

* Тикагрелор 90 мг в составе двойной антитромбоцитарной терапии (ДАТ) vs клопидогрел в составе ДАТ у пациентов с ОКС¹ или тикагрелор 60 мг в составе ДАТ vs монотерапия аспирином у пациентов со стабильной ИБС и высоким ишемическим риском^{4,5,6}

БРИЛАНТА® 90 мг (тикагрелор) КРАТКАЯ ИНСТРУКЦИЯ ПО МЕДИЦИНСКОМУ ПРИМЕНЕНИЮ. Регистрационный номер: ПИ-000395. Торговое название: Бриланта®. Международное непатентованное название: тикагрелор. Лекарственная форма: таблетки, покрытые пленочной оболочкой. Показания к применению: «Бриланта (тикагрелор)» применяется однократно с антиагрегантными кислотами, показан для профилактики атеротромботических осложнений у пациентов с острым коронарным синдромом (неустойчивой стенокардией, инфарктом миокарда без подъема сегмента ST или инфарктом миокарда с подъемом сегмента ST (STEMI)), а также у пациентов, получающих лечение травмой и пациентов, подвергшихся коронарному вмешательству (ЧКВ) или коронарному шунтированию (КАЧ). Противопоказания: Повышенная чувствительность к тикагрелору или любому из компонентов препарата. Активное патологическое кроветечение. Внутреннее кровоизлияние в анамнезе. Печеночная недостаточность тяжелой степени. Совместное применение тикагрелора с мощными ингибиторами СР3АА (например, итеноксазолом, клофидрогелем, нефлоксином, ритонавиром и атазанавиром). Детский возраст до 18 лет (в связи с отсутствием данных об эффективности и безопасности применения данного препарата у детей). Вероятность периода грудного вскармливания. «Бриланта» противопоказана в случаях кровотечения (например, в связи с наличием почечной травмы), недавней проведенной операции, нарушениями свертываемости крови, активной или недавней желудочно-кишечной кровотечением) или повышенный риск травмы. Сопутствующая травма (переломы, вывихи, растяжения мышц, повышенный риск кровотечения (т.е. нестероидные противовоспалительные препараты, пероральные антикоагулянты или фибринолитики) в течение 24 часов до приема препарата Бриланта®. Понижение печеночной недостаточности средней степени тяжести. Пациенты с повышенным риском развития брадикардии (например, пациенты без электрокардиографии с умеренной слабостью синусового узла, с атриовентрикулярной блокадой 2-ой или 3-ей степени, обморочком, связанным с брадикардией); совместное применение с препаратами, вызывающими брадикардию. Пациенты с брадикардией (средней или тяжелой) и/или синобрадикардией (включая частоту сердечных сокращений (ЧСС) менее 50 ударов в минуту (У/мин)). Пациенты в возрасте от 75 лет и старше; пациенты с умеренной или тяжелой почечной недостаточностью; пациенты, получающие терапию антиагонистами рецепторов ангиотензина II. Пациенты с приемом лекарственных препаратов. Сопутствующая терапия дислипидемии: мощными ингибиторами липопротеина СР3АА (например, верапамилом или клопидогрелом); селективными ингибиторами обратного захвата серотонина (например, парoksetином, сертралином и циталопрамом); препаратами, влияющими на гексозы. Совместное применение с ДАТ: Применение препарата Бриланта® следует начинать с двойной антиагрегантной терапии (ДАТ) (например, верапамилом или клопидогрелом); селективными ингибиторами обратного захвата серотонина (PLA2 или PEGASUS); липидными средствами (например, АС (с 75 мг до 150 мг при постоянной терапии)), если отсутствует специфическое противопоказание. Побочные действия: «Профиль безопасности препарата Бриланта» изучался в двух крупных рандомизированных исследованиях (PLATO и PEGASUS), в которых пациенты участвовали в течение 3000 пациентов. Нежелательные реакции, отмеченные в клинических исследованиях или при постмаркетинговом применении препарата Бриланта®, распределены по классу системы органов и частоте развития. Частота развития нежелательных реакций определяется с использованием следующей категории: очень часто (≥10%), часто (≥1%), нечасто (≥1/1000, <1/100), очень редко (≥1/10000, <1/1000), неизвестно (невозможно оценить по полученным данным). Доброкачественные, ложноопухольчатые и неопухольчатые новообразования (включая частоту и тип): нечасто – кровотечения из опухоли. Нарушения со стороны крови и лимфатической системы: очень часто – кровотечения; связанное с заболеваниями крови. Нарушение со стороны иммунной системы: нечасто – гиперчувствительность, включая анафилактическую реакцию. Нарушения со стороны обмена веществ и питания: очень часто – падение/подъездригической АТТ. Нарушения со стороны зрения: нечасто – спутанность сознания. Нарушения со стороны нервной системы: часто – головомозжение, обмороч, головная боль, нечасто – вегетативные нарушения, головокружение и/или лабиринтные нарушения; часто – вертиго; нечасто – головокружение в леж. Нарушения со стороны скелетно-мышечной и соединительной ткани: нечасто – артериальная гипотензия. Нарушения со стороны дыхательной системы, органов грудной клетки и средостения: очень часто – одышка; часто – кровотечения из органов дыхательной системы. Нарушения со стороны желудочно-кишечного тракта: часто – желудочно-кишечное кровотечение, диарея, тошнота, диспепсия, запор; нечасто – дисперсионное кровотечение. Нарушения со стороны кожи и подкожных тканей: часто – одышка; часто – кожные высыпания, кожный зуд, кожная сыпь. Нарушения со стороны скелетно-мышечной и соединительной ткани: нечасто – кровотечения из мышц. Нарушения со стороны почек и мочевыделительной системы: часто – кровотечения из мочевыделительной системы. Нарушения со стороны половых органов и молочной железы: нечасто – кровотечения из половых путей. Лабораторные и инструментальные данные: часто – повышение концентрации креатинина в крови. Функция ангиотензина и системы маневрирования: часто – увеличение после проведения маневрирования, транзиторное кроветечение. Дата утверждения – 11.06.2020.

БРИЛАНТА® 60 мг (тикагрелор) КРАТКАЯ ИНСТРУКЦИЯ ПО МЕДИЦИНСКОМУ ПРИМЕНЕНИЮ. Регистрационный номер: ПИ-003779. Торговое название: Бриланта®. Международное непатентованное название: тикагрелор. Лекарственная форма: таблетки, покрытые пленочной оболочкой. Показания к применению: «Бриланта (тикагрелор)» применяется однократно с антиагрегантными кислотами, показан для профилактики атеротромботических осложнений у взрослых пациентов с инфарктом миокарда в анамнезе (инфаркт миокарда без подъема сегмента ST или без подъема и/или инфаркт миокарда с подъемом сегмента ST (STEMI)), а также у пациентов, получающих лечение травмой и пациентов, подвергшихся коронарному вмешательству (ЧКВ) или коронарному шунтированию (КАЧ). Противопоказания: Повышенная чувствительность к тикагрелору или любому из компонентов препарата. Активное патологическое кроветечение. Внутреннее кровоизлияние в анамнезе. Печеночная функция легкой степени тяжести. Совместное применение тикагрелора с мощными ингибиторами изофермента СР3АА (например, итеноксазолом, клофидрогелем, нефлоксином, ритонавиром и атазанавиром). Детский возраст до 18 лет (в связи с отсутствием данных об эффективности и безопасности применения данного препарата у детей). Вероятность периода грудного вскармливания. «Бриланта» противопоказана в случаях кровотечения (например, в связи с наличием почечной травмы), недавней проведенной операции, нарушениями свертываемости крови, активной или недавней желудочно-кишечной кровотечением) или повышенный риск травмы. Сопутствующая травма (переломы, вывихи, растяжения мышц, повышенный риск кровотечения (т.е. нестероидные противовоспалительные препараты, пероральные антикоагулянты или фибринолитики) в течение 24 часов до приема препарата Бриланта®. Понижение печеночной недостаточности легкой степени тяжести. Пациенты с повышенным риском развития брадикардии (например, пациенты без электрокардиографии с умеренной слабостью синусового узла, с атриовентрикулярной блокадой 2-ой или 3-ей степени, обморочком, связанным с брадикардией); совместное применение с препаратами, способными вызвать брадикардию. Пациенты с брадикардией (средней или тяжелой) и/или синобрадикардией (включая частоту сердечных сокращений (ЧСС) менее 50 ударов в минуту (У/мин)). Пациенты в возрасте от 75 лет и старше; пациенты с умеренной или тяжелой почечной недостаточностью; пациенты, получающие терапию антиагонистами рецепторов ангиотензина II. Пациенты с приемом лекарственных препаратов. Сопутствующая терапия дислипидемии: мощными ингибиторами липопротеина СР3АА (например, верапамилом или клопидогрелом); селективными ингибиторами обратного захвата серотонина (например, парoksetином, сертралином и циталопрамом); препаратами, влияющими на гексозы. Совместное применение с ДАТ: Применение препарата Бриланта® следует начинать с двойной антиагрегантной терапии (ДАТ) (например, верапамилом или клопидогрелом); селективными ингибиторами обратного захвата серотонина (PLA2 или PEGASUS); липидными средствами (например, АС (с 75 мг до 150 мг при постоянной терапии)), если отсутствует специфическое противопоказание. Побочные действия: «Профиль безопасности препарата Бриланта» изучался в трех крупных рандомизированных исследованиях (PLATO, PEGASUS и THEMIS), в которых было 32000 пациентов, и которых было 32000 приемов тикагрелора. Нежелательные реакции, отмеченные в клинических исследованиях или при постмаркетинговом применении препарата Бриланта®, распределены по классу системы органов и частоте развития. Частота развития нежелательных реакций определяется с использованием следующей категории: очень часто (≥10%), часто (≥1%), нечасто (≥1/1000, <1/100), очень редко (≥1/10000, <1/1000), неизвестно (невозможно оценить по полученным данным). Доброкачественные, ложноопухольчатые и неопухольчатые новообразования (включая частоту и тип): нечасто – кровотечения из опухоли. Нарушения со стороны крови и лимфатической системы: очень часто – кровотечения; связанное с заболеваниями крови. Нарушения со стороны иммунной системы: нечасто – гиперчувствительность, включая анафилактическую реакцию. Нарушения со стороны обмена веществ и питания: очень часто – падение/подъездригической АТТ. Нарушения со стороны нервной системы: часто – головомозжение, обмороч, головная боль, нечасто – вегетативные нарушения, головокружение и/или лабиринтные нарушения; часто – вертиго; нечасто – головокружение в леж. Нарушения со стороны скелетно-мышечной и соединительной ткани: нечасто – артериальная гипотензия. Нарушения со стороны дыхательной системы, органов грудной клетки и средостения: очень часто – одышка; часто – кровотечения из органов дыхательной системы. Нарушения со стороны желудочно-кишечного тракта: часто – желудочно-кишечное кровотечение, диарея, тошнота, диспепсия, запор; нечасто – дисперсионное кровотечение. Нарушения со стороны кожи и подкожных тканей: часто – одышка; часто – кожные высыпания, кожный зуд, кожная сыпь. Нарушения со стороны скелетно-мышечной и соединительной ткани: нечасто – кровотечения из мышц. Нарушения со стороны почек и мочевыделительной системы: часто – кровотечения из мочевыделительной системы. Нарушения со стороны половых органов и молочной железы: нечасто – кровотечения из половых органов. Лабораторные и инструментальные данные: часто – повышение концентрации креатинина в крови. Функция ангиотензина и системы маневрирования: часто – увеличение после проведения маневрирования, транзиторное кроветечение. Дата утверждения – 24.02.2021.

Ссылки для информации по применению: 1. Полная редакция раздела «Способ применения и дозы» см. в инструкции в полном варианте инструкции. 2. Полная редакция раздела «Побочные действия» см. в инструкции в полном варианте инструкции. 3. Полная редакция раздела «Побочные действия» см. в инструкции в полном варианте инструкции. 4. Т. спонтанное, связанное с приемом препарата или транзиторное вегетативное кровоизлияние. 5. Отмечено при постмаркетинговом применении. 6. Препараты назначены для профилактики тромбообразования, поэтому, с полной инструкцией по медицинскому применению. Дальнейшая информация предоставляется по требованию: 006-AR-Registraция Фармакологическая.

1. Melloni L et al. *Engl J Med*. 2009;361:1045-1052. 2. Инструкция по медицинскому применению лекарственного препарата «Бриланта» (таблетки, покрытые пленочной оболочкой, 60 мг). Регистрационное удостоверение ПИ-003779 от 12.08.2016 г. (перереформулировано 24.02.2021). 3. Государственный реестр лекарственных средств. Электронный реестр. URL: <http://grls.rosminzdrav.ru/Default.aspx> (дата обращения: 23.03.2021). 4. Venok M, Bhatt DL, et al. *N Engl J Med*. 2015; 373:1199-1209. 5. Steg PG, et al. *Am J Cardiol*. 2019; 59: 2839-2841. 6. URL: <http://1105-1107>. 7. Инструкция по применению лекарственного препарата Бриланта® (таблетки, покрытые пленочной оболочкой) 90 мг. Регистрационное удостоверение ПИ-000395 от 27.02.2011 г. (перереформулировано 11.06.2020). 8. Тромба Макардуза. Россия от 09.01.2020. 9. Об утверждении перечня лекарственных препаратов для медицинского применения для обеспечения в условиях отсутствия данных об амбулаторных условиях или, которые перекрестно относятся к одному из классов лекарственных средств, а также который был выдан в виде исключения для применения в амбулаторных условиях при стабилизации коронарных артерий (с терапевтическим и хирургическим вмешательством) (Зарегистрировано в Минздраве России 24.10.2020 №12722).

Материал подготовлен для специалистов здравоохранения. Имеются противопоказания. Перед началом приема проконсультируйтесь с врачом. Информация о наличии инструкции по медицинскому применению лекарственного препарата 006-AR-«Бриланта» Фармацевтический, Россия 121312 Москва, 11 Напросветовской проезд. ДМ. стр. 1. Тел: + (495) 799 56 99, факс: + (495) 799 56 98 www.astrazeneca.ru ВР 98-10002. Дата формирования: 08.04.2021. Дата изменения: 09.04.2021.



А что для Вас значит надежно и бережно заботиться о близких?

- Даже у пожилых пациентов с ФП Ксарелто[®] снижал риск инсульта и жизнеугрожающих кровотечений в сравнении с варфарином^{1,*}
- Ксарелто[®] способствовал лучшему сохранению функции почек у пациентов с ФП в сравнении с варфарином^{2,***}
- У широкого круга пациентов, в том числе пожилых с ФП, Ксарелто[®] снижал риск как инсульта, так и ИМ/ОКС^{3,‡}
- Однократный режим дозирования и календарная упаковка Ксарелто[®] могут помочь пожилым пациентам соблюдать ваши рекомендации⁴⁻⁶

ЕЩЁ ОСТАВ ДЕДУШКИНЫ ШУТОК

КАК ВАЖНО ЭТО СОХРАНИТЬ!

КСАРЕЛТО[®] Международное непатентованное наименование: ривароксабан. **Лекарственная форма:** таблетки покрытые пленочной оболочкой. Таблетка покрыта пленочной оболочкой содержит 15,00 мг или 20,00 мг ривароксабана микроинкапсулированного. **ПОКАЗАНИЯ К ПРИМЕНЕНИЮ** – профилактика инсульта и системной тромбоэмболии у пациентов с фибрилляцией предсердий незначительного происхождения – лечение тромбоза глубоких вен и тромбоэмболии легочной артерии и профилактика рецидивов ТГВ и ТЭЛА. **ПРОТИВОПОКАЗАНИЯ:** повышенная чувствительность к ривароксабану или любым его компонентам (веществам, содержащимся в таблетке), химически значимые активные кровотечения (например, внутреннее кровоизлияние, желудочно-кишечные кровотечения), повреждение или состояние, связанное с повышенным риском большого кровотечения, например, имеющаяся или недавно перенесенная желудочно-кишечная язва, наличие злокачественных опухолей с высоким риском кровотечения, недавние травмы головы или спинного мозга, операции на головном, спинном мозге или глазах, внутреннее кровоизлияние, до-ангиоплазмированный или протромбированный варикоз вен пищевода, артериовенозные мальформации, аневризмы сосудов или патологии сосудов головного или спинного мозга, сопутствующая терапия камили-тибо другими антикоагулянтами, например, нефракционированным гепарином, низкомолекулярными гепаринами (энноксапарин, далтепарин и др.), прокаинамином гепарином (фосфадарином и др.), пероральными антикоагулянтами (варфарин, аписксабан, дабигатран и др.), кроме случаев перелива или при ривароксабане или при применении нефракционированного гепарина в дозах, необходимых для обеспечения функционирования центрального венозного или артериального катетера. Заболевания печени, прогрессирующие с сопутствием, которые обуславливают клинически значимый риск кровотечений. Беременность и период грудного вскармливания. Детский и подростковый возраст до 18 лет (эффективность и безопасность у пациентов данной возрастной группы не установлены). Тяжелая степень нарушения функции почек (ККР <15 мл/мин). Клинические данные о применении ривароксабана у данной категории пациентов отсутствуют. врожденный дефицит лактазы, непереносимость лактозы, глюкозо-6-фосфатная мальабсорбция (в связи с наличием в составе лактозы). **ОСТОРОЖНОСТЬ:** При лечении пациентов с повышенным риском кровотечения (в том числе при врожденной или приобретенной тромбоцитопении, кровотечениях, некторируемой тяжелой артериальной гипертензии, явственной болезни желудка и 12-перстной кишки в стадии обострения, недавно перенесенной язвенной болезни желудка и 12-перстной кишки, соудостомии ретинопатии, бронхоэктазах или легочном кровотечении в анамнезе). При лечении пациентов со средней степени нарушения функции почек (ККР 30-49 мл/мин), получающих одновременно препараты, повышающие концентрацию ривароксабана в плазме крови. При лечении пациентов с тяжелой степенью нарушения функции почек (ККР 15-29 мл/мин). У пациентов, получающих одновременно лекарственные препараты, влияющие на гемостаз, например, нестероидные противовоспалительные препараты (НПВП), антиагреганты, другие антигипертензивные средства или селективные ингибиторы обратного захвата серотонина (СИОЗС) и селективные ингибиторы обратного захвата серотонина и нуринеридина (СИОЗСН). Ривароксабан не рекомендуется применять у пациентов, получающих системные препараты азоловой группы или ингибиторы протазы ВИЧ, после начала лечения должны находиться под пристальным контролем для своевременного обнаружения ослабления в ферре активности. **ПОБОЧНОЕ ДЕЙСТВИЕ.** Учитывая механизм действия, применение препарата Ксарелто[®] может сопровождаться повышением риска развития желудочно-кишечного кровотечения из любых органов у тканей, которое может приводить к постгеморрагической анемии. Риск развития кровотечения может увеличиваться у пациентов с неконтролируемой артериальной гипертензией и/или при совместном применении с гепаринами,

влияющими на гемостаз. Признаки, симптомы и степень тяжести (включая возможный летальный исход) варьируют в зависимости от локализации, интенсивности или продолжительности кровотечения и/или анемии. Геморрагическое осложнение могут проявляться в виде слабости, бледности, головокружения, головной боли или необычных отеков, одышки или шока, развитие которого нельзя объяснить другими причинами. В некоторых случаях вследствие анемии развивались симптомы ишемии миокарда, такие как боль в груди и стенокардия. Чисто отчетливых анемии (включая соответствующие лабораторные параметры), головная боль, кровоизлияние в глаз (включая кровоизлияние в конъюнктиву), выраженное снижение артериального давления, гематома, носовое кровоизлияние, кровоизлияние, кровоизлияние десны, желудочно-кишечное кровоизлияние (включая ректальное кровоизлияние), повышение концентрации мочевой[†], гиподард[†], периферические отеки, снижение силы и тонуса (включая слабость, астению), повышение активности печеночных трансаминаз, кровоизлияние после проведенных процедур (включая послеоперационную анемию и кровоизлияние из раны), гематома.

[†] наблюдались преимущественно после больших ортопедических операций на нижних конечностях.
[‡] наблюдались при лечении ВТЭ как очень частые у женщин в возрасте <55 лет.
Регистрационный номер: ЛП-014572. Актуальные версии инструкции от 10.03.2020. **ВЛАДЕЛЕЦ РЕГИСТРАЦИОННОГО УДОСТОВЕРЕНИЯ И ПРОИЗВОДИТЕЛЬ:** Bayer AG, Германия. Отпускается по рецепту врача. Подробная информация содержится в инструкции по применению.

ФП – фибрилляция предсердий; **ИМ** – инфаркт миокарда; **ОКС** – острый коронарный синдром.
***** Результаты представлены для общей популяции исследования ROCKET AF, средний возраст в которой составил 73 года. Согласно результатам субанализа у пациентов с ФП в возрасте 75 лет и старше в исследовании ROCKET AF частота инсульта/ОКС и больших кровотечений была сопоставимой на терапии ривароксабаном и варфарином, при более высокой частоте больших и небольших клинически значимых кровотечений на терапии ривароксабаном. ****** В отношении исходных: снижение рСКФ на ≥30%, увеличение своротночного уровня креатинина, строгое почечное повреждение, согласно данным наблюдательного исследования. **‡** По данным крупного мета-анализа PAF у пациентов с различными показателями к применению ОАК терапия ривароксабаном была связана со снижением риска развития ИМ/ОКС в сравнении с ривароксабаном, терапией варфарином, энноксапарин, дигидратом цитиловой кислоты, плацебо.
† Ишемия коронарных артерий, указанные в перекрестках. Полные результаты исследования представлены в перекрестках.

PP-24AR-14U-0434-1



**Одним ударом –
по двум факторам риска¹**



**Лидирующие классы
препаратов в 1 таблетке²**



Впервые в Европе и России!³



Роксатенз

индапамид/периндоприл/розувастатин

-инда

ОПЕРЕЖАЯ ВРЕМЯ

Телмиста® АМ 24

амлодипин/телмисартан
5/40 мг, 5/80 мг и 10/80 мг

Оптимальный выбор для
стабильного контроля АД 24 часа!^{4,7}



Для надежного снижения
АД на 24 часа^{4,7}



Для снижения
рисков ССО⁵



Новый** союз 2-х молекул
в 1 таблетке⁶

2 в 1

24 часа

* обусловлено эффектами телмисартана по данным исследования ONTARGET
** В линейке препаратов под торговой маркой KRKA

АД - артериальное давление, ССО - сердечно-сосудистые осложнения

Источники информации: 1. ИМП по препарату Роксатенз-инда. 2. Индапамид, периндоприл и розувастатин являются лидирующими молекулами по объему продаж в рубль в своих соответствующих классах (по данным IQVIA на 02.2020). 3. Состав Роксатенз-инда – индапамид/периндоприл/розувастатин. В РФ – согласно данным сайта ГЛС от 03.2020, в Европе – 1. Roxiper (Perindopril/Indapamide/Rosuvastatin 4 mg/1.25 mg/10 mg), film-coated tablet, Marketing Authorisation No: 5756812, Portugal Roxiper (Perindopril/Indapamide/Rosuvastatin 4 mg/1.25 mg/20 mg), film-coated tablet, Marketing Authorisation No: 5756838, Portugal Roxiper (Perindopril/Indapamide/Rosuvastatin 8 mg/2.5 mg/10 mg) film-coated tablet, Marketing Authorisation No: 5756820, Portugal Roxiper (Perindopril/Indapamide/Rosuvastatin 8 mg/2.5 mg/20 mg), film-coated tablet, Marketing Authorisation No: 5756846, Portugal. 4. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004;17 (4): 347-53. 5. The ONTARGET Investigators Telmisartan, Ramipril, or both in Patients at high risk for vascular events N Engl J Med 2008; 358:1547 – 1559. 6. Инструкция по медицинскому применению препарата Телмиста® АМ. 7. Остроумова О.Д., Кочетков А.И., Буторов В.Н., Кроткова И.Ф. Как выбрать оптимальную фиксированную комбинацию антигипертензивных препаратов первой линии? Преимущества комбинации телмисартана и амлодипина. Рациональная Фармакотерапия в Кардиологии 2020; 16 (4).



Санofi — №1 среди производителей телмисартанов в России¹



Жизнь пациента — ценность!²⁻⁴



Телзап® — лидер по рекомендациям среди врачей⁵



Телзап® — это широкий спектр дозировок и форм выпуска⁶⁻⁸



Телзап® — это качество от одного из ведущих⁹ европейских производителей^{7, 10}

1. Согласно данным баз ООО «АЙКЬЮВИА Солюшнс» «Розничный аудит ГЛС и БАД в РФ», «Бюджетный аудит (искл. ДЛО и РЛО)», «ДЛО (ОНЛС/ВЗН) в РФ» и «Региональная льгота в РФ», по итогам периода январь–апрель 2021 года корпорация Санofi занимает позицию №1 по объему продаж в таблетках среди лекарственных препаратов, содержащих телмисартан (МНН телмисартан, гидрохлоротиазид + телмисартан и амлодипин + телмисартан) [Эл. ресурс] // URL: [https:// docsfera.ru/upload/pdf/sanofi_leader_2021_04_28.pdf](https://docsfera.ru/upload/pdf/sanofi_leader_2021_04_28.pdf). (дата последнего доступа: 20.07.2021). 2. Согласно данным баз ООО «АЙКЬЮВИА Солюшнс» «Розничный аудит ГЛС и БАД в РФ», «Бюджетный аудит (искл. ДЛО и РЛО)», «ДЛО (ОНЛС/ВЗН) в РФ» и «Региональная льгота в РФ», на российском фармацевтическом рынке по итогам периода январь–апрель 2021 года корпорация Санofi занимает позицию №3 по объему продаж в рублях в оптовых ценах. [Эл. ресурс] // URL: https://docsfera.ru/upload/pdf/sanofi_top_3_iqvia_2021_04.pdf (дата последнего доступа: 20.07.2021). 3. ONTARGET Investigators // N. Engl. J. Med. — 2008. — Vol. 358. — P. 1547–1559 (исследование ONTARGET // Мед. журнал Новой Англии. — 2008. — Т. 358. — С. 1547–1559). 4. TRANSCEND Investigators // Lancet. — 2008. — Vol. 372. — P. 1174–1183 (исследование TRANSCEND // Ланцет. — 2008. — Т. 372. — С. 1174–1183). 5. По данным Prindex™ на первый квартал 2021 года, препараты группы Телзап занимают первое место в рейтинге назначений препаратов, содержащих телмисартан в моноформе и в комбинации с амлодипином и/или гидрохлоротиазидом, в коммерческом сегменте совокупно врачами 16 специальностей амбулаторно-поликлинического звена [Эл. ресурс] // URL: https://docsfera.ru/upload/pdf/ipsos_telzap_prescriptions_q1_2021_full.pdf (дата последнего доступа: 20.07.2021). 6. Инструкция по медицинскому применению лекарственного препарата Телзап® (ЛП-№(000065)-(PFRU) от 28.05.2020). 7. Инструкция по медицинскому применению лекарственного препарата Телзап® Плюс ЛП-№(000182)-(PFRU) от 30.03.2021. 8. Инструкция по медицинскому применению препарата Телзап® АМ ЛП-005472 от 20.09.2019. 9. Согласно данным баз ООО «АЙКЬЮВИА Солюшнс» «Розничный аудит ГЛС и БАД в РФ» «Бюджетный аудит (искл. ДЛО и РЛО)» «ДЛО (ОНЛС/ВЗН) в РФ» и «Региональная льгота в РФ» корпорация Санofi входит в топ-3 по объему продаж в оптовых ценах по состоянию на апрель 2021 года. [Эл. ресурс] // URL: https://docsfera.ru/upload/pdf/ sanofi_top_3_iqvia_2021_04.pdf (дата последнего доступа: 20.07.2021). 10. Государственный реестр лекарственных средств [Эл. ресурс] // <https://goo.su/67f5> (дата последнего доступа: 20.07.2021).

Информация предназначена для специалистов здравоохранения.
АО «Санofi Россия», 125009, Москва, ул. Тверская, д. 22,
тел.: (495) 721-14-00, www.sanofi.ru. МАФРУ-2102912 — 1.0 — 07/2021.

ПРЕДУКТАЛ® ОД

Триметазидин 80 мг

ДЕЙСТВУЕТ
В МИТОХОНДРИЯХ
КАРДИОМИОЦИТОВ

// СПОСОБСТВУЕТ УМЕНЬШЕНИЮ
частоты приступов стенокардии^{1,2}

// УВЕЛИЧИВАЕТ
переносимость физической нагрузки^{1,2}

// СОХРАНЯЕТ
уровень АТФ в клетке¹

ЛЕЧИТ СТЕНОКАРДИЮ ТАМ, ГДЕ ОНА ВОЗНИКАЕТ

Предуктал ОД показан в качестве длительной терапии стабильной стенокардии.

СОСТАВ: 1 капсула с пролонгированным высвобождением содержит триметазидина дигидрохлорида 80 мг. **ПОКАЗАНИЯ К ПРИМЕНЕНИЮ*** Длительная терапия ишемической болезни сердца: профилактика приступов стабильной стенокардии в составе моно- или комбинированной терапии, СПОСОБ ПРИМЕНЕНИЯ И ДОЗЫ¹. Внутрь, по 1 капсуле 1 раз в сутки, утром во время завтрака. Оценка пользы от лечения может быть проведена после трех месяцев приема препарата. Прием препарата следует прекратить, если за это время улучшения не наступило. Пациента с нарушениями функции почек/печени/печень/печень пациенты у пациентов с умеренным нарушением функции почек (КК 30-60 мл/мин) рекомендуется сниженную дозу, т.е. 1 таблетка, содержащая 35 мг триметазидина, в день. **ПРОТИВОПОКАЗАНИЯ*** Повышенная чувствительность к действующему веществу или любому из вспомогательных веществ, входящих в состав лекарственного препарата. Болезнь Паркинсона, симптомы паркинсонизма, тремор, синдром «беспокойных ног» и другие связанные с ним двигательные нарушения, Тяжелая почечная недостаточность (КК <30 мл/мин). Непереносимость фруктозы/сахаров, наличие синдрома глюкозо-галактозной мальабсорбции, сахарозо-наследственной недостаточности и других ферментопатий, связанных с непереносимостью сахаров, входящей в состав препарата. Из-за отсутствия достаточного количества клинических данных пациентам до 18 лет назначение препарата не рекомендуется. Беременность и период грудного вскармливания. **ОСОБЫЕ УКАЗАНИЯ*** Предуктал ОД не предназначен для купирования приступов стенокардии и не показан для начального курса терапии нестабильной стенокардии или инфаркта миокарда на догоспитальном этапе или в первые дни госпитализации. В случае развития приступа стенокардии следует вновь оценить степень поражения коронарных артерий и при необходимости адаптировать лечение (лекарственную терапию или возможно проведение процедуры реваскуляризации). Триметазидин может вызывать или усиливать симптомы паркинсонизма (тремор, анкилоз, повышение тонуса), поэтому следует проводить регулярное наблюдение пациентов, особенно пожилого возраста. Могут отмечаться случаи падения, связанные с неустойчивостью походки или артериальной гипотензией, особенно у пациентов, принимающих гипотензивные препараты. **ВЗАИМОДЕЙСТВИЕ С ДРУГИМИ ЛЕКАРСТВЕННЫМИ СРЕДСТВАМИ*** ПРИМЕНЕНИЕ ВО ВРЕМЯ БЕРЕМЕННОСТИ И В ПЕРИОД ГРУДНОГО ВСКАРМЛИВАНИЯ*. Применение препарата Предуктал ОД во время беременности триггировало, но не вызвало, случаи выкидыша. При необходимости применения препарата Предуктал ОД в период лактации грудное вскармливание необходимо прекратить. **ВЛИЯНИЕ НА СПОСОБНОСТЬ УПРАВЛЯТЬ ТРАНСПОРТНЫМИ СРЕДСТВАМИ, МЕХАНИЗМАМИ*** Наблюдены случаи головокружения и сонливости, что может повлиять на способность к управлению автомобилем и выполнению работ, требующих повышенной скорости физической и психической реакций, **ПОБОЧНОЕ ДЕЙСТВИЕ*** Частое головокружение, головная боль, боль в животе, диарея, диспепсия, тошнота, рвота, кожная сыпь, кожный зуд, крапивница, астения, Редко: ощущение сонливости, эйфории, тахикардия, артериальная гипотензия, ортостатическая гипотензия, которая может сопровождаться общим недомоганием, головокружением или падением, особенно при одновременном приеме гипотензивных препаратов, «рифимы» крови в моче. Неустойчивость походки, синдром «беспокойных ног», другие связанные с ним двигательные нарушения, обычно обратимые после прекращения терапии, нарушения сна (бессонница, сонливость), вертиго, запор, острый генерализованный экзактантозный приступ, ангионевротический отек, агранулоцитоз, тромбоцитопения, тромбоцитопеническая пурпура, гепатит, ПЕДАЛИРОВКА*, ФАРМАКОЛОГИЧЕСКИЕ СВОЙСТВА*. Триметазидин предотвращает снижение внутримитохондриальной концентрации аденозинтрифосфата (АТФ) путем сохранения энергетического метаболизма клеток в состоянии покоя. Триметазидин не оказывает прямого воздействия на показатели гемодинамики. **ФОРМА ВЫПУСКА*** Капсулы с пролонгированным высвобождением 80 мг. По 3 капсулы в блистер из фольги ПА/Ал/ПВХ и фольги алюминиевой. По 3 или 6 блистеров с инструкцией по медицинскому применению в пачку картонную. По 3 капсулы в блистер из фольги ПА/Ал/ПВХ и фольги алюминиевой. По 3 блистера с инструкцией по медицинскому применению в пачку картонную.

*Смотрите полную информацию о препарате в инструкции по применению. Регистрационное удостоверение: ЛП-003410.

1. Инструкция по медицинскому применению лекарственного препарата Предуктал® ОД. 2. Glezler M, CHOICE-2 study investigators. The effectiveness of trimetazidine treatment in patients with stable angina pectoris of various durations: results from the CHOICE-2 study. Adv Ther. 2018;35:1103-1113. doi: 10.1007/s12325-018-0674-4.

АО «Сервье». 125196, г. Москва, ул. Лесная, д. 7, этаж 7/8/9. Тел.: (495) 937-0700, факс: (495) 937-0701




Эдарби® Кло
азилсартана медоксомил + хлорталидон

МОЩНЫЙ СОЮЗ

ДЛЯ СНИЖЕНИЯ АД
В ТЕЧЕНИЕ 24 ЧАСОВ^{1,2}

АЗИЛСАРТАН
ПРЕВОСХОДИТ ДРУГИЕ САРТАНЫ*
В АНТИГИПЕРТЕНЗИВНОМ ЭФФЕКТЕ^{3,4}

ХЛОРТАЛИДОН
ИМЕЕТ ОБШИРНУЮ
ДОКАЗАТЕЛЬНУЮ БАЗУ⁵⁻⁹
ПО СНИЖЕНИЮ РИСКА ССО**
У ПАЦИЕНТОВ С АГ

STADA

Наша миссия - ваше здоровье

МОЩНЫЙ СОЮЗ

*По сравнению с валсартаном и олдесартаном. **ССО — сердечно-сосудистые осложнения. 1. Инструкция по применению лекарственного препарата для медицинского применения Эдарби® Кло, таблетки, покрытые пленочной оболочкой, 40 мг + 12,5 мг, 40 мг + 25 мг. Рег. уд. ЛП-002941 от 02.04.2016. 2. Cushman W.C., et al. Hypertension. 2012; 60: 310–318. 3. Sica D., et al. J. Clin. Hypertens. 2011; 13: 467–472. 4. White W.B., et al. Hypertension. 2011; 57: 413–420. 5. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979; 242: 2562–2571. 6. Multiple Risk Factor Intervention Trial Research Group. Circulation. 1990; 82: 1616–1626. 7. Dorsch M.P., et al. Hypertension. 2011; 51: 689–694. 8. SHEP Cooperative Research Group. JAMA. 1991; 265: 3255–3264. 9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA. 2002; 288: 2981–2997.

Сокращенная информация по применению

Торговое название: Эдарби® Кло. **Международное непатентованное или группировочное название:** азилсартана медоксомил + хлорталидон. **Лекарственная форма и дозировка:** таблетки, покрытые пленочной оболочкой, 40 мг + 12,5 мг, 40 мг + 25 мг. **Показания к применению:** эссенциальная гипертензия (пациентам, которым показана комбинированная терапия). **Противопоказания:** повышенная чувствительность к действующим веществам и другим компонентам препарата; рефрактерная гипокалиемия; рефрактерная гипонатриемия; анюрия; беременность и период грудного вскармливания; одновременный прием препаратов, содержащих алискирен, у пациентов с сахарным диабетом и/или умеренными и тяжелыми нарушениями функции почек (скорость клубочковой фильтрации (СКФ) менее 60 мл/мин/1,73 м² площади поверхности тела); одновременное применение с ингибиторами АПФ у пациентов с диабетической невропатией; тяжелые формы сахарного диабета; возраст до 18 лет (эффективность и безопасность не установлены); нарушения функции печени тяжелой степени (более 9 баллов по шкале Чайлд-Пью) (отсутствует опыт применения); почечная недостаточность тяжелой степени (клиренс креатинина (КК) менее 30 мл/мин) (отсутствует опыт применения).

Способ применения и дозы. Препарат Эдарби® Кло принимают внутрь один раз в сутки независимо от времени приема пищи. Рекомендованная начальная доза препарата Эдарби® Кло составляет 40 мг азилсартана медоксомила + 12,5 мг хлорталидона 1 раз в сутки. При необходимости дополнительного снижения АД дозу препарата Эдарби® Кло можно увеличить до максимальной; 40 мг азилсартана медоксомила + 25 мг хлорталидона 1 раз в сутки. Препарат Эдарби® Кло следует принимать ежедневно, без перерыва. В случае прекращения лечения пациент должен сообщить об этом врачу. **Побочное действие:** для комбинации азилсартана медоксомила и хлорталидона: очень часто: повышение концентрации креатинина; часто: головокружение, постуральное головокружение, обморок (синкопе), выраженное снижение АД, диарея, тошнота, гиперурикемия, повышение концентрации мочевины, повышенная утомляемость, периферические отеки; для хлорталидона (монотерапия): очень часто: гиперлипидемия, гипокалиемия; часто: выраженное снижение АД, потеря аппетита, желудочно-кишечные расстройства, крапивница, снижение потенции, гипомagnesемия; для азилсартана медоксомила (монотерапия): часто: головокружение, диарея, повышение активности креатинфосфокиназы. **Полный перечень побочных эффектов содержится в инструкции по применению.** **С осторожностью:** тяжелая хроническая сердечная недостаточность (IV функциональный класс по классификации NYHA); нарушение функции почек (КК более 30 мл/мин); нарушение функции печени легкой и умеренной степени (5–9 баллов по шкале Чайлд-Пью); двусторонний стеноз почечных артерий и стеноз артерии единственной функционирующей почки; ишемическая кардиомиопатия; ишемические цереброваскулярные заболевания; состояние после трансплантации почки; состояние, сопровождающееся снижением объема циркулирующей крови (в том числе рвота, диарея, прием высоких доз диуретиков), а также у пациентов, соблюдающих диету с ограничением поваренной соли; первичный гиперальдостеронизм, гиперурикемия и подагра; бронхиальная астма; системная красная волчанка; стеноз аортального и митрального клапана; гипертрофическая obstructивная кардио-миопатия; возраст старше 75 лет; гипокалиемия, гипонатриемия. **Полная информация по препарату содержится в инструкции по медицинскому применению.**



АО «Нижфарм», Россия, 603950,
г. Нижний Новгород, ул. Саганская, 7.
Тел.: +7 (831) 278 80 88,
E-mail: med@stada.ru
www.stada.ru

Дата выхода материала: октябрь 2021 г. 100623

КАРДИОМАГНИЛ

НАДЕЖНЫЙ ПОМОЩНИК В ЗАЩИТЕ ВАШИХ ПАЦИЕНТОВ ОТ ТРОМБОЗОВ И ИНФАРКТОВ!¹



- ♥ Длительный ежедневный прием ацетилсалициловой кислоты 75 мг – доказанная профилактика сердечно-сосудистой смертности²
- ♥ Кардиомагнил 75 мг – лучше профиль безопасности* за счет оптимальной дозы ацетилсалициловой кислоты³
- ♥ Защита желудка благодаря антациду в составе¹

* Ниже риск кровотечений по сравнению с препаратами ацетилсалициловой кислоты ≥ 100 мг.

Адаптировано из материалов:

1. Инструкция по применению лекарственного препарата для медицинского применения Кардиомагнил. РУ №:013875/01 от 25.12.07.
2. Консенсус экспертов по антитромботическим препаратам. Британский медицинский журнал. 2002; 324: 71–86.
3. Серебряный В. и соавт. Американский гематологический журнал. 2004; 75: 40–47.

Сокращенная информация по применению: Торговое название: Кардиомагнил®. МНН: ацетилсалициловая кислота (АСК) + магния гидроксид. Лек. форма и дозировка: таблетки покрытые пленочной оболочкой 75 мг + 15,2 мг, 150 мг + 30,39 мг. Показания к применению: Нестабильная стенокардия и стабильная стенокардия. Профилактика повторного инфаркта миокарда. Профилактика повторной ТИА и повторного ишемического инсульта у пациентов, ранее перенесших нарушение мозгового кровообращения. Профилактика тромботических осложнений после операций и инвазивных вмешательств на сосудах. **Противопоказания:** Повышенная чувствительность к АСК, вспомогательным веществам препарата и другим НПВП, кровоизлияние в головной мозг; склонность к кровотечению (недостаточность витамина К, тромбоцитопения, геморрагический диатез); бронхиальная астма, индуцированная приемом салицилатов и НПВП; полное или неполное сочетание бронхиальной астмы, рецидивирующего полипоза носа и околоносовых пазух и непереносимости АСК или других НПВП, включая ингибиторы ЦОГ-2; эрозивно-язвенное поражение желудочно-кишечного тракта (в фазе обострения); желудочно-кишечное кровотечение; тяжелое нарушение функции печени; тяжелая почечная недостаточность (клиренс креатинина <30 мл/мин); ХСН III-IV ФК по классификации NYHA; беременность (I триместр, в сроке более 20 недель); период грудного вскармливания; дефицит глюкозо-6-фосфатдегидрогеназы; одновременный прием с метотрексатом (>15 мг в неделю); детский возраст до 18 лет. **Способ применения и дозы:** Внутрь. 1 таблетка Кардиомагнила, содержащего АСК в дозе 75–150 мг, 1 раз в сутки. **Побочное действие:** головокружение, шум в ушах, носовое кровотечение, ринит, диспепсия, боль со стороны ЖКТ и в животе, желудочно-кишечное воспаление, кровотечения из ЖКТ, кожная сыпь, кожный зуд, кровотечения из мочевыводящих путей и др. **С осторожностью:** При подагре, тиреотоксикозе, наличии в анамнезе язвенных поражений ЖКТ или желудочно-кишечных кровотечений, нарушении функции печени, нарушении функции почек, бронхиальной астме, сенной лихорадке, полипозе носа, во II триместре беременности до 20 недель и др. **Условия хранения:** В защищенном от света месте, при температуре не выше 25 °С. Хранить в недоступном для детей месте. **Срок годности:** 3 года. **Условия отпуска:** Отпускают без рецепта. Полная информация по препарату содержится в инструкции по медицинскому применению.

ИНФОРМАЦИЯ ПРЕДНАЗНАЧЕНА ДЛЯ СПЕЦИАЛИСТОВ ЗДРАВООХРАНЕНИЯ

АО «Нижфарм»:
603950; г. Нижний Новгород, ул. Салганская, д. 7,
тел.: +7 831 278 8088, факс: +7 831 430 7228,
e-mail: med@stada.ru, www.stada.ru

STADA



RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY 2022



SEPTEMBER 29 — OCTOBER 1, 2020 | KAZAN